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Introduction
Despite intensive treatment, long term survival rates of patients suffering from acute 
myeloid leukemia (AML) are still low. A major cause is resistance to chemotherapy, 
that can be mediated by overexpression of drug-effluxing transporters, but a role for 
dysregulated cholesterol metabolism has also been suggested. Blocking cholesterol 
synthesis using statins, cholesterol-lowering drugs widely used for the prevention of 
cardiovascular disease, has been proposed as a promising approach to improve current 
antileukemic treatment. Work described in this thesis explores the use of statins in 
AML, with a focus on cotreatment with other agents and on the mechanism(s) of action. 
Normal and leukemic hematopoiesis
Normal hematopoiesis comprises the formation of the different blood cell lineages 
during the life-span of an organism. This is a hierarchically organized process in which 
the most undifferentiated hematopoietic stem cell (HSC) gives rise to (multipotent) 
progenitor cells (Figure 1). These progenitor cells differentiate to mature blood cells 
of different lineages. In addition, HSCs can give rise to new HSCs, a process called 
Figure 1. Hierarchical structure of hematopoiesis. Schematic representation of hematopoiesis displaying 
the development of mature blood cell lineages from hematopoietic stem cells. LT-HSC: long-term 
hematopoietic stem cell; ST-HSC: short-term HSC; MPP: multipotent progenitor; CMP: common myeloid 
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self-renewal1,2, which underlies the capacity to repopulate the bone marrow of irradi-
ated recipients3. The processes of self-renewal, proliferation, and differentiation need 
to be tightly regulated, as dysregulation of hematopoiesis might result in severe defects 
in the generation of one or more of the cell lineages.
In contrast to normal hematopoiesis, leukemic hematopoiesis is characterized by 
a block in differentiation capacity in combination with defects in self-renewal and cell 
survival, which ultimately results in the accumulation of myeloid blasts in the bone 
marrow and suppression of normal hematopoiesis4-7. Researchers have proposed that 
within AML a hierarchical structure similar to that of normal hematopoiesis is present 
and that the leukemic stem cell (LSC), the leukemic counterpart of the HSC, resides on 
top of this hierarchy2,8,9. However, recently cells with leukemia-initiating capacity were 
also found among cells that display expression markers that are associated with normal 
committed progenitors, indicating that leukemia-initiating cells are not restricted to 
the phenotype associated with normal HSCs10. 
 
Stem cells
Normal and leukemic stem cells are characterized by the expression of the membrane 
antigen CD34 and the lack of CD38 (CD34+CD38-)3,11-15, although it has recently been 
shown that also the CD34+CD38+ and even the CD34- cell fraction contain leukemia-
initiating cell capacity16,17. There is increasing evidence that LSCs play an important 
role in the leukemogenic process18. In murine models, AML arises in HSCs by leukemic 
transformation, rather than in committed progenitors15,18, with the exception of acute 
promyelocytic leukemia, where transformation takes place in more committed cells19. 
However, recent reports show that LSCs are phenotypically more similar to normal 
progenitor populations than to stem cells20, and that, in contrast to a hierarchical 
structure, leukemias reveal a non-linear branching clonal architecture with subclones 
having distinctive genetic signatures21. During leukemic transformation, two separate 
events can be distinguished: leukemic initiation and maintenance. It is thought that 
both events are interconnected and dependent on multiple events that ultimately lead 
to enhanced self-renewal and differentiation defects of the LSC. Not only intrinsic 
defects like gene mutations in the Ras, c-Kit, or Bcr/Abl gene are part of the trans-
formation22-24, but also extrinsic factors, like increased production of cytokines and 
growth factors4,25-27. In addition, localization in and interaction with the bone marrow 
microenvironment play a role in the development and maintenance of AML28. Although 
chemotherapy is able to eradicate the dividing AML blast cells, it may not be effective 
for elimination of the LSC population, as this population is relatively quiescent and 
may have acquired resistance29,30.
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Microenvironment
Normal and leukemic stem cells reside in the bone marrow surrounded by their 
microenvironment. This so-called niche consists of two separate regions; the endosteal 
niche, that is composed of osteoblasts, osteoclasts and stromal cells, and the vascular 
niche, a region closer to the vasculature that comprises sinusoid endothelial cells. The 
cells of the niche allow interaction with HSCs and provide important hematopoietic 
cytokines, both of which are essential for survival and maintenance of HSCs31. 
In the bone marrow microenvironment oxygen levels are low (1-6%) in comparison 
with the levels in the bloodstream (21%)32. At these low oxygen levels, cells switch to 
glycolysis for their energy supply. This results in a decreased generation of ATP, which 
is thought to slow down cell proliferation and to sustain the quiescent state of HSCs33. 
As HSCs and progenitors migrate towards the more oxygen-rich regions of the bone 
marrow and the vasculature, proliferation and differentiation of these cells are favored.
Acute myeloid leukemia
AML is the most common acute leukemia in adults, and its incidence increases with 
age. There are different subtypes of AML; for classification of AML the World Health 
Organization (WHO) system is currently being used in the clinic. This system catego-
rizes leukemia especially according to cytogenetic abnormalities34. These abnormali-
ties provide prognostic information resulting in the categorization of AML patients in 
different risk groups.
Patients with AML are treated with intensive chemotherapy, which consists 
frequently of the combination of cytarabine (ARA-C) and an anthracycline (e.g., dauno-
rubicin), aimed at induction of a remission. At older age (>70-75 years) palliative care 
is offered instead. After having obtained a complete remission, consolidation therapy 
is applied, which consists of an additional course of chemotherapy, but may include 
a stem cell transplantation as well, depending on the risk group the patient belongs 
to35,36. The chances of full recovery from the disease for a specific patient depend on a 
number of prognostic factors including cytogenetics37 and gene mutations38,39. Due to 
intensive treatment options, 50% of the good-risk patients are cured, which contrasts 
with only 4% of AML patients belonging to the unfavorable risk group40. For patients 
over 65 years the figures are even lower41.
Cholesterol
Cholesterol is an essential molecule for cells as a major constituent of all cellular 
membranes. Besides being required for the formation of new membranes during 
cell division, cholesterol content influences membrane organization and, thereby, 
membrane properties. Cholesterol is often clustered in microdomains within 
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plasma membranes that are commonly referred to as lipid rafts42. Lipid rafts play an 
important role in signal transduction. Furthermore, cholesterol is a precursor for 
steroid hormones, bile acids, and some vitamins.
Cellular cholesterol homeostasis is maintained by tightly controlled mechanisms 
of de novo cholesterol synthesis, cellular influx, and cellular efflux (Figure 2). Choles-
terol is synthesized from acetyl coenzyme A (acetyl-CoA) moieties in a number of steps 
via the mevalonate pathway, and involves the action of the rate-controlling enzyme 
3-hydroxy-3-methyl glutaryl-CoA reductase (HMG-CoAR). This mevalonate pathway is 
described below in more detail. Influx of cholesterol in the form of LDL (low-density 
lipoprotein) is mediated by LDL receptor (LDLR). LDLR expression is regulated by sterol 
response element-binding protein 2 (SREBP2), and is induced when cellular cholesterol 
levels are low43,44. In this way cellular cholesterol levels exhibit a negative feedback 
on cholesterol influx45. In addition, scavenger receptor-BI (SR-BI) takes up cholesterol 
esters from high-density lipoprotein (HDL)46. Cholesterol efflux is induced by liver X 
receptor (LXR), of which two isoforms have been identified (LXRα and LXRβ). LXR is 
activated by oxysterols, oxygenated derivatives of cholesterol, and, upon heterodimeri-
zation with retinoid X receptor (RXR), induces the transcription of ABCA1 and ABCG1, 
and other target genes involved in cholesterol transport47-49.
ABCA1 and ABCG1 belong to the superfamily of adenosine triphosphate (ATP)-
binding cassette (ABC) transporters, and are known to mediate cellular cholesterol 
efflux towards acceptors such as ApoA-I and high-density lipoproteins (HDL)50-52. The 
ABC superfamily of transporters comprises 49 functionally distinct transmembrane 
proteins that transport compounds across plasma and intracellular membranes. The 
transporters can be divided in 7 subfamilies (ABCA through ABCG). Although some 
of these transporters efflux specific compounds, many of them are able to extrude a 
variety of structurally unrelated compounds. Hydrolysis of ATP provides the trans-
porters with energy to actively export natural and chemical (drugs) compounds across 
cell membranes against concentration gradients. A number of ABC transporters is 
highly expressed at the mRNA level in normal HSCs, including the ones involved in 
cholesterol transport53-57. 
Cholesterol in AML 
Over 40 years ago a relationship between aberrant cholesterol metabolism and cancer 
was identified58. In 1978, Goldstein and Brown were the first to report altered cholesterol 
metabolism in AML59. In AML cells mRNA levels of HMG-CoAR and LDLR are increased 
,and activity of these proteins is higher compared with normal bone marrow cells60,61. 
Additional studies revealed that AML cells often do not display efficient feedback 
repression of cholesterol synthesis and influx when exposed to high-cholesterol media 
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in vitro. This feature appeared to be associated with increased survival62,63. In addition, 
AML cells from a subgroup of patients showed in vitro an acute increase in cellular 
cholesterol content in response to chemotherapy (DNR, ARA-C) exposure63. This choles-
terol increment could be (partly) prevented by cholesterol synthesis inhibitors, and 
this, surprisingly, resulted in an improved chemosensitivity62,64. These findings suggest 
a role for cholesterol inhibitors to improve standard antileukemic treatment. 
Mevalonate pathway
Cholesterol is synthesized from acetyl-CoA moieties by the mevalonate 
pathway (Figure 3). The initial step in this complex synthetic pathway is the 
formation of HMG-CoA from acetyl-CoA and acetoacetyl-CoA, which is catalyzed 
by HMG-CoA synthase. Subsequently, HMG-CoA is converted to mevalonate by 
Figure 2. Schematic representation of cellular cholesterol homeostasis. LDLR: low-density lipoprotein 
(LDL) receptor; SREBP2: sterol response element-binding protein-2; acetyl-CoA: acetyl coenzyme A; 
HMG-CoAR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; LXR: liver X receptor; RXR: retinoid X receptor; 
LXRE: LXR response element; ABCA1 and ABCG1: ATP-binding cassette transporter A1 and G1; ApoA-I: 
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HMG-CoAR, representing the rate-controlling step of the mevalonate pathway. 
Mevalonate is subsequently converted in several steps to farnesyl pyrophosphate 
(FPP). FPP then can be converted to squalene and subsequently, in multiple steps, to 
cholesterol. Oxygenated forms of cholesterol, oxysterols, bind to the nuclear transcrip-
tion factor LXR, which activates the transcription of ABCA1 and ABCG1, amongst others. 
Besides a cholesterol synthesis branch, the mevalonate pathway also comprises 
an isoprenylation branch. The earlier mentioned isoprenoid FPP can be converted 
to another isoprenoid, geranylgeranyl pyrophosphate (GGPP). Both isoprenoids are 
utilized for the isoprenylation of small guanosine triphosphate hydrolases (GTPases), 
such as Ras and Rho, which are involved in control of proliferation, signal transduc-
tion, and apoptosis65-68. Covalent attachment of a farnesyl group (farnesylation) or a 
geranylgeranyl group (geranylgeranylation) to small GTPases is catalyzed by farnesyl-
transferase (FTase) or geranylgeranyltransferase I (GGTase), respectively. Rho can 
only be geranylgeranylated69, whereas H-Ras is exclusively farnesylated, and K-Ras 
and N-Ras can be both farnesylated and geranylgeranylated70. Isoprenylation is a 
posttranslational modification that is necessary for plasma membrane binding and 
Figure 3. Schematic representation of the mevalonate pathway. HMG-CoAR: 3-hydroxy-3-methyl-glutaryl-
CoA reductase; FPP: farnesyl pyrophosphate; FTase: farnesyltransferase; FTI: FTase inhibitor; GGPP: gera-
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the subsequent activity and participation in signal transduction of small GTPases. 
Other products of the mevalonate pathway include dolichol, required for glycoprotein 
synthesis, and ubiquinone, that is involved in oxidative respiration65. 
Signal transduction 
Constitutive activation of Ras is implicated in malignant growth of hematopoietic cells 
and activating mutations, predominantly in N-Ras and less often in K-Ras, are found 
in 15-30% of AML cases67,71. In addition, deregulation of Rho-GTPases is associated with 
hematological disease, including AML72. Ras- and Rho-GTPases are the most well-
described subgroups of the Ras family of small GTPases. The Ras subgroup contains 
Ras, Rap1 and Ral73, whereas the Rho-GTPases are Rho, Rac, and CDC4274. 
GTPases function as molecular switches within a cell, cycling between an active, 
GTP-bound state and an inactive, GDP-bound state. Upon stimulation of cells, e.g., 
by cytokines or growth factors, the GTPase is activated by exchanging GDP for GTP, 
which leads to the activation of downstream signaling pathways. Different small 
GTPases have separate functions in cells, which may even differ within cell types. 
Ras, for example, mediates proliferation, differentiation and apoptosis by activating 
the Raf/MEK/ERK pathway and/or the PI3K/Akt pathway75,76. Rho is mostly known 
for its role in cytoskeleton function77, although it is also involved in cell adhesion 
and proliferation, cell migration, apoptosis and survival, cell cycle progression, and 
genomic stability72,78,79.:
Statins
Statins inhibit the mevalonate pathway by competitively inhibiting HMG-CoAR. Several 
HMG-CoAR inhibitors have been developed for clinical use, four of which are naturally 
occurring and/or derived from fungal fermentation (simva statin, lova statin, prava-
statin, and mevastatin), whereas the remaining five are synthetic (atorvastatin, ceriva-
statin, fluvastatin, pitavastatin, and rosuvastatin). Statins are clinically used for the 
treatment of hypercholesterolemia (10-80 mg/day), as statins reduce plasma choles-
terol levels, thereby preventing the development of atherosclerotic plaques and conse-
quent cardiovascular disease80. However, because additional ‘pleiotropic’ effects have 
been attributed to statins due to blockage of the mevalonate pathway, statins are also 
explored for alternative indications, including treatment strategies for certain malig-
nancies81. Several (pre)clinical trials have been done to investigate the potential benefi-
cial effects of statins in AML82-85. These trials showed that statins can be given to cancer 
patients in relatively high dosages, i.e., 25 mg/kg/day for lova statin and 15 mg/kg/day 
for simva statin82,85..
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Scope of the thesis
Based on the finding that cholesterol metabolism is dysregulated in AML and the 
possible additional effects of statins for treatment, this thesis aims to explore the 
actions of statins in AML. We will focus on cotreatment with other agents and on the 
mechanism(s) involved, since targeting the mevalonate pathway by statins also inter-
feres with signaling events and thus may have potential relevance for the treatment 
of AML. Chapter 2 reviews recent developments in the role of cholesterol and the 
mevalonate pathway and in intervention with this pathway in AML. As statins are 
reported to sensitize AML cells to chemotherapy, we investigated in chapter 3 whether 
lova statin could potentiate chemotherapy-induced cytotoxicity in the primitive CD34+ 
fraction of AML cells. This CD34+ fraction is less susceptible to chemotherapy due to its 
relative quiescent state, and has a higher cholesterol turnover than more mature cells. 
We assessed viability and colony forming cell frequency upon treatment of primary 
AML CD34+ cells with either lova statin, chemotherapy, or the combination. Likewise, 
we studied in chapter 4 whether the effects of another statin, simva statin, could be 
promoted by cotreating CD34+ AML cells with tipifarnib, a farnesyltransferase inhibitor. 
Both compounds act on the mevalonate pathway, and are already being tested in 
clinical settings. Alternative prenylation by geranylgeranyltransferase may bypass the 
inhibitory effects of tipifarnib. In addition, statins are, in theory, capable of blocking 
both geranylgeranylation and farnesylation. Therefore, the combined use of tipi-
farnib with simva statin may have more pronounced antileukemic effects. We assessed 
viability of AML cell lines and primary CD34+ cells upon treatment with simva statin 
combined with tipifarnib. In chapters 3 and 4, we noted that some AML patient samples 
responded well to statin treatment, whereas other samples were not responsive at all. 
In chapter 5, we tried to elucidate the mechanism behind this heterogeneity in respon-
siveness. We used AML cell lines and primary AML cells with different sensitivities to 
simva statin and investigated the role of the cholesterol synthesis route and the isopre-
nylation synthesis route of the mevalonate pathway in these heterogeneous effects. 
To translate our in vitro findings to an in vivo setting, we studied samples of AML 
patients treated with simva statin, which is described in chapter 6. In addition, mice 
were studied in order to have additional access to liver tissue, which is the primary 
target of statins, as to compare our findings in liver cells with those in bone marrow. 
We assessed the in vivo effects of simva statin treatment on the different routes of the 
mevalonate pathway by gene expression analysis and protein Western blots. Finally, 
chapter 7 summarizes the main findings of the thesis and discusses implications for 
future research and clinical application.
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Abstract
The mevalonate pathway is of crucial importance for the maintenance of cellular 
cholesterol homeostasis. It takes care of adequate cholesterol production to balance 
variations in cholesterol uptake and efflux. This pathway also generates isoprenoid 
moieties, i.e., farnesyl and geranylgeranyl pyrophosphates that are indispensable for 
the function of small GTPases, such as Ras and Rho. There is a growing interest in 
the role of cholesterol and intermediates of the mevalonate pathway in acute myeloid 
leukemia (AML). Recently, important roles for cholesterol transporting ABC trans-
porters and for high-density lipoproteins in hematopoietic stem cell proliferation 
have been demonstrated. In addition, therapies aimed to block cholesterol synthesis 
result in cholesterol-independent effects that may be beneficial in the treatment of 
AML patients. However, clinical studies on statin use in AML have shown thus far unsat-
isfactory results. This review describes the recent advances in our understanding of 
cholesterol metabolism and the mevalonate pathway in hematopoietic disorders, with 
a focus on AML. Additionally, it evaluates the consequences of (pre)clinical interven-
tion in these processes. Also, alternative and thus far underexposed implications of 
statin treatment are discussed, such as the effects on the bone marrow microenviron-
ment and on the occurrence of graft-versus-host disease.
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Introduction
Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by the accu-
mulation of immature myeloid blasts in the bone marrow and suppression of normal 
hematopoiesis. The accumulation of blasts is caused by a block in differentiation 
capacity in conjunction with defects in self-renewal and cell survival1-4. Within AML 
there are several subtypes that can be distinguished by chromosomal and molecular 
markers5. These characteristics serve as prognostic factors, allowing to categorize the 
patients into favorable, intermediate, or unfavorable risk groups6,7. Despite intensive 
treatment, only 30-40% of AML patients between 18 and 65 years old are cured and for 
patients over 65 years this figure is only 5-10%8. A major problem in the treatment of 
AML is the intrinsic or acquired resistance to chemotherapy. One of the causes of this 
multidrug resistance is a dysregulation of cellular cholesterol homeostasis9.
Figure 1. Schematic representation of cellular cholesterol homeostasis. LDLR: low-density lipoprotein 
(LDL) receptor; SREBP2: sterol response element-binding protein-2; acetyl-CoA: acetyl coenzyme A; 
HMG-CoAR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; LXR: liver X receptor; RXR: retinoid X receptor; 
LXRE: LXR response element; ABCA1 and ABCG1: ATP-binding cassette transporter A1 and G1; ApoA-I: 
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More than 40 years ago, a relationship between cholesterol metabolism and cancer 
was first suggested10, which was in 1978 shown for AML11. Both synthesis and influx of 
cholesterol are increased in patients’ AML cells. This can be attributed to an increased 
mRNA expression and protein activity of 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMG-CoAR), the rate-controlling enzyme of the mevalonate pathway, and low-density 
lipoprotein receptor (LDLR), responsible for cholesterol influx (Figure 1)12. Moreover, 
leukemic cells do not exhibit adequate feedback repression of these genes upon 
exposure to excess cholesterol13. AML cells increase their cholesterol contents after in 
vitro exposure to chemotherapeutic drugs, which might render them less susceptible 
to the effects of these agents. In addition, cholesterol-effluxing ABC transporters play a 
role in hematopoietic cell proliferation14. Considering these findings, interfering with 
cholesterol homeostasis may offer an opportunity to improve antileukemic treatment12. 
The most widely used cholesterol-lowering agents are statins, cholesterol synthesis 
inhibitors developed for the prevention of cardiovascular diseases. Based on the above 
described findings, statins have also been proposed for treatment of AML. Statins 
underwent clinical testing with dosages up to 50-fold higher than used to treat hyper-
cholesterolemia. However, it has become increasingly evident that not the effects on 
cholesterol synthesis, but rather the ‘pleiotropic’ effects, i.e., interference with isopre-
noid synthesis, are most relevant for statin-mediated preclinical antitumor effects15-18. 
This review aims to picture current knowledge of the role of the mevalonate pathway 
in AML and addresses recent developments and (pre)clinical experience with the inter-
vention with this pathway by statins.
The role of extracellular and intracellular cholesterol in AML
Cholesterol is an important component of cell membranes and essential for growth 
and proliferation of normal as well as cancer cells19,20. It is required for the formation 
of cell membranes of dividing cells, as well as the formation of lipid rafts that are 
crucial for adequate signal transduction. Elevated plasma cholesterol levels modulate 
features of bone m arrow cells. For example, in mice a high cholesterol diet resulting 
in elevated plasma LDL levels is associated with increased bone marrow cell prolif-
eration21. This is likely due to an increase of cholesterol content in lipid rafts. Human 
breast and prostate cancer cell lines display higher levels of cholesterol-rich lipid rafts 
than their normal counterparts22. In addition, in human prostate cancer xenografts in 
SCID mice elevated serum cholesterol levels increase the cholesterol content in lipid 
rafts of tumor cells, thereby affecting tumor cell signaling, promoting tumor growth 
and reducing apoptosis23. 
Seemingly conflicting with these observations is the finding that AML patients 
generally have low plasma cholesterol levels24. A retrospective study showed that 
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low serum LDL cholesterol levels (≤ 70 mg/dL) are associated with an increased risk 
to develop hematologic malignancy25. However, these low LDL cholesterol levels are 
likely the effect instead of the cause of malignant cell growth. A recent study in acute 
lymphoid leukemia (ALL) patients revealed that primary lymphocytes contain high 
levels of cholesterol despite low serum cholesterol levels26. Also AML cells display 
increased LDL receptor-mediated uptake of cholesterol in conjunction with lower 
plasma cholesterol levels27. This suggests a higher cholesterol consumption for tumor 
cell proliferation, which is supported by the finding that after chemotherapy, when the 
leukemic cells are absent, plasma cholesterol levels normalized27. 
Whereas high LDL levels are associated with increased cell proliferation21, high 
levels of high-density lipoprotein (HDL), responsible for picking up effluxed choles-
terol, decrease proliferation of hematopoietic cells14. The excessive proliferation of 
myeloid cells containing high cholesterol levels in Abca1/Abcg1 double knockout (KO) 
mice could be reversed by transplanting bone marrow cells of these mice into Apoa-I 
transgenic mice that display high HDL levels14. This observation, which showed that 
high HDL levels were able to suppress proliferation in the absence of ABCA1 and ABCG1, 
indicates that HDL can promote cholesterol efflux by alternative pathways, like passive 
cholesterol efflux28. 
Exposure of patient AML cells to cytotoxic drugs, such as cytarabine and daunoru-
bicin, causes an increase in LDLR and HMG-CoAR mRNA levels in many human AML cell 
samples, resulting in increased cellular cholesterol levels9,29. This is thought to protect 
cells against cytotoxic effects, contributing to leukemic therapy failure in part of the 
AML patients30. It is uncertain how these increases of mRNA levels relate to protein 
activity, and whether the chemotherapy-mediated cholesterol increments are caused 
by accelerated influx of LDL or by increased de novo synthesis. LDL accumulation did 
not correlate with cholesterol increments in cultured cytarabine-treated AML cells9. 
This suggests that cholesterol increments do not result from high cholesterol influx 
and that probably de novo synthesis of cholesterol is involved9. In addition, in contrast 
to cytarabine treatment, in vitro daunorubicin treatment-mediated induction of 
HMG-CoAR and LDLR mRNA levels in AML cells did not correlate with cholesterol incre-
ments. These findings indicate that drugs differ with respect to their ability to induce 
cholesterol responses in AML cells, and that posttranscriptional regulation contrib-
utes to the adaptive responses9. However, it is clear that cholesterol plays a role in the 
response to chemotherapy. In a clinical trial in AML patients, two distinct response 
patterns were observed upon treatment with the cholesterol synthesis inhibitor 
pravastatin30. Here, serum cholesterol levels either permanently decreased or an initial 
decrease was followed by a rebound to pretreatment levels. These rebounds in choles-
terol levels were associated with resistance to chemotherapy; patients achieving a 
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complete remission (CR) upon combined idarubicin and high-dose cytarabine showed 
no rebound in serum cholesterol levels30. However, the mechanism responsible for the 
rebound in resistant patients remains to be investigated.
Esterified cholesterol (cholesteryl ester) can be stored in adipocytes. Adipocytes 
are constituents of the bone marrow that increase in number upon aging. They have 
not been intensively investigated thus far, likely because they are perceived as ‘passive 
space fillers’. However, more recently fascinating advances have been made. Besides 
bone marrow, also adipose tissue was identified as a reservoir for functional hema-
topoietic stem and progenitor cells31. In addition, the number of adipocytes in bone 
marrow was inversely correlated with hematopoietic activity of the bone marrow: in 
adipocyte-poor bone marrow more progenitors in the S/G2/M phase of cell cycle were 
found32. As in AML patients irradiation or chemotherapy is usually followed by fatty 
infiltration of the bone marrow, this can delay marrow recovery after stem cell trans-
plantation: engraftment in mice is higher and faster if the bone marrow contains few 
or no adipocytes32. The more efficient engraftment in adipocyte-poor bone marrow 
can be explained by a concomitant induction of osteogenesis, promoting a more sup-
portive environment for hematopoietic reconstitution33. Additionally, adipocytes 
protect leukemia cells against the cytotoxic effects of chemotherapy34. This may be 
caused by the fact that adipocytes accumulate hydrophobic drugs, or, more likely, that 
in the presence of adipocytes leukemic cells increase the expression and activation of 
anti-apoptotic proteins such as Bad, Bcl-2 and Pim234.
The mevalonate pathway: the cholesterol synthesis route and the isoprenylation route
Maintenance of intracellular cholesterol homeostasis is achieved by controlling 
cholesterol influx by LDLR, its efflux by ABC transporters ABCA1 and ABCG1, and via 
regulation of de novo cholesterol synthesis. The mevalonate pathway is of crucial 
importance for cellular cholesterol homeostasis, as cholesterol is synthesized via this 
pathway (Figure 2). In addition, oxidized derivatives of cholesterol (oxysterol, such 
as 24(S),25-epoxycholesterol, 20(S)-hypoxycholesterol (20(S)-HC), 22(R)-HC, 24(S)-HC 
and 27-HC35), can activate the nuclear receptor liver X receptor (LXR). This results in 
the expression of target genes that control cellular cholesterol (e.g., ABCA1 and ABCG1) 
and fatty acid metabolism (e.g., SREBP-1c and fatty acid synthase)36. ABCA1 mediates 
efflux of excess cellular cholesterol to apolipoprotein A-I (ApoA-I) and nascent HDL, 
whereas ABCG1 mediates efflux of cholesterol to more mature HDL particles (Figure 1). 
Uptake of cholesterol is mediated by LDLR, the expression and activity of which is 
regulated in a complex fashion independent of the mevalonate pathway (reviewed by 
Goldstein and Brown54).
Targeting the mevalonate pathway in AML • 29
2
Apart from cholesterol and oxysterols, the mevalonate pathway also leads to 
the production of the isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP) (Figure 2). FPP is a precursor for ubiquinone and dolichol. 
Ubiquinone, also called coenzyme Q10, is an anti-oxidant that serves as an electron 
shuttle in mitochondria, whereas dolichol plays a role in N-glycosylation of proteins. 
In addition, FPP and GGPP are essential for isoprenylation of proteins, a posttrans-
lational modification that is necessary for biological activity of small guanosine 
triphosphate hydrolases (GTPases) like Ras and Rho. Isoprenylation is catalyzed by 
farnesyltransferase (FTase) or geranylgeranyltransferase I (GGTase I), and allows small 
GTPases to bind to the plasma membrane. This binding is required for participation in 
signal transduction pathways that regulate cell proliferation and survival, such as the 
Ras/MEK/ERK and PI3K/Akt pathways. 
Figure 2. Schematic representation of the mevalonate pathway. HMG-CoAR: 3-hydroxy-3-methyl-glutaryl-
CoA reductase; FPP: farnesyl pyrophosphate; FTase: farnesyltransferase; FTI: FTase inhibitor; GGPP: gera-
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In the mevalonate pathway HMG-CoAR is the rate-controlling enzyme that converts 
HMG-CoA to mevalonate. This enzyme is highly expressed in AML12,13. Cellular choles-
terol levels regulate the expression of HMG-CoAR in normal cells, but AML cells display 
a deficient feedback inhibition of HMG-CoAR37, which is likely the cause of the elevated 
HMG-CoAR expression. Complementary to these data, ectopic HMG-CoAR expres-
sion in murine bone marrow increases myeloid colony formation as assessed by 
methyl cellulose assays38. In addition, a meta-analysis of 865 patients retrieved from 
six primary patient microarray data sets showed that high HMG-CoAR mRNA levels, 
as well as mRNA levels of additional mevalonate pathway genes, are associated with 
poor prognosis in breast cancer patients38. Together, these findings indicate a role for 
HMG-CoAR and the downstream mevalonate pathway in the promotion of (leukemic) 
transformation, but the mechanism of action is still enigmatic. 
ABCA1 and ABCG1 are thought to play a role in hematopoiesis. A first indication 
was the finding that ABCA1 and ABCG1 are highly expressed in primitive normal and 
leukemic hematopoietic cells39,40, and that especially ABCG1 is strongly downregulated 
upon maturation of these primitive cell fractions in mice (personal communication 
with A. Gerrits, G. de Haan) and humans39,40. More recently, the relevance of these two 
proteins in hematopoiesis has been demonstrated14. Abca1/Abcg1 double KO mice that 
display an impaired cholesterol efflux showed increased proliferation of myeloid cells, 
even after transplantation into wild type recipients. Moreover, stem cell and progenitor 
cell fractions were enlarged in bone marrow of these double KO mice, which could be 
explained by increased cyclic activity of the bone marrow cells14. These effects could 
be attributed to an increased lipid raft formation14. As a result of this, increased cell-
surface expression of the common β subunit of the IL-3/GM-CSF receptor was observed, 
causing stronger proliferative responses upon IL-3 and GM-CSF exposure. This, in turn, 
lead to increased downstream Ras/ERK signaling and elevated levels of PU.1, a tran-
scription factor that promotes myeloid lineage development, and cyclinD1 in double 
KO mice14. No hematopoietic phenotype was observed when either Abca1 or Abcg1 
alone were deleted14, which may be due to functional redundancy of the transporters, 
as ABCA1 mRNA is increased in Abcg1 KO mice (K. van der Weide, unpublished data). 
Surprisingly, in contrast to Abca1/Abcg1 double KO mice, Lxr KO mice do not exhibit 
expansion of myeloid cells41, and their stem cell and progenitor frequencies are similar 
to those of wild type mice (K. van der Weide, unpublished data). This can be explained 
by the fact that Lxr-deficient hematopoietic cells display an increased expression of 
ABCA1 and ABCG1 despite the absence of their upstream regulator LXR42.
Many GTPases are known to require isoprenylation by FPP (farnesylation) or 
GGPP (geranylgeranylation) for activation, and this list is still growing43,44. Among 
these proteins, Ras and Rho are the most intensively studied. N-Ras and K-Ras can be 
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either farnesylated or geranylgeranylated, whereas H-Ras can only be farnesylated45. 
Constitutive activation of Ras is implicated in the malignant growth of hematopoi-
etic cells. Activating mutations, predominantly in N-Ras and less often in K-Ras, are 
found in 15-30% of AML cases46,47. Ras activation leads to the subsequent activation 
of the Raf/MEK/ERK signaling pathway and/or the PI3K/Akt pathway. Both pathways 
are targets for therapeutic intervention in leukemia48,49. Members of the Rho-protein 
family are generally geranylgeranylated50. Rho GTPase family members, such as Rac 
and CDC42, are essential for interaction of hematopoietic stem and progenitor cells 
with the bone marrow microenvironment, for stem cell mobilization, and for their 
proliferation and survival51. Deregulation of Rho GTPases is associated with hemato-
logical diseases, including AML52,53. 
The mevalonate pathway as a therapeutic target: preclinical data with statins 
Statins inhibit HMG-CoAR activity, which leads to inhibition of cholesterol synthesis, 
but also to a decreased production of isoprenoids. This results in vitro in cell cycle 
arrest17,55, apoptosis15,56-58 and cell differentiation55,59 in AML. The only study in SCID 
mice showed indeed decreased proliferation of injected AML HL60 cells upon statin 
treatment60. Whether this also holds true for primary patient AML cells is unclear. HL60 
is one of the most statin-sensitive AML cell lines16,56, whereas primary AML cells require 
an at least 20-fold higher statin concentration for comparable inhibitory effects61. 
Several statins are available for clinical use, which are either fermentation-derived 
(simva statin, lova statin, pravastatin, mevastatin) or synthetically produced (atorva-
statin, cerivastatin, fluvastatin, pitavastatin, rosuvastatin). Studies with these different 
statins resulted in varying results. Some in vitro effects are only seen with the natural 
statins62, which may be due to their chemical structure and binding affinities for 
HMG-CoAR63. In addition, cerivastatin appeared to be at least ten times more potent 
in AML cells than other statins64, and simva statin is more effective in myeloma cells 
than lova statin or atorvastatin65. Therefore, data of studies employing different statins 
should be carefully interpreted.
Being the direct target of statins, it is not surprising that HMG-CoAR is thought to 
play a key role in the statin-induced cytostatic and cytotoxic effects in tumor cells. 
Addition of mevalonate, the direct downstream product of HMG-CoAR, prevents in 
vitro statin-induced effects15,16,57,58,66. Moreover, the statin-induced response in AML is 
inversely correlated with expression levels of HMG-CoAR58, although this could not be 
confirmed by others16.
Different biochemical mechanisms of statin-induced effects have been proposed. 
Both statins and zaragozic A, a cholesterol synthesis inhibitor downstream from FPP 
(Figure 2), sensitized AML cells to chemotherapy9,29,67. In contrast, by mechanistically 
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uncoupling cholesterol synthesis from isoprenoid synthesis, others have demonstrated 
a more prominent role for isoprenylation, rather than cholesterol synthesis in statin-
induced cell death of AML cells15,16,18,68. With a similar setup, it was shown that leukemia 
cells are more dependent on geranylgeranylation than on farnesylation for survival15,17,65. 
However, the reduced ability of FPP to prevent simva statin-induced cytotoxicity may 
be due to the additional production of squalene from FPP. Therefore, it is not entirely 
justified to conclude that FPP is less relevant than GGPP for statin-induced cytotoxic 
effects. Indeed, in AML cells both farnesylation and geranylgeranylation were shown to 
play an active role in cell survival16. In addition, in multiple myeloma, FPP synthase and 
GGPP synthase are upregulated upon lova statin treatment in statin-insensitive cells but 
not in sensitive cells69. These findings suggest a role for both FPP and GGPP in statin-
induced cytotoxicity.
Inhibition of isoprenoid synthesis by statins can result in inhibition of Rac-170,71, 
Ras18,67,71,72, and Rho activation73-75. As these small GTPases are relevant for cell growth 
and survival, it was thought that the antitumor effects of statins are dependent on inhi-
bition of Ras function60,67. However, patient AML cells bearing an activating Ras-muta-
tion were usually not more sensitive to in vitro statin treatment than cells without this 
mutation60,67. In addition, in NIH-3T3 cells transformed with myristylated Ras (myr-
Ras), and therefore independent of isoprenylation for appropriate membrane localiza-
tion and function, are equally sensitive to statin-induced growth inhibition as cells 
transfected with wild type Ras76. So, statin-induced effects are not solely dependent on 
Ras function and may also involve other isoprenylated proteins43,44.
In patients, plasma concentrations of up to 3.9 μM lova statin can be achieved with 
a lova statin dosage of 25 mg/kg/day77. In many of the in vitro studies, statin concentra-
tions applied are much higher, starting at 20 μM18,29,56,61,78,79. It is therefore important 
to determine the effects in vivo at low, nontoxic concentrations that can be clini-
cally achieved. It appeared that inhibition of farnesylation takes place at simva statin 
concentrations of 5-10 μM in several relevant cell lines. Even higher concentrations 
were required in AML patient-derived cells. Yet, inhibition of geranylgeranylation 
could be realized at concentrations of less than 1 μM in both AML cell lines and AML 
patient cells (this thesis, chapter 6)16. This may, given the maximal achievable plasma 
concentration, have implications for the in vivo effects of statins. 
An alternative manner by which statins can affect AML cell growth is by affecting 
the in vivo microenvironment. This microenvironment consists of an endosteal niche, 
composed of osteoblasts, osteoclasts and stromal cells, and a vascular niche, con-
taining sinusoid endothelial cells. Osteoblasts can interact with normal and leukemic 
hema topoietic stem cells, thereby preserving their stem cell phenotype. This causes a 
release of hematopoietic cytokines and growth factors, and a subsequent activation of 
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signal transduction pathways80. Statins induce differentiation of osteoblasts and inhibit 
proliferation of bone marrow stromal cells at low concentrations (0.01-1 μM)81-84. This 
may disrupt interaction of (leukemic) bone marrow cells with their microenviron-
ment. Thus, the suppressive effects of statins are not only directed to the malignant 
cell, but can also indirectly affect the leukemic cells by modulating the microenvi-
ronment. However, the effects of statins on the bone marrow microenvironment and 
cytokine production by AML cells are as yet insufficiently established.
Clinical application of statins
The first clinical trial with statins in cancer patients, not involving AML patients, 
showed that lova statin administered at a dosage of 25 mg/kg/day for 7 consecutive days 
was well tolerated with only minimal dose-related side effects77. This dosage is about 
50-fold higher than administered to hypercholesterolemic patients85,86, and resulted 
in plasma concentrations of 0.1 to 3.9 μM77. However, there was a marked interpatient 
variability independent of the administered dosage77. To evaluate the safety and efficacy 
of lova statin in AML patients, a trial was conducted using a dosage of 10-20 mg/kg/day 
for 2 weeks. This study was prematurely closed because of drug-related side effects63. 
In a single case study in a patients with relapsed AML, it was shown that a low dosage 
lova statin (2 mg/kg/day) could be given for a prolonged period of time (54 days). In 
addition, AML blast cell counts were decreased, which persisted for 3 months after 
cessation of therapy87. A phase 1 study conducted in 37 AML patients showed that 
pravastatin (up to ~25 mg/kg/day) followed by idarubicin and cytarabine treatment 
could safely be given. Although the small number of patients and non-randomized 
nature of the trial impedes to draw solid conclusions on the benefit of the treatment, 
some encouraging response rates were observed30. For example, the CR rate of newly 
diagnosed patients with unfavorable cytogenetics and first relapse patients was higher 
than the historical CR rates. 
Limitations of statin use
The use of statins as complementary antileukemic treatment of AML patients will 
not be effective in all patients. Therefore, it is of interest to select biomarkers that 
can help to predict which patients may benefit from statin treatment. In vitro studies 
have already shown differences in sensitivities within AML cell lines and primary AML 
samples16,56,61,78. These different studies showed consistent results regarding the propor-
tion of statin sensitive patient samples: about half of the patient AML samples required 
less than 100 μM statin to obtain 50% cytotoxicity56,61,78. Interestingly, when examining 
separately primitive CD34+(CD38-) AML cells and more mature CD34- AML cells, the 
heterogeneity in response appeared to reside in the CD34+(CD38-) fraction61,78. CD34+ 
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and CD34- cells are essentially different regarding long term proliferation capacity and 
susceptibility to apoptosis88,89 and CD34+ (AML) cells display higher expression levels of 
cholesterol metabolism genes39,40. Therefore, it is of interest to use primitive CD34+ AML 
cells in the search for predictive biomarkers. 
Recently, we and others aimed to get insight in the mechanisms underlying the differ-
ences in response to statins. In multiple myeloma, statin-resistant cell lines expressed 
higher HMG-CoAR as well as HMG-CoA synthase 1 mRNA and protein levels, which were 
further upregulated upon statin treatment. In contrast, statin-sensitive myeloma cells 
did not show increased expression of these genes69. Also AML cells express higher levels 
of HMG-CoAR compared with their normal counterparts13, and are more sensitive to 
statins than normal hematopoietic cells56. However, basal HMG-CoAR expression was 
not necessarily higher in statin-insensitive AML cells compared with statin-sensitive 
AML cells, nor was statin-mediated induction of expression of HMG-CoAR mRNA16. This 
suggests that the mechanism behind heterogeneity in statin response does not solely 
exist at the level of HMG-CoAR expression. Alternative splicing of HMG-CoAR, which 
renders the protein inactive, can also induce intra-individual differences in response 
to statins90. However, this splice variant is expressed considerably lower than the 
full-length protein69, and the variation in statin-induced HMCGR-D13 expression only 
accounts for 6-15% of the variation in statin response91.
Studies in AML suggest that the cause of heterogeneity in statin response lies 
within the isoprenylation pathway16,92. In AML cell lines with different sensitivities to 
simva statin, especially in the sensitive cell lines statin-induced cytotoxicity could be 
prevented by FPP or GGPP. In addition, sensitive cell lines display a higher degree of 
isoprenylation inhibition of proteins like Ras as well as inhibition of phosphorylation of 
the Ras-target ERK upon statin treatment than insensitive cell lines16. The exact players 
are however as yet unknown, and it is likely that isoprenylated proteins other than 
Ras contribute to the differences. The ratio of the expression of RASGRP1 and APTX is a 
predictor for the response of AML patients to treatment with tipifarnib, a farnesyltrans-
ferase inhibitor93. As sensitivity to tipifarnib corresponds with sensitivity to statins in 
AML cells16, the mechanism of resistance to these compounds may overlap, so assessing 
the ability of the RasGRP1:APTX ratio to predict statin sensitivity might be of interest.
Compared to in vitro studies, statin treatment in AML patients adds additional 
factors that cause different responses in AML patients. For example, activity of CYP3A4, 
the enzyme that converts most of the statins into their active form, varies among 
patients due to genetical differences or extrinsic factors, e.g., the use of other drugs and 
diet composition94. Besides CYP3A4, there are many other gene products responsible 
for varying pharmacokinetics and pharmacodynamics of statins that cause variation 
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in plasma statin levels and their efficacy, among which are proteins that affect intestinal 
cholesterol absorption (ABCG5, ABCG8, ApoE), cholesterol production (HMG-CoAR), 
and lipoprotein catabolism (ApoB, LDLR)86. There are nowadays over 30 genes known 
as potential determinants of the cholesterol-lowering capacity of statins95. Another 
hurdle for the application of statins in AML patients is that, due to an extensive first-
pass metabolism by the liver, the plasma levels reached are too low to induce cytotoxic 
effects, even with high dosages of the drug96. Interestingly, this first-pass effect may 
explain the finding in a mouse model where simva statin affected cholesterol metabo-
lism gene expression in the liver, but not in bone marrow or peripheral blood cells 
(this thesis, chapter 6). The plasma concentration that can be achieved with high-dose 
(25 mg/kg/day) lova statin, namely 3.9 μM77, is insufficient to induce cytotoxic effects 
or changes in cholesterol metabolism in cultured patient AML cells (this thesis, 
chapter 6). Moreover, in rats the concentration of orally administered lova statin was 
in bone marrow 10-fold lower than in plasma97. Still, these concentrations may be high 
enough to induce inhibition of geranylgeranylation, as observed for concentrations of 
as low as 0.2 μM in cell lines as well as primary normal or AML bone marrow cells (this 
thesis, chapter 6).
To increase statin plasma levels, higher dosages should be administered, which 
may lead to major side effects such as myopathy. Ubiquinone supplementation has 
been used to prevent myopathy, as it does not abrogate the potential therapeutic effects 
in AML98. In a phase 1 study evaluating the effects of high-dose lova statin, ubiquinone 
supplementation reduced the severity, not the incidence, of myopathy77, but in general 
the evidence demonstrating the efficacy of ubiquinone is thin99.
Another way to increase plasma statin levels would be by alternative administra-
tion routes to bypass first pass clearance by the liver, like intravenous administration. 
Unfortunately, intravenous applicable formulations of statins are not available100. There 
are synthetic statins available with a longer half-life, such as rosuvastatin and atorva-
statin, which may also contribute to higher plasma levels. Regretfully, these statins are 
likely less effective in AML cells, because their hydrophilic nature impedes their passive 
diffusion across the cell membrane94.
Statins are administered in most clinical trials for 7 days. However, as statins can 
induce toxicity in AML cells already within 72 hours101, a shorter treatment period can 
be of interest. In a trial in patients with advanced malignancies, high dosages lova statin 
(~50 mg/kg/day) were administered orally every 6 hours for 4 days. Peak plasma levels 
of 12 μM were reached and no drug-related toxicity was observed102. This indicates that 
higher dosages applied for a shorter period of time result in higher statin plasma levels 
without inducing side-effects. 
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Combination treatment with statins
Although statins will not be used as single agent in AML treatment, these drugs are of 
potential interest in combination with standard antileukemic agents. Several statins 
increase the cytotoxicity of cytarabine29,61,66,67,103, daunorubicin61, paclitaxel104, and 
all-trans retinoic acid55 in cultured AML cells, and sensitize these cells to radiation29. 
Suggested mechanisms underlying these synergistic interactions are inhibition of 
NF-κB62, cell cycle arrest in G1105, attenuation of cholesterol increments29, and abroga-
tion of cell adhesion-mediated drug resistance by inhibition of Rho-activity106.
A mevalonate-independent mechanism of statins in sensitization to chemotherapy 
is due to interference with P-glycoprotein (P-gp) action107. P-gp, also called ABCB1, 
is a member of the ABC transporter family. It is a drug efflux pump for xenobiotics 
including chemotherapeutics, which can result in resistance to chemotherapy. Lova-
statin directly binds to P-gp and thus prevents P-gp-mediated drug efflux in multidrug 
resistant tumor cells107. In contrast to fungal-derived statins (e.g., atorvastatin, rosu-
vastatin), synthetic statins with a different chemical structure do not block P-gp108. 
Other researchers show a mevalonate-dependent inhibition of P-gp109. This is possibly 
mediated by depletion of dolichol, a mevalonate derivative essential for glycosyla-
tion of P-gp109. In addition, P-gp expression can be downregulated by either statins 
or deprivation of LDL cholesterol in KG1a AML cells110. P-gp was also downregulated in 
peripheral blood mononuclear cells upon a 4-week atorvastatin treatment of hyper-
cholesterolemia patients111. This provides another mechanism by which statins may 
overcome chemo resistance, although recent studies with specific P-gp inhibitors 
added to chemotherapy did not improve the clinical outcome in AML patients112. 
The (pre)clinical benefits of combining chemotherapy with statins are not yet 
apparent. Out of 7 AML patients treated with high-dose simva statin the cultured AML 
cells of two patients were more sensitive to chemotherapy compared with the cells from 
the same patients before treatment (this thesis, chapter 6). The only clinical study in 
which a statin, pravastatin, was combined with chemotherapy (idarubicin/high-dose 
cytarabine) did not allow to draw valid conclusions about the antitumor efficacy of 
the combination treatment compared with single treatment due to its phase 1 nature. 
However, it did show that a high dosage pravastatin can be safely administered in 
combination with chemotherapy30. Currently, phase 2 trials are ongoing to assess the 
efficacy of combined treatment with statins and chemotherapy.
Isoprenylation inhibitors as alternatives for statins
Farnesyltransferase inhibitors (FTIs) act indirectly on the mevalonate pathway by 
blocking the transfer of farnesyl isoprenoid groups to small GTPases. FTIs have been 
developed to specifically target oncogenic Ras proteins. These proteins are frequently 
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mutated in human cancers. In addition, there are several additional targets for FTIs 
such as RhoB, nuclear lamins and the centromere proteins CENP-E and -F113,114. FTIs, 
including tipifarnib, inhibit the proliferation of leukemic cells113 in preclinical studies. 
In the initial phase 1 clinical trial, refractory and relapsed AML patients received 
100-1200 mg tipifarnib twice daily for 21 consecutive days during 4 weeks. There was 
no toxicity, and an interesting overall response rate of 29%, including 2 CRs (6%), was 
observed115. In a subsequent phase 2 study in 158 previously untreated older adults with 
poor-risk AML, the overall response rate was 23% with 14% CR. Yet, serious side effects 
were observed in 47% of the patients116. A parallel and comparable study in 252 patients 
resulted in an 11% overall response rate and 4% CRs117. Overall, these results do not 
advocate the use of tipifarnib as a single agent. The combined use of tipifarnib with 
cytarabine and daunorubicin was well tolerated up to a tipifarnib dosage of 600 mg 
twice daily118. However, in a phase 3 study in which tipifarnib treatment was compared 
with best supportive care (including hydroxyurea) in elderly patients with AML, there 
was no survival benefit for the tipifarnib arm119. In addition, a phase 1-2 study in 95 AML 
patients showed for the combination tipifarnib, cytarabine and idarubicin a response 
rate similar to cytarabine and idarubicin alone120. 
A potential explanation for the limited responses on tipifarnib is that, although 
tipifarnib inhibits farnesylation of Ras proteins, K-Ras and N-Ras can undergo alterna-
tive prenylation by geranylgeranyltransferase (GGT) in FTI-treated cells121. Therefore, it 
may be of potential interest to combine FTI treatment with GGT inhibitors (GGTIs) or 
statins. Indeed, in vitro cotreatment of simva statin and tipifarnib results in additive 
cytotoxic effects in primary AML cells. In addition, phosphorylation of the Ras target 
ERK is inhibited by the combination, whereas either agent alone does not alter the 
phosphorylation status of ERK78. Studies in mice and AML patients indicate that inhi-
bition of geranylgeranylation occurs at clinically relevant statin concentrations (this 
thesis, chapter 6). GGTIs are more specific and selective than statins and do indeed act 
synergistically in multiple myeloma cells 122,123. However, combining an FTI with a GGTI 
seems clinically not feasible as GGTI treatment appeared lethal in a mouse study124.
Bisphosphonates (BPs) are used to treat metabolic bone disease, as they inhibit 
osteoclast-mediated bone resorption and bone metastases. In addition, anti-cancer 
properties have been described (reviewed by Green and Lipton125). BPs inhibit 
farnesylpyrophosphate synthase, which results in a decreased production of both FPP 
and GGPP. Application of a standard dosage (4 mg/15 minutes iv) of the BP zoledronic 
acid results in maximal plasma concentrations of 1 μM126, which is much lower than the 
concentration required for cytotoxic effects in AML cells127. However, the concentration 
of BPs that can be achieved in bone marrow is much higher than in plasma128,129, so 
clinical testing in the setting of AML may be worthwhile.
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Potential role of statins in GVHD in allogeneic bone marrow transplantation
Recently, an additional role of statins in AML was recognized in bone marrow trans-
plantation. Allogeneic hematopoietic stem cell transplantation coincides with 
morbidity and mortality due to graft-versus-host disease (GVHD). Statins affect the 
immune responses through a variety of mechanisms (reviewed by Arnaud et al.130), 
which can be ascribed to their inhibitory effects on isoprenylation and subsequent 
activation of small GTPases131-134. However, statins can also inhibit lymphocyte function-
associated antigen-1 (LFA-1), involved in T cell activation through binding to an allos-
teric L-site of LFA-1. Statins were shown to protect against GVHD in a mouse model135,136 
and a retrospective study in 67 patients of whom 10 took statins suggested a lower 
incidence of acute GVHD for statin users, while graft-versus-leukemia was preserved137. 
In addition, a retrospective analysis in patients with hematopoietic malignancies who 
underwent allogeneic hematopoietic stem cell transplantation demonstrated an asso-
ciation between statin use of their donor and a decreased risk of grade 3-4 GVHD in the 
patients138. These retrospective studies are challenging, but, given their retrospective 
nature, inconclusive. Therefore, prospective clinical studies, such as the ongoing trial 
with atorvastatin for acute GVHD prophylaxis in patients undergoing allogeneic bone 
marrow transplantation (http://www.clinicaltrials.gov: NCT01175148), are of interest. 
So, by lowering the incidence of GVHD, low-dose statins offer another therapeutic 
implication in the treatment of AML.
Concluding remarks
AML cells display an aberrant cholesterol metabolism, which provoked the application 
of statins in the treatment of the disease. It is currently known that statins, apart from 
suppressing cholesterol synthesis, exert additional cellular effects such as the inhibi-
tion of isoprenoid production. Blockade of isoprenoid synthesis, rather than of choles-
terol synthesis, appears to be mainly responsible for the observed antitumor effects of 
statins. The initial enthusiasm for statin use in AML patients was halted by results of 
clinical studies, in which the activity of the single agent or the activity when combined 
with chemotherapy was not evident. A hurdle in this respect is that the plasma levels 
achieved, even at high dosages of these drugs, are insufficient to induce cytotoxic 
effects. However, statins do inhibit geranylgeranylation in vivo, and it is important to 
identify more relevant therapeutic targets of statins. The clinical relevance of solely 
inhibi ting geranylgeranylation is still unclear, especially since alternative farnesylation 
can overcome the potentially beneficial effects. Therefore, combination with other 
agents such as chemotherapy or FTIs may be of interest, even more because combina-
tion treatment could require lower plasma levels of the agents. In vitro data indicate 
that the cells of a subset of AML patients certainly show a response to statin treatment, 
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whereas others appear to remain unaffected. When the mechanisms underlying the 
heterogeneity in response of AML cells are known, this could lead to biomarkers that 
can predict which patients will benefit from statin treatment. The heterogeneity in 
AML response to statins resides in the isoprenylation pathway, but more research is 
required to pinpoint the exact mechanisms of action and corresponding molecular 
markers. Furthermore, it is also important to focus on the indirect effects of achievable 
concentrations of the clinically proven and safe statins in humans that affect leukemic 
cell survival as well, which include a decreased incidence of GVHD and effects on the 
bone marrow microenvironment.
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Abstract
In the present study, we questioned whether the cholesterol synthesis inhibitor lova-
statin potentiates the cytotoxicity of chemotherapeutic agents in the primitive CD34+ 
subpopulation of acute myeloid leukemia (AML) cells. AML mononuclear cells (n=17) 
were sorted in CD34+ and CD34- fractions and compared to normal CD34+/- cells (n=7). 
The percentage of surviving cells upon exposure to lova statin (25-100 μM) and/or 
chemotherapeutics (cytarabine or daunorubicin) was determined with a luminescent 
cell viability assay. The results demonstrate that the primitive CD34+ subpopulation 
of normal and AML cells displayed a higher sensitivity to lova statin than the more 
mature CD34- subpopulation. The combination of lova statin and chemotherapeutics 
resulted in a more pronounced inhibitory effect on both subpopulations. In contrast 
to the homogeneous results in normal CD34+ cells, a distinct heterogeneity in lova-
statin sensitivity was found in AML samples. Therefore, a group of normal (n=11) 
and abnormal (n=6) responders were identified based on a reduced or increased cell 
survival compared to normal CD34+ cells. This distinction was not only observed in the 
CD34+ AML subfraction but also in CD34+CD38- AML cells. In the abnormal responder 
group, 50% of patients presented with unfavorable cytogenetics and significant higher 
peripheral blast cell counts, which coincided with poor treatment results. In summary, 
the findings indicate that the primitive subfraction of CD34+ AML cells is in the majority 
of cases affected by lova statin treatment, which is potentiated when combined with 
chemotherapeutics. Heterogeneity of the response observed in AML patients allowed 
identification of a subgroup with poor prognosis. 
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Introduction
Acute myeloid leukemia (AML) is characterized by accumulation of immature myeloid 
cells in the bone marrow. These malignant cells are usually hierarchically structured, 
similar to the normal hematopoietic system. We have reported that, according to this 
hierarchal structure, ATP-binding cassette (ABC) transporters are expressed in a differ-
entiation-dependent manner1. Specifically, in primitive CD34+CD38- cells, a high expres-
sion of a number of ABC transporters genes was noticed in comparison to the more 
differentiated CD34+CD38+ cells. Notably, in the leukemic counterpart, a much more 
heterogeneous pattern of ABC transporter gene expression was observed1. Recently, de 
Grouw et al. published expression data for all 45 ABC transporters in AML cells2. They 
found 22 ABC transporters to be lower expressed in the CD34+CD38+ subpopulation 
compared to the CD34+CD38- subpopulation. In addition to the two major cholesterol 
efflux transporters (ABCA1 and ABCG1), two genes critical in cholesterol metabolism 
((3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase and low-density lipoprotein 
receptor (LDLR)) were highly expressed in normal CD34+CD38- cells, indicative for an 
active cholesterol metabolism1,3.
In AML cells, an aberrant cellular cholesterol metabolism has been demonstrated, 
including a higher LDLR activity4. Interestingly, it was recently shown in vitro that 
cells isolated from a subgroup of AML patients demonstrated in their leukemic cells 
‘an acute cholesterol response’, i.e., a rapid increase in cellular cholesterol content 
in response to cytotoxic agents5. These AML cells were further characterized by an 
increased chemosensitivity upon blocking this acute cholesterol response by pretreat-
ment of cells with a statin4. Statins act as competitive inhibitors of the enzyme HMG-CoA 
reductase and hence block cellular cholesterol synthesis. Consequently, a role for 
these cholesterol synthesis inhibitors to improve standard antileukemic treatment 
has been suggested4,6-10. In the present study, we focused on a subpopulation of AML 
cells (CD34+), i.e., cells that have more in common with the more primitive leukemic 
progenitor/stem cell compartment11, and questioned whether this subpopulation of 
cells is especially prone to the effects of lova statin and chemotherapeutic agents. Our 
data demonstrate a higher sensitivity of the primitive CD34+ subpopulation for lova-
statin compared to the more mature CD34- subpopulation of normal as well as AML 
cells. Heterogeneity of the response observed in AML patients allowed identification of 
a subgroup with poor prognosis. 
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Materials and methods
Normal CD34+/- hematopoietic cells
Normal mobilized peripheral blood cells were collected either from healthy donors or 
from patients awaiting autologous stem cell transplantation, undergoing granulocyte 
colony-stimulating factor (G-CSF) treatment, in accordance with institutional guide-
lines. CD34+, CD34-14+15+ (CD34-), CD34+CD38- and CD34+CD38+ cells were obtained by 
means of the MoFlo flow cytometer (Dako Colorado Inc., Fort Collins, Co). 
Patients 
After informed consent, bone marrow or peripheral blood cells were collected of AML 
patients at diagnosis. The Human Subject Review Board of the University Medical 
Center Groningen (the Netherlands) approved the protocol. Patients were classified 
according to the WHO classification12. Mononuclear cells were enriched by Ficoll-
Isopaque (Nycomed, Oslo, Norway) density gradient centrifugation and cryopre-
served in RPMI 1640 medium (BioWhittaker, Brussels, Belgium) supplemented with 
10% fetal calf serum (FCS; Hyclone, Logan, UT) and 10% dimethyl sulfoxide (Merck, 
Amsterdam, the Netherlands), and stored at –196°C as described13. 
Materials
Mevinolin (L-154, 803-00G17) in the lactone form was obtained from Merck, Sharp & 
Dohme Research Laboratories (Rahway, NJ, USA), converted to its sodium salt, and a 
stock solution of mevinolin (lova statin) at a concentration of 4 mg/mL was prepared as 
previously described. The cytotoxic agents daunorubicin (Aventis Pharma BV, Hoeve-
laken, the Netherlands) and cytarabine (Mayne Pharma (Benelux) SA-NV, Brussels, 
Belgium) were used. 
Flow cytometric sorting 
The normal and AML samples were incubated with a fluorescein isothiocyanate (FITC)-
conjugated antibody against CD34 (Becton Dickinson, San Jose, CA, USA) and a phyco-
erytrin (PE)-conjugated antibody against CD14 and CD15 or CD38. Sorting was done 
using a MoFlo flow cytometer. Erythrocytes and dead cells were excluded from analysis 
by gating on forward and sideward light scatter. For RNA extraction, at least 3 × 104 
CD34+ and 3 × 104 CD34-CD14+CD15+ cells were sorted. No difference existed in average 
CD34 expression between normal and leukemic cells mean fluorescence intensity.
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Luminescent cell viability assay and quantitative PCR
A cell viability assay was used for determining the number of viable cells in culture 
based on quantitation of the ATP present, which signals the presence of metabolically 
active cells. The amount of ATP is directly proportional to the number of cells present 
in the culture. The ATP measurement was carried out according to the manufactur-
er’s instructions using the Cell Titer-Glo Luminescent cell viability assay (Promega, 
Madison, WI, USA). We prepared 96-well plates with 100 μL RPMI 1640 medium supple-
mented with 10% FCS and sorted by the MoFlo flow cytometer, either 104 CD34+ cells 
or CD34-CD14+CD15+ cells per well. The wells were incubated with different concentra-
tions of lova statin (25, 50, and 100 μM) with and without different concentrations of 
either daunorubicin (0.01-0.5 μM) or cytarabine (0.0001-0.1 mg/mL) using easy load 
pipet tips (Greiner Bio-One, Alphen aan den Rijn, the Netherlands) and analyzed after 
20 hours. All experiments were done in duplicate. No difference existed in baseline 
average and median ATP levels between CD34+ and CD34- cells. RNA extraction, cDNA 
synthesis, and quantitative polymerase chain reaction were done as described before13.
Colony-forming cell assay
One thousand normal or AML CD34+ cells were sorted into Iscove’s Modified Dulbec-
co’s Media (IMDM) containing 10% FCS, 20 ng/mL interleukin-3 (IL-3), 100 ng/mL 
c-Kit ligand, 100 ng/mL Flt-3 ligand and 100 ng/mL thrombopoietin as described. 
Twenty-four hours after treatment with different concentrations lova statin, cytarabine 
and daunorubicin, cells were plated into MethoCult H4230 (StemCell Technologies, 
Vancouver, Canada) supplemented with 20% IMDM, 20 ng/mL IL-3, 20 ng/mL G-CSF, 
20 ng/mL IL-6, 20 ng/mL c-Kit ligand and 1 U/mL EPO (Cilag: Eprex, Brussels, Belgium).
Statistical analysis
Friedman’s and Mann-Whitney’s nonparametric tests were done to calculate signifi-
cant differences, p-values of <0.05. SPSS 14.0 statistical software (SPSS Inc. 2005) was 
used to analyze the data. Additionally, we looked for additive and synergistic effects 
of the combination treatment of lova statin and chemotherapeutics. Additivity was 
defined as an increased inhibitory effect on cell survival of the combination exposure 
compared to the single exposure of lova statin or chemotherapeutics. Synergism was 
defined by two individual agents (lova statin and chemotherapeutics) acting together 
and creating an inhibitory effect on cell survival greater than predicted by knowing 
only the separate inhibitory effects of the individual agents.





















































































































































































































































































































































































































































































































































































































































































































































































































































































The AML patients (n=17) studied, median age of 51 (range 19-79), were classified 
according to the WHO classification: AML with cytogenetic abnormalities (n=5), 
AML with prior dysplastic syndrome (n=2), and the additional group consisting of 
M1 (n=4), M2 (n=3) and M4/M5 (n=3). The clinical and cellular characteristics of the 
patients are shown in Table 1. The median peripheral blast cell count at diagnosis was 
48.6 × 109/L (range 2.2-200). The majority of the patients were treated according to 
ongoing Haemato-Oncology Co-operative Group (HOVON) protocols, i.e., the HOVON 
Swiss Group for Clinical Cancer Reseach AML-42 study for patients <60 years14 
and the HOVON 43 study for patients >60 years15. Palliative treatment was given to 
patients that were ineligible for intensive chemotherapy (n=2). These patients were 
treated with 6-mercaptopurine16. Eleven patients reached complete remission (CR) on 
protocol. In six patients, CR was not attained due to progression (n=2) or to treatment 
related toxicity (n=4). The median event-free survival (EFS) of all patients attaining CR 
was 13 months (range 1-37). 
The CD34+ subpopulation of normal and AML hematopoietic cells is more sensitive to 
lova statin treatment than the more mature CD34- subpopulation
To evaluate whether differences exist in statin sensitivity between primitive and more 
differentiated cells, normal CD34+ and CD34-14+15+ subfractions (n=7) were sorted 
from the mononuclear cell fraction from normal peripheral blood stem cells. A clear 
discrepancy between both fractions was observed upon lova statin exposure. The CD34+ 
subpopulation demonstrated a reduction of cellular ATP to 64% at a dose of 50 μM lova-
statin compared to 123% in the CD34- fraction (p=0.008; Figure 1A). 
































A BNormal CD34+ and CD34- cells AML CD34+ and CD34- cells
Figure 1. Cell survival of CD34+ and CD34- normal (A: n=7) and AML cells (B: n=17) upon incubation with 
increasing lova statin concentrations (25-100 μM). SEM are indicated.
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A similar experimental setup was used for the AMLs (n=17). From the total AML cell 
fraction the CD34+ subfraction was separated from the CD34- fraction by MoFlo. The 
percentage of CD34+ cells varied strongly between the different AML samples as depicted 
in Table 1 (median 41% (range 7%-92%)). Subsequently, the CD34+ and CD34- fractions 
were exposed to varying concentrations of lova statin (25-100 μM) for 20 hours and the 
effects on cell survival were assessed. As depicted in Figure 1B, a significant difference 
in sensitivity for lova statin was observed for the AML CD34+ versus CD34- fraction. At 
50 μM, a median reduction of 30% in survival (range minus 24-54) was observed for 
the CD34+ cells compared to 12% (range minus 51-42) in the CD34- fraction (p=0.029). A 
similar pattern was also observed at 100 μM (43% versus 23%, p=0.029). Subsequently, 
we compared the AML subpopulations with the normal CD34+ and CD34- cell fractions 
and observed a significant increased lova statin sensitivity of the AML CD34- fraction 
compared to the normal the CD34- subpopulations (p=0.005; Figure 1). This was not 
noticed for the AML and normal CD34+ cell fractions (p=0.095). Based on the pattern 
of lova statin sensitivity of the normal CD34+ cells, two subgroups within the AMLs 
could be distinguished. Eleven AML CD34+ samples had a response pattern comparable 
to normal CD34+ cells, whereas six showed a reduced lova statin sensitivity (Figure 3; 
Table 1). A comparable pattern was observed for the AML CD34- fraction.
The combination of lova statin and chemotherapeutics potentiates cell death 
To evaluate whether the cytotoxic effects of two frequently used cytostatic agents, cyta-
rabine and daunorubicin, might be promoted by cotreatment with lova statin, the AML 
CD34+ and CD34- subfractions were incubated with varying concentrations of lova statin 
(25, 50, and 100 µM) in the presence or absence of varying concentrations of daunoru-
bicin (0.01-0.5 µM) or cytarabine (0.0001-0.1 mg/mL) for 24 hours. A dose-dependent 
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A BAML CD34+ cells AML CD34- cells
Figure 2. Effects of increasing concentrations of chemotherapeutic drugs on in vitro survival of subpopula-
tions of AML cells. CD34+ (A) and CD34- (B) AML cells of all patients (n=17) were incubated with lova statin 
in combination with variable concentrations of daunorubicin (0.01-0.5 μM). SEM are indicated.
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decrease in cell survival was seen as depicted in Figure 2, which was augmented by 
lova statin treatment. A median survival reduction of 21% (range minus 28-64%) was 
accomplished by exposing the AML CD34+ cells to 0.1 μM daunorubicin, which was 43% 
(range minus 56-78%) when the CD34+ AML cells were exposed to the combination of 
daunorubicin and 25 μM lova statin (Figure 2A). 
The combined use was slightly more effective in the CD34+ subpopulation 
compared to the CD34- subpopulation (Figure 2B; median 43% versus 36%) but the 



















































































































Figure 3. Effects of increasing concentrations of lova statin in combination with chemotherapeutic drugs on 
in vitro survival of CD34+ (A-C) and CD34- (D-F) normal and AML cells. Three groups are demonstrated in 
graphs 3A-F. Two AML patient groups (normal responders (n=13) and abnormal responders (n=4); in 
total: n=17) and a normal CD34+/- group (n=7) are shown. SEM are indicated.
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cytarabine (data not shown). However, also here within the group of AMLs, different 
subgroups could be distinguished when looking at cell survival. Most AML CD34+ cells 
with a reduced statin sensitivity demonstrated also a diminished susceptibility for the 
combined use of statins plus cytarabine or daunorubicin (Figure 3). To investigate 
whether the observed effects were also noticed in the most primitive AML cell popula-
tion, AML CD34+ cells were sorted into the CD34+CD38- cell fraction and the CD34+CD38+ 
fraction (n=7). Four AML samples belonged to the normal responder group and three 
samples to the abnormal responder group. As depicted in Figure 4, the same distinc-
tion in responsiveness to cytostatic agents was observed in the absence or presence of 
lova statin. Especially in the CD34+CD38- subfraction the discrepancy between normal 
versus abnormal responders was most noticeable (e.g., for ARA-C in combination 
with 25 μM lova statin, p=0.01 for CD34+CD38- versus p=0.2 for CD34+CD38+; for DNR, 
p=0.05 versus p=0.5). 








































































Figure 4. Effects of increasing concentrations of lova statin in combination with chemotherapeutic drugs on 
in vitro survival of sorted CD34+CD38- (A,B) and CD34+CD38+ (C,D) AML cells. Two groups are shown: normal 
responders (n=4) and abnormal responders (n=3). SEM are indicated.
Variable lova statin-response in CD34+ AML cells • 59
3
To verify whether similar results can be obtained in a clonogenic assay, normal 
and AML CD34+ cells were exposed to lova statin and/or cytostatic agents for 24 
hours and subsequently cultured in CFC medium. However, CD34+ cells from six out 
of seven AML samples did not show any in vitro colony formation in the CFC assay. 
Normal CD34+ cells (n=5) showed an inhibition of 12% and 8% with 25 μM lova statin 
or daunorubicin, respectively, which increased to 36% inhibition when both agents 
were used (p=0.01, data not shown). Comparable results were obtained cytarabine 
(28% versus 60%, p=0.04). 
Given the observed variability in effects of lova statin on the CD34+ AML cells, we 
questioned whether this might be explained by a difference in expression or modula-
tion of downstream targets. Therefore, the ABCG1 and ABCA1 mRNA expression levels 
were studied both in the normal responder and abnormal responder AML group and 
compared to normal CD34+ cells. A nonsignificant higher ABCG1 mRNA expression was 
observed in the normal responder AML group compared to the abnormal responder 
AML group and normal CD34+ cells. In addition, the lova statin-induced ABCG1 mRNA 
expression was studied in the different groups. No statistically significant difference 
was found between normal CD34+ cells (0.4 fold downregulation, range 0.29-0.36) 
versus the normal and abnormal AML responder group, 0.2 (range minus 0.16-0.53), 
and 0.5 fold (range 0.16-0.70) downregulation respectively. 
In vitro response pattern and clinical outcome
In view of the observed in vitro difference for statin sensitivity, we questioned whether 
these findings might correspond to patient characteristics or patient outcome. In the 
AML responder group, a normal or favorable cytogenetic pattern was found in 100% 
of the patients, whereas in the abnormal responder group, an unfavorable cytoge-
netic pattern was present in 50% of the patients. In the responder group, the median 
peripheral blast cell count at presentation was 16.6 × 109/L (range 2.2-128.3) and in 
the abnormal responder group 81.4 × 109/L (range 48.6-200, p=0.02). Based on these 
factors three prognostic risk groups can be defined, i.e., favorable risk (favorable 
cytogenetics in combination with a peripheral blood blast cell count <20 × 109/L at 
diagnosis), poor risk (those with poor-risk cytogenetics), and intermediate risk group 
(all others)17,18. In the responder group, 100% of the patients belonged to the good or 
intermediate risk group whereas in the abnormal responder group, this value was only 
50% (Table 1). These findings correlated with treatment results. Complete remission 
on intensive chemotherapy was attained in 91% of the patients in the AML normal 
responder group with an EFS of 12.5 months (range 1-37). In the abnormal responders, 
CR was attained in 17% of the patients with a EFS of 0 months (range 0-15).
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Discussion
In the present study, we analyzed the in vitro effect of lova statin on the survival of AML 
subpopulations in the absence or presence of conventional applied chemotherapeu-
tics. Thus far, in vitro studies on statins in AML have been focused on the total AML cell 
population6-9. However, information of well-defined subpopulations might provide 
additional information especially regarding the primitive CD34+ AML cells that are 
responsible for the ongoing in vivo propagation18,19. By studying two different subpop-
ulations of AML cells (primitive CD34+ cells and more mature CD34- cells), we were 
able to demonstrate a significant difference in lova statin susceptibility. The inhibitory 
effects of lova statin were especially observed on the primitive CD34+ subpopulation. 
The effects on the more mature CD34- subpopulation were less pronounced, suggesting 
that the primitive cell fraction is more dependent on cholesterol synthesis, which is in 
line with the high expression of ABC transporters in these cells. In addition, there were 
increased although variable inhibitory effects by the combined use of lova statin and 
cytotoxic agents in both the AML and normal CD34+ cells. 
Interestingly, we found that some AML CD34+ cells followed a response pattern 
similar to normal CD34+ cells whereas 35% of the AML CD34+ cells showed no change. 
This could not be reversed in a number of cases by co-exposure the cells to chemother-
apeutic agents. Interestingly, the distinction between normal and abnormal responders 
for the AML CD34+ fraction was most pronounced in the CD34+CD38- cell fraction, a 
population that is enriched for leukemic stem cells20. The difference in responsiveness 
between the normal and abnormal responder AML groups could not be explained by 
a difference in the percentage of AML CD34+ cells. In addition, no difference in suscep-
tibility for lova statin-mediated upregulation of ABCG1 mRNA was observed which is 
a major downstream target of lova statin. It is more conceivable that the difference 
is linked to additional cellular characteristics of the AML cells belonging to both 
groups. Patient characteristics demonstrated that the abnormal responder group had a 
significant higher peripheral blast cell count at presentation. Moreover the group was 
characterized by a high frequency of poor-risk cytogenetic abnormalities. The cause 
of the difference in susceptibility is not resolved but might be linked to differences 
in the farnesylation or geranylgeranylation pathways that are also affected by lova-
statin3,6. It has been demonstrated that statins disrupt the localization and function of 
isoprenylated molecules in the cell membrane3,6. This change will result in an altered 
GTPase function of the Ras or Rho signaling that has an important impact on cellular 
processes such as proliferation and survival21,22. Alternatively, the difference may be 
linked to an altered expression of anti-apoptotic proteins between both AML groups. 
It has been described that overexpression of Bcl-xL protects against statin-induced 
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apoptosis in murine tubular cells23. Both of these possible explanations are currently 
under evaluation. 
In summary, these results demonstrate distinct differences in lova statin suscepti-
bility between CD34+ and CD34- in the normal and leukemic counterpart and between 
different AML subtypes. Additional studies will clarify whether the described in vitro 
assay can be used for in vivo identification of patients that might benefit from applica-
tion of statins in combination with chemotherapeutic agents.
acknowledgments
We thank Bart-Jan Wierenga for his help with the cell viability assay. 
62 • Chapter 3
References
1.  Peeters SD, van der Kolk DM, de Haan G, Bystrykh L, Kuipers F, de Vries EG et al. Selective 
expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous 
expression pattern in AML cells. Exp Hematol 2006; 34: 622-630.
2.  de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ 
et al. Preferential expression of a high number of ATP binding cassette transporters in both normal 
and leukemic CD34+. Leukemia 2006; 20: 750-754.
3.  Wong J, Quinn CM, Brown AJ. Statins inhibit synthesis of an oxysterol ligand for the liver x 
receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc 
Biol 2004; 24: 2365-2371.
4.  Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill 
acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol 
responses. Blood 2003; 101: 3628-3634.
5.  Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA. Cholesterol synthesis and 
import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004; 
104: 1816-1824.
6.  Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH et al. Increased 
sensitivity of acute myeloid leukemias to lova statin-induced apoptosis: A potential therapeutic 
approach. Blood 1999; 93: 1308-1318.
7.  Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes 
acute myelogenous leukemia cells to lova statin-induced apoptosis. Cancer Res 2004; 64: 6461-6468.
8.  Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. Lova statin induced control of blast cell growth 
in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 2001; 40: 659-662.
9.  Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE. Mevastatin can increase toxicity 
in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated 
with ras hotspot mutations or overexpression. Leuk Res 2003; 27: 133-145.
10.  Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S et al. Blockade of adaptive 
defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to 
idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007; 109: 2999-3006.
11.  van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, Schuringa JJ. Establishing 
long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 
2007; 35: 1538-1549.
12.  Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health 
Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report 
of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 
1999; 17: 3835-3849.
13.  Schepers H, van GD, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E. STAT5 is required for 
long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007; 110: 
2880-2888.
14.  Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E et al. Value of 
different modalities of granulocyte-macrophage colony-stimulating factor applied during or after 
induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15: 3496-3506.
15.  Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF et al. The 
value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk 
myelodysplastic syndromes and AML in elderly patients. Blood 2004; 103: 2908-2913.
16.  Daenen SM, de Wolf JThM, Vellenga E, van Imhoff GW, van den Berg-de Ruiter E, Smit JW. 
6-Mercaptopurine, still valuable for the palliative treatment of acute myeloid leukemia. Hematol 
Variable lova statin-response in CD34+ AML cells • 63
3
2001; 6: 231-240.
17.  Breems DA, Boogaerts MA, Dekker AW, van Putten WL, Sonneveld P, Huijgens PC et al. 
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult 
patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective 
randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for 
Clinical Cancer Research (SAKK) trial. Br J Haematol 2005; 128: 59-65.
18.  Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive 
leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 
3142-3149.
19.  Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic 
stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007; 62: 214-226.
20.  Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from 
a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
21.  Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. 
Annu Rev Biochem 1996; 65: 241-269.
22.  Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell 
growth by farnesyltransferase inhibitors. Cancer Res 1999; 59: 5492-5496.
23.  Blanco-Colio LM, Justo P, Daehn I, Lorz C, Ortiz A, Egido J. Bcl-xL overexpression protects from 
apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. Kidney Int 2003; 64: 
181-191.

  4Combining simva statin with the farnesyl-transferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ AML samples
Karen van der Weide
Susan D. P. W. M. de Jonge-Peeters
Folkert Kuipers
Elisabeth G. E. de Vries
Edo Vellenga
Clin Cancer Res 2009; 15: 3076-3083
66 • Chapter 4
Abstract
Purpose: To show whether the inhibitory effects of the cholesterol synthesis inhibitor 
simva statin on human CD34+ acute myeloid leukemia (AML) cells can be further 
promoted by combining it with the farnesyltransferase inhibitor tipifarnib. Experi-
mental design: Normal CD34+, AML CD34+ and CD34- sorted subfractions, and AML cell 
lines (TF-1 and KG1a), were exposed to simva statin and tipifarnib. Results: Both simva-
statin and tipifarnib showed a cytotoxic effect on AML cell lines, which was additive 
when used in combination. In primary sorted CD34+ AML cells a heterogeneous 
response pattern was observed upon treatment with simva statin when analyzing cell 
survival. A group of normal (n=12) and abnormal (n=10) responders were identi-
fied within the AML CD34+ subfraction when compared with normal CD34+ cells. This 
distinction was not observed within the AML CD34- cell fraction. When the CD34+ AML 
cells were exposed to simva statin and tipifarnib, a significant enhanced inhibitory 
effect was shown exclusively in the normal AML responder group, whereas the AML 
CD34- cell fractions all showed an enhanced inhibitory effect. The observed heteroge-
neity in AML responsiveness could not be explained by differences in effects on choles-
terol metabolism genes or extracellular signal-regulated kinase phosphorylation in 
response to simva statin and tipifarnib treatment. Conclusion: The results suggest that 
combined treatment with statins and farnesyltransferase inhibitors may be beneficial 
for a subset of AML patients that can be defined by studying the AML CD34+ fraction.
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Introduction
Acute myeloid leukemia (AML) is a clonal hematopoietic disease, characterized by 
the accumulation of immature myeloid blasts in the bone marrow. A minor tumor 
subpopulation with self-renewal potential, referred to as leukemic stem cells is respon-
sible for the sustained expansion of the leukemia1,2. Thus far, these leukemic stem cells 
are phenotypically characterized by CD34+CD38- 3,4, but a recent study has challenged 
this view suggesting that leukemic stem cells might also belong to the CD34+CD38+ 
cell fraction5. 
Cholesterol synthesis and the processing of low-density lipoprotein (LDL) is hyper-
active in AML6,7, as indicated by high mRNA levels of 3-hydroxy-3-methylglutaryl coA 
reductase (HMG-CoAR) and LDL receptor (LDLR) as well as LDL uptake studies. These 
findings are in line with the high expression of key genes of cholesterol metabolism in 
CD34+CD38- AML cells8. In addition, AML cells possess several mechanisms to protect 
them against the cytotoxic effects of chemotherapeutics, including a rapid increase in 
their cellular cholesterol levels after exposure to chemotherapeutic drugs9,10. Therefore, 
interfering with this protective mechanism potentially offers the opportunity to 
improve standard antileukemic treatment. 
Statins, targeting HMG-CoAR, are widely used plasma cholesterol-lowering drugs. 
Statins inhibit cholesterol synthesis at the level of the conversion of mevalonate and, 
as a consequence, also inhibit the production of various byproducts of the mevalonate 
pathway. These byproducts include farnesyl and geranylgeranyl isoprenoids that are 
involved in the signaling of GTPases, including the small G protein Ras9,11. Ras GTPases 
must be transferred from the cytoplasm to the plasma membrane by isoprenylation to 
allow them to function as signal transducers12-14. Inhibiting farnesylation is of interest, 
because farnesylated proteins, particularly the protein products of the RAS gene family, 
are frequently activated in AML; e.g., by RAS mutations or due to the autocrine or 
paracrine production of growth factors15. However, the statin concentrations necessary 
to inhibit specific protein isoprenylation are 100-fold to 500-fold higher than those 
required to inhibit cholesterol synthesis16. 
The specific inhibition of Ras farnesylation can also be realized by the use of the 
Ras inhibitor tipifarnib. Tipifarnib is an oral nonpeptidomimetic Ras inhibitor, which 
selectively inhibits intracellular farnesyltransferase (FTase). Both statins as well as tipi-
farnib have been investigated as single agents in AML patients17-21, resulting in modest 
response rates. Because alternative prenylation by geranylgeranyltransferase may 
bypass the inhibitory effect of tipifarnib22 and statins are capable of blocking both gera-
nylgeranylation and farnesylation, it is tempting to speculate that the combined use 
might have a more pronounced antileukemic effect. Therefore, sorted AML CD34+ cells, 
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enriched for leukemic stem cells, were exposed to the cholesterol synthesis inhibitor 
simva statin, the Ras inhibitor tipifarnib or to both compounds, and the findings were 
compared with normal CD34+ cells. The results show that, given the heterogeneous 
response pattern between patient AML samples, a combination treatment with statins 
and farnesyltransferase inhibitors may be beneficial for around 50% of AML patients.
Materials and methods 
Normal and AML hematopoietic cells and cell lines
Normal mobilized peripheral CD34+ blood cells were collected from either healthy 
donors or patients awaiting autologous stem cell transplantation undergoing granulo-
cyte colony-stimulating factor treatment, in accordance with institutional guidelines. 
After informed consent, bone marrow or peripheral blood cells were collected from 
AML patients at diagnosis. The Medical Ethical Committee of the University Medical 
Center Groningen (the Netherlands) approved the protocol. Patients were classified 
according to the French-American-British AML classification23. Mononuclear cells 
were enriched by density gradient centrifugation (Lymphocyte Separation Medium 
LSM 1077; PAA Laboratories GmbH, Cölbe, Germany) and freshly used or cryopre-
served in RPMI 1640 (BioWhittaker, Brussels, Belgium) supplemented with 10% 
v/v fetal calf serum (FCS; Hyclone, Logan, UT) and 10% dimethyl sulfoxide (Merck, 
Amsterdam, the Netherlands), and stored at –196ºC. Prior to analysis, the mono-
nuclear cells were thawed, treated with DNase (Boehringer Mannheim, Almere, the 
Netherlands), washed, and incubated in RPMI 1640, supplemented with 10% FCS, 100 
U/mL penicillin, and 100 μg/mL streptomycin (ICN, Zoetermeer, the Netherlands), at 
37°C and 5% CO2. Cytogenetic analysis was done as described earlier24. The normal 
and AML samples were incubated with a fluorescein isothiocyanate (FITC)-conjugated 
antibody against CD34 and phycoerythrin (PE)-conjugated antibodies against CD14 
and CD15 (Becton Dickinson, Alphen aan den Rijn, the Netherlands). Sorting of CD34+ 
and CD34-(CD14+CD15+) was done with the use of a MoFlo cell sorter (DakoCytoma-
tion, Carpinteria, CA). 
The human AML cell line KG1a was cultured in Iscove’s Modified Dulbecco’s 
Medium (PAA Laboratories GmbH) supplemented with 10% FCS and 2 nM L-glutamine 
(ICN). The human erythroleukemic cell line TF-1 was cultured in RPMI 1640 supple-
mented with 10% FCS and 10 ng/mL granulocyte macrophage colony-stimulating 
factor (GM-CSF; Genetics Institute Inc, Cambridge, MA). Cultures were kept at 37°C 
and 5% CO2.
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Reagents
Simva statin was obtained as a sodium salt from Merck Chemical Ltd. (Nottingham, 
UK) and dissolved in DMSO to obtain a 50 mM stock solution. R115777 (Tipifarnib, 
Zarnestra) was provided by Janssen Research Foundation and dissolved in DMSO to 
obtain a concentration of 10 mM. 
Cell viability assay, annexin V and propidium iodide assay and cell-cycle analysis
Cell viability assays were done in duplicate according to the manufacturer’s instruc-
tions with the use of the Cell Titer-Glo Luminescent cell viability assay (Promega, 
Madison, WI). Plates (96-well) were prepared with 100 μL RPMI 1640 medium supple-
mented with 10% FCS, and up to 10,000 cells per well were added (cell lines) or sorted 
(CD34+ and CD34- AML cells). The cells were incubated with different concentrations of 
simva statin (5, 25 and 50 μM) with and without different concentrations of tipifarnib 
(0.2- 5 μM) with the use of easy load pipet tips (Greiner Bio-One, Alphen aan den Rijn, 
the Netherlands) and analyzed after 24 (cell lines) or 48 (AML cells) hours. 
Cell death was assessed with the use of an annexin V staining kit (IQ products, 
Groningen, the Netherlands) according to the manufacturer’s recommendations. 
Briefly, after 48 hours of treatment with different concentrations of simva statin 
and/or tipifarnib, cells were harvested, resuspended in 60 μL calcium buffer containing 
3 μL of annexin V-FITC and incubated for 20 minutes at 4°C in the dark. Cells were 
washed with 2 mL calcium buffer and subsequently resuspended in 200 μL containing 
1.7 μL propidium iodide (PI, Sigma). Binding of FITC-conjugated annexin V and PI 
was measured by fluorescence-activated cell sorting (FACS) analysis on a FACScalibur 
(Becton Dickinson). Data were analyzed with the use of Winlist 3D (Verity Software 
House, Topsham, ME).
Cell-cycle analysis was done by determining the DNA content of cells by staining 
with PI (IQ products) in sodium citrate (1 mg/mL; Sigma-Aldrich, Zwijndrecht, the 
Netherlands) containing 100 μg/mL RNase A (Sigma-Aldrich), 20 μg/mL PI and 0.1% 
Triton X-100 (Sigma-Aldrich) for 60 minutes at room temperature. PI fluorescence 
was analyzed by FACS analysis. Cell cycle distributions were calculated with ModFit LT 
(Verity Software House).
Western blotting 
TF-1 cells were treated in GM-SCF-free medium for 48 hours with simva statin and/or 
tipifarnib, after which GM-CSF (10 ng/mL) was added for 15 minutes. Unsorted mono-
nuclear AML cell fractions were cultured in RPMI 1640 supplemented with 10% FCS 
and treated for 24 hours. Whole cell extracts were obtained by lysing 5 × 105 cells in 
boiling Laemmli sample buffer for 5 minutes. Samples were separated by 10% SDS-PAGE 
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and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA) 
in Tris-buffer with the use of a semidry electroblotter from Bio-Rad Laboratories 
(Veenendaal, the Netherlands). Membranes were probed with antibodies according to 
the manufacturer’s protocols. The antibodies used were extracellular signal-regulated 
kinase (ERK) 1/2 (K23; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and phospho-
ERK1/2 (Thr202/Tyr204; Cell Signaling Technology Inc., Beverly, MA). Immunodetec-
tion of phospho-ERK and total ERK was done according to standard procedures, and 
binding of antibodies was detected by enhanced chemiluminescence. Densitometry 
was carried out with the use of ImageJ.
Quantitative real-time PCR
Total RNA was isolated with the use of the RNeasy mini kit (Qiagen, Venlo, the Nether-
lands) and was reverse transcribed with the use of RevertAid™ H Minus M-MuLV reverse 
transcriptase (Fermentas, St Leon-Roth, Germany). Quantitative PCR was done with 
the use of the ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, 
CA). Primers and probes for the human ATP-binding cassette (ABC) transporters and 
cholesterol metabolism genes were used as described before8,25. As endogenous control, 
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used. 
The primers were obtained from Invitrogen (Breda, the Netherlands). The probes were 
labeled by a 5’ 6-carboxyfluorescein (FAM) reporter and quenched by 6-carboxytetra-
methylrhodamine (TAMRA) at its 3’ end (Eurogentec, Maastricht, the Netherlands). We 
used 4 μL of diluted cDNA in each PCR reaction in a final volume of 20 μL, containing 
900 nM of sense and antisense primers, 200 nM of the Taqman probe, 5 mM MgCl2, 
KCl, TrisHCl, 0.2 mM dATP, dCTP, dGTP, dTTP, and dUTP, and 0.5 U of AmpliTaq DNA 
polymerase (qPCR Core Kit, Eurogentec). The PCR program was 95°C for 10 minutes, 
followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. The expression of the 
genes was standardized for the expression of GAPDH. Serial cDNA dilutions of the AML 
samples were used to generate calibration curves. The expression of each gene in each 
sample was analyzed in duplicate. 
Statistical analysis
Student’s t-test was used to calculate the differences between cell line samples; Fried-
man’s and Mann-Whitney’s nonparametric tests were done to calculate signifi-
cant differences between AML samples. Data were expressed as mean ± SD or SEM, 
as indicated. All p values are given for two-sided tests and p≤0.05 was considered 
significant. Additivity was defined as an increased effect of the combination exposure 
compared with the single exposure of simva statin or tipifarnib. Normal CD34+ AML 
responders were defined as follows: at the concentration of either simva statin or 
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tipifarnib at which the first significant effect was observed (i.e., 25 μM simva statin and 
1 μM tipifarnib) with the use of the cell viability assay, the decrease in viability of the 
normal CD34+ cells ± standard deviation was considered as normal. AML CD34+ cells 
with viabilities above this value were considered to give an abnormal response. 
Results 
Patient characteristics
The 22 AML patients studied, with a median age of 52 years (range 19-79), were clas-
sified as the French-American-British classification groups M0 (n=1), M1 (n=6), M2 
(n=5), and M4/5 (n=10). The clinical characteristics of the patients are shown in Table 1. 














simva + tipi in 
CD34+ cells‡
1 M2 56 29 N Yes Yes
2 M1 200 87 inv(3q),7-,10- Yes Yes
3 M5 109 1 ND Yes Yes
4 M5b 25 28 N Yes Yes
5 M5b 97 15 N Yes Yes
6 M4 89 43 inv(16) Yes Yes
7 M1 128 24 N Yes Yes
8 M2 7 28 N Yes Yes
9 M1 17 40 N Yes Yes
10 M1 36 80 N Yes No
11 M5 102 60 inv(16) Yes No
12 M2 2 36 N Yes No
13 M4/M5 50 7 N No Yes
14 M5 67 8 3q-, 5q+,+8 No Yes
15 M5b 220 23 t(11;20) No No
16 M2 59 17 del9 q12q22 No No
17 M2 10 23 N No No
18 M1 64 35 t(6;9), trisomy 13 No No
19 M1 96 92 N No No
20 M5a 49 85 N No No
21 M0 102 90 5q-, trisomy 6 No No
22 M5a 8 11 46N,xy +11q23 No No
* Percentage of CD34+ cells in the AML mononuclear cell fraction.
† Cytogenetics: N: normal; inv: inversion; ND: not determined.
‡ Normal responders (Yes) and abnormal responders (No) to simva statin and tipifarnib were defined 
as described in materials and methods. 
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The median peripheral blast cell count at diagnosis was 62 × 109/L (range 2-220). The 
majority of patients were treated according to ongoing HOVON protocols, i.e., for 
patients <60 years the HOVON SAKK AML-42 study26 and for patients >60 years the 
HOVON 43 study27. Palliative treatment consisting of treatment with 6-mercaptopu-
rine28 was given to patients who were ineligible for intensive chemotherapy (n=3). 
Tipifarnib and simva statin decrease cell viability by inducing apoptosis and cell cycle 
arrest
First, the effects of tipifarnib and simva statin on the hematopoietic cell lines KG1a and 
TF-1 were assessed. With simva statin alone, a dose-dependent decrease in cell survival 
of up to 30% was shown (Figure 1) in both cell lines. Similar results were obtained with 
tipifarnib (up to 60% decrease of survival), whereas the combined use showed an even 
more efficient decrease of up to 75% in cell viability, which was additive compared with 
either treatment alone. To define whether this decline in cell survival was due to cell 
cycle arrest or apoptosis, cell cycle status and cell survival were defined by PI staining 
and an annexin V/PI assay, respectively. Treatment of TF1 cells with tipifarnib increased 
the number of cells in the G2/M cell cycle phase (9% versus 27% at 0.2 μM; p=0.002), 
and lowered the number of cells in the G0/G1 phase (51% versus 36% at 0.2 μM; 
p=0.049; Figure 2A). Cells in S phase remained the same. Treatment with 50 μM simva-
statin resulted in fewer cells in the S phase (40% versus 24%) and more in G0/G1 (51% 
versus 69%; Figure 2A), but these differences did not reach significance (p=0.2). When 
combining both treatments, we observed an inhibitory effect on the cells in the S phase 
(p=0.02), and there were more cells in G0/G1 phase (p=0.09) or G2/M phase (p=0.05) 
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Figure 1. Cell viability of TF-1 (A; n=4) and KG1a (B; n=2) treated for 48 hours with tipifarnib, simva statin, or the 
combination. Data are shown as the percentage of ATP levels compared with control cells. Data shown 
are mean values ± SD, *p<0.05, **p<0.001; †addition.
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In KG1a cells, we observed similar effects: combination of both treatments resulted 
in an increase of cells in G0/G1 phase (Figure 2B; 47% versus 64% at 50 μM simva-
statin and 5 μM tipifarnib; p=0.002) and a decrease of cells in S phase (41% versus 25%; 
p<0.001). Thus, treatment of TF-1 and KG1a cells with simva statin and tipifarnib results 
in a G0/G1 cell cycle arrest. It seemed that this cell cycle arrest was associated with an 
increased number of cells in apoptosis, which was especially noticed for the TF-1 cell line 
(Figure 2C,D). Also here we found additive effects when combining both treatments.
The effect of simva statin and tipifarnib on primitive CD34+ normal and AML cells
To show whether in patient AML cells comparable effects can be noticed, AML mono-
nuclear cells (n=22) were sorted into CD34+ and CD34- subfractions and exposed to the 
two agents. The results were compared with the effects seen in normal CD34+ (n=8). 
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Figure 2. The effect of simva statin and tipifarnib on cell cycle status and cell death in TF-1 and KG1a cells after 
48 hours of treatment. Percentage of TF-1 (A) and KG1a (B) cells in G0/G1, S and G2/M phases are shown 
after treatment with either tipifarnib or simva statin alone, or after combination treatment. Data are 
shown as a mean of 3 independent experiments. The effect of simva statin and tipifarnib treatment cell 
death in TF-1 (C) and KG1a (D) cells after 48 hours of treatment. Data are represented as a percentage of 
(late) apoptotic cells. The average results of five and four independent experiments are shown for TF-1 
and KG1a, respectively. *p<0.05; †addition.
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cells showed a concentration-dependent decrease in cell survival, which was signifi-
cant at a concentration of 25 μM simva statin (p<0.001) and 1 μM tipifarnib (p=0.01). 
Treatment of normal CD34+ cells with 25 μM simva statin in combination with tipi-
farnib showed an additive inhibitory effect on cell survival compared with the effects 
of the separate compounds (Figure 3B). However, within the CD34+ AML cell fraction, a 
marked variability in responsiveness could be observed. Based on the response pattern 
of normal CD34+ cells, two AML subgroups could be distinguished (see materials and 
methods) when the CD34+ AML cells were exposed to simva statin. Fifty-five percent 
(n=12) of the AML CD34+ cells had a response pattern comparable to normal CD34+ 
(e.g., p=0.6 at 25 μM) whereas 45% (n=10) of the AML CD34+ cells showed reduced 
simva statin sensitivity (Figure 3A; e.g., p=0.003 at 25 μM). In contrast, the CD34- AML 
subfraction showed a response pattern comparable to normal CD34+ cells, and no 
difference was observed between normal and abnormal responders within CD34- AML 
cells (e.g., p=0.6 at 25 μM). 



































































Figure 3. Effect of simva statin and tipifarnib on in vitro survival of normal and AML CD34+ (A, B) and CD34- (C, 
D) AML cells. Two groups of AML patients, consisting of either normal or abnormal responders, and a 
control group are shown. The responder group is defined as having a decrease in cell viability which is 
mean ± SD of control cells at 25 μM simva statin or 25 μM simva statin + 1 μM tipifarnib. Normal CD34+ 
cells (PBSCs) n=8; AML normal responders n=12 (A) or n=11 (B); AML abnormal responders n=10 (A) or 
n=11 (B). SEM is indicated. *p<0.05 and **p<0.01 normal versus abnormal responder; †p<0.01 versus 25 
μM simva statin alone.
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Next, we studied whether the suppressive effects of simva statin on AML cells can 
further be promoted by cotreatment with tipifarnib as shown for normal CD34+ cells. 
The results show that 50% (n=11) of the AML CD34+ cells had a response pattern compa-
rable to normal CD34+ cells, whereas the other half of the AML CD34+ cells showed 
reduced sensitivity for the combined treatment of simva statin (25 μM) and tipifarnib 
(1 μM; Figure 3B; p<0.001). It appeared that 8 of 10 of the AMLs that were not respon-
sive to simva statin were also not affected when both compounds were used. When the 
abnormal responder group was exposed to 1 μM tipifarnib and 25 μM simva statin, the 
decrease in cell survival was not enhanced compared with the effect of simva statin 
alone (p=0.5). In contrast, in the AML CD34+ responder group, a significant enhance-
ment in cell death was observed when both compounds were used at low dose (1 μM; 
p=0.01). At higher concentrations, a strong reduction in cell survival was observed in 
normal CD34+ cells, as well as in the AML abnormal and normal responder group, but 
these concentrations are physiologically not relevant. The AML CD34- subpopulation 
showed a comparable response pattern to normal CD34+ cells, and no clear distinction 
could be made between responders and abnormal responders when both compounds 
were used (p=0.03 and p=0.05 for 0.2 μM and 1 μM tipifarnib, respectively; Figure 3D).
Heterogeneity in AML response pattern is not related to differences in modulation of 
cholesterol metabolism genes and ERK phosphorylation by simva statin and tipifarnib
To investigate whether the functionality of either simva statin or tipifarnib was 
different in the normal versus the abnormal responder group, we studied important 
downstream targets of simva statin and tipifarnib. The functionality of simva statin was 
tested based on reported upregulation of HMG-CoAR and LDLR and a downregulation 
of ABCA1 and ABCG1 at the mRNA level29,30, whereas the downstream effects of tipi-
farnib were analyzed by studying the change in ERK1/2 phosphorylation, a downstream 
target of Ras. In the 6 AML samples (3 normal responders and 3 abnormal responders 
to simva statin, tipifarnib, and both drugs) studied, the expression of HMG-CoAR and 
LDLR was almost 2.5-fold higher after treatment with 25 µM simva statin (Figure 4A; 
p=0.001 and p=0.003, respectively), and ABCA1 and ABCG1 expression was 2-fold 
decreased (p<0.001). Treatment with tipifarnib did not alter mRNA expression, and 
the combination of tipifarnib and simva statin had no additive effect compared with 
treatment with simva statin alone (data not shown). 
Tipifarnib (0.5 and 1 µM) did not affect ERK phosphorylation in any of the studied 
AMLs of the normal responder or abnormal responder group (Figure 4B). Also simva-
statin did not lead to inhibition of ERK-phosphorylation. However, combining simva-
statin and tipifarnib resulted, in 69% of the 16 tested AML samples, in a decrease of 
phospho-ERK expression (88% ± 10% for 1 μM tipifarnib and 25 μM simva statin; n=11) 
76 • Chapter 4



















0         0       0.5       1        0.5        1  
0       25        0         0        25    25
0         0        0.5        1        0.5        1  
0        25        0          0        25      25Simvastatin (μM)
Tipifarnib (μM)
Abnormal responder Normal responder
pERK
tERK
- 0.2    0.5     1        5      - - - 0.2   0.5      1       5








Figure 4. Effect of simva statin and tipifarnib on mRNA expression levels and ERK phosphorylation in primary 
AML samples and TF-1 cells. (A) Cells were treated for 24 hours with 25 μM simva statin. mRNA expression 
levels of cholesterol metabolism genes in total mononuclear cell (MNC) fractions of normal (n=3) and 
abnormal (n=3) responder AML samples are shown. Results are displayed as mean ± SD, compared with 
untreated cells, which were set to 1. Data were normalized to GAPDH. (B) Effects of tipifarnib and simva-
statin on phosphorylation of ERK in AML samples. The total MNC fraction was incubated with 0.5 and 1 
μM tipifarnib and/or 25 μM simva statin for 48 hours before harvesting. Anti-ERK was used as a loading 
control. This experiment is representative of 7 abnormal responder and 4 normal responder AMLs. 
(C). Effects of tipifarnib and simva statin on phosphorylation of ERK in TF-1 cells. Cells were deprived 
of GM-CSF, incubated with tipifarnib and simva statin for 48 hours, and stimulated with GM-CSF for 15 
minutes. ‘Unst’ indicates unstimulated cells. Anti-ERK was used as a loading control.
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irrespective of the AML used. Similar results were observed when TF-1 cells were 
cultured with GM-CSF and incubated with simva statin and tipifarnib (Figure 4C).
In vitro response pattern and patient characteristics 
In view of the observed in vitro difference for simva statin and tipifarnib sensitivity we 
questioned whether these findings might correspond to patient characteristics. In the 
group responding in vitro to both tipifarnib and simva statin, the median percentage 
of CD34+ cells in the AML mononuclear cell fraction at presentation was 28% (mean 
28; range 1-87), and in the non-responder group 50% (mean 36; range 11-92; p=0.08; 
Table 1). No correlation was found between AML responder groups and cytogenetics 
and peripheral blast count. The French-American-British classifications were distrib-
uted equally over the normal and abnormal responder groups.
Discussion 
In this study, we addressed the question of whether the combined use of a choles-
terol synthesis inhibitor and a farnesyltransferase inhibitor might have an augmented 
cytotoxic effect on CD34+ AML cells. The results show that, in human CD34+ AML 
leukemic cell lines, simva statin and tipifarnib have an enhanced suppressive effect 
on cell survival compared with either compound alone, which was characterized by 
an inhibition of cell cycle progression and enhanced apoptosis. Several studies have 
shown that geranylgeranylated proteins, not farnesylated proteins, are required for 
the G1 to S phase transition31 and that statins are able to block cell cycle in G1 due 
to geranylgeranylation rather than farnesylation32. Apparently, this mechanism varies 
among different cell types. We observed G1 cell cycle arrest after treatment with both 
simva statin and tipifarnib, whereas only a limited effect was observed with either 
compound alone. This suggests that farnesylated proteins are also responsible for cell 
cycle progression in AML cells. Likewise, ERK phosphorylation was strongly inhibited 
only when both simva statin and tipifarnib were used. It may be that geranylgeranyla-
tion of Ras can overcome the inhibitory effects of tipifarnib on Ras farnesylation, and 
both geranylgeranylation and farnesylation must be blocked to decrease Ras activa-
tion. This is consistent with the idea that K-Ras and N-Ras can be both farnesylated 
and geranylgeranylated22. 
In contrast with AML cell lines, the observed inhibitory effect of simva statin and tipi-
farnib was not found to be a general phenomenon for all primary AML samples. Most 
studies on statins have been focused on the total AML mononuclear cell fraction33-35. In 
the total mononuclear AML fraction a heterogeneous response to lova statin has been 
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observed33. Our data show that a heterogeneous response also exists within the more 
homogeneous primitive AML CD34+ subfraction. Two subgroups could be defined 
based on sensitivity to simva statin alone. Almost 50% of the AML CD34+ showed a 
reduced sensitivity to simva statin, tipifarnib, or to both compared with normal CD34+ 
cells, whereas the remaining AML samples showed a response pattern comparable to 
normal CD34+ cells. 
A remarkable finding was the fact that, within the AML CD34- subpopulation, no 
distinction could be made between normal and abnormal responders. These findings 
show that immature AML cells are intrinsically different from the CD34- cell popula-
tion. This is in line with previous studies showing that the total AML cell fraction is 
a heterogeneous cell population3,36, that leukemic stem cells belong to the CD34+ cell 
population1,37, and that CD34+ AML cells have almost exclusive self-renewal properties 
as defined in long-term cell culture assays as well as engraftment studies in severe 
combined immunodeficient mice38,39. Moreover, it shows that by using the total mono-
nuclear cell population, the differences in response would have been unnoticed, espe-
cially when the total AML cell fraction comprises a low percentage of CD34+ cells.
Several clinical studies have already been done with either statins or with tipi-
farnib17,19-21,40. In AML, statins have been combined with intensive chemotherapy 
whereas tipifarnib has been used as single agent. Phase 1 and 2 studies have shown 
that only a minority of the patients were responsive to treatment. Likewise, the results 
of the present study suggest that, in vitro, not all AML patients are responsive to clini-
cally relevant concentrations of simva statin and tipifarnib17,19, and that this distinction 
can be made by using exclusively the CD34+ fraction. Therefore, it might be useful to 
determine whether the in vitro response is predictable for clinical response in order to 
be able to select patients who are eligible for treatment.
Importantly, to be able to predict response, the rationale behind the difference 
in susceptibility of AML cells to simva statin and tipifarnib should be elucidated. We 
observed a considerable overlap between the simva statin and tipifarnib responders, 
and no differences on studied downstream targets of simva statin and tipifarnib were 
observed, suggesting that there might be a common mechanism of resistance. 
It is conceivable that a specific set of anti-apoptotic proteins are responsible for 
the differences in response. It has been shown that sorted CD34+ AML cells are more 
resistant to (spontaneous) apoptosis than the corresponding CD34- fractions, which 
is paralleled by higher Bcl-2, Bcl-xL, Mcl-1, P-gp, and low Bax expression levels41. In 
addition, it has been shown that overexpression of Bcl-xL and Bcl-2 protects against 
statin-induced apoptosis42,43. It is unlikely that simva statin and tipifarnib responsive-
ness correlates with the Ras activity status of the AML cells, because both normal and 
abnormal responders show a basal phosphorylation level of ERK and a decrease of 
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ERK activity upon combination treatment, which is in line with the results of Stirewalt 
et al.11, who suggested that neither Ras mutations, nor high Ras protein expression 
are found to be consistently associated with increased statin sensitivity. Likewise, in 
clinical studies using tipifarnib in AML, the Ras mutational status and inhibition of 
phophorylated ERK did not correlate with clinical responsiveness to tipifarnib19,20. 
Thus far, the clinical data on the use of either agent are encouraging, but not 
convincing. Because we observed in vitro significant cytotoxic effects in an AML 
subgroup with clinically achievable concentrations, we predict that combining both 
agents in vivo will be advantageous in a subset of AML patients.
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Abstract
3-Hydroxy-3-methylglutaryl CoA reductase is the rate-controlling enzyme of the 
mevalonate pathway that yields cholesterol as well as isoprenoids, such as farnesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Inhibition of 
HMG-CoAR activity by statins revealed differences in cytotoxic effects among patients 
with acute myeloid leukemia (AML). We studied the mechanism underlying this 
hetero geneity by comparing AML cells with different sensitivities to simva statin and 
showed that heterogeneity in simva statin-induced cytotoxicity was not due to differen-
tial effects on cholesterol synthesis. Yet, simva statin-induced cytotoxicity in sensitive 
cell lines (half maximal effective concentration (EC50) 1-5 µM), and in a subset of 
patient AML samples (n=11) could effectively (up to 100%) be prevented by cotreatment 
with FPP and GGPP, whereas insensitive cell lines (EC50 50-100 µM) were not notably 
protected (maximal 33%). Similarly, inhibition of isoprenylation in AML cell lines by 
either simva statin or specific inhibitors of the isoprenylation pathway demonstrated 
that the heterogeneity in response to simva statin was related to the extent of isopre-
nylation inhibition and to sensitivity to ERK inhibition. These data indicate that inter-
ference with the Ras-isoprenylation route, rather than with the cholesterol synthesis 
route, determines simva statin-induced cytotoxicity in AML, which may provide means 
to predict its clinical usefulness in AML patients.
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Introduction
Acute myeloid leukemia (AML) is characterized by the accumulation of immature 
myeloid blasts in the bone marrow. Different mechanisms have been identified that 
protect AML cells against cytotoxic actions of chemotherapy, including dysregula-
tion of cellular cholesterol homeostasis1,2. Both synthesis and influx of cholesterol 
are increased in AML cells, as indicated by increased 3-hydroxy-3-methylglutaryl CoA 
reductase (HMG-CoAR) and low-density lipoprotein receptor (LDLR) mRNA expression 
and protein activity in these cells3-5. In addition, AML cells increase their cholesterol 
contents upon in vitro exposure to chemotherapeutic drugs, which might render them 
less susceptible to the effects of these cytotoxic agents1,6. Therefore, interfering with 
cholesterol metabolism, by using statins to suppress cholesterol synthesis, has been 
proposed as an opportunity to improve antileukemic treatment.
Statins (e.g., simva statin) are widely used plasma cholesterol-lowering drugs, that 
inhibit cholesterol synthesis at the level of HMG-CoAR by blocking the conversion of 
HMG-CoA to mevalonate (Figure 1). Mevalonate is also precursor of isoprenoids such 
as farnesyl and geranylgeranyl. Farnesylation or geranylgeranylation, collectively 
referred to as isoprenylation, is required for the attachment of small GTPases (e.g., Rho, 
Ras) to the plasma membrane and their subsequent participation in signal transduc-
tion pathways that regulate growth and survival. Examples hereof are the PI3K/Akt and 
Ras/MEK/ERK pathways1,7,8. Isoprenylation is catalyzed by geranylgeranyltransferase 
(GGTase) or farnesyltransferase (FTase)9,10. Whereas Rho only undergoes geranylgera-
nylation, H-Ras can be farnesylated and N-Ras and K-Ras can be both farnesylated 
and geranylgeranylated11,12. Particularly the protein products of the RAS gene family 
are frequently activated in AML cells by mutations or due to autocrine or paracrine 
production of growth factors13.
Statins induce cell death in various human AML cell lines as well as in primary 
human AML cells in vitro14-18. Different mechanisms can be responsible for simva statin-
mediated cell death. Simva statin may exert its cytotoxic effects by blocking choles-
terol synthesis, or by inhibiting the actions of signaling molecules, such as Ras, by 
preventing their isoprenylation1,7,19,20. However, the exact mechanism of simva statin-
induced cytotoxicity has remained elusive thus far.
We recently observed a heterogeneity in cytotoxicity among primary human AML 
samples upon in vitro treatment with simva statin15, suggesting that only a subset of 
AML patients may benefit from statin treatment. In order to be able to predict which 
patients may benefit from statin treatment, we investigated whether differences in 
simva statin-induced cytotoxicity are confined to differential effects on the cholesterol 
synthesis route, or on the isoprenylation route. We show in human AML cell lines and 
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primary AML cells that inhibition of the isoprenylation route, rather than the choles-
terol synthesis route, by simva statin is responsible for its cytotoxic effects. Heteroge-
neity in simva statin-induced cytotoxicity in AML cell lines was shown to be linked to 
the extent of inhibition of isoprenylation, as well as to sensitivity to isoprenylation 
inhibitors, and more specifically to the degree of phospho-ERK inhibition.
Materials and methods
Human AML hematopoietic cell lines and primary AML samples
The human myeloid leukemia cell lines HL60 and NB4 were cultured in RPMI 1640 
















































Figure 1. The mevalonate pathway. The mevalonate pathway, that can be inhibited by simva statin, leads 
to the synthesis of cholesterol and the isoprenoids FPP and GGPP. Oxidized cholesterol (oxysterol) binds 
to the nuclear receptor LXR, which leads to the transcription of ABC transporters ABCA1 and ABCG1. 
These transporters are together responsible for cholesterol efflux. LDLR mediates cholesterol influx. 
Isoprenylation with FPP or GGPP is required for the plasma membrane binding of small GTPases such 
as Rho and Ras, in order to activate pathways involved in proliferation and survival. Ch: cholesterol; 
F: farnesyl pyrophosphate; FTase: farnesyltransferase; GG: geranylgeranyl pyrophosphate; GGTase: gera-
nylgeranyl transferase; LDLR: low-density lipoprotein (LDL) receptor; LXR: liver X receptor; Ox: oxysterol; 
RXR: retinoid X receptor; ZGA: zaragozic acid A.
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Laboratories GmbH, Cölbe, Germany). TF-1 was cultured in RPMI 1640 supplemented 
with 10% FCS and 10 ng/mL granulocyte macrophage colony-stimulating factor 
(GM-CSF; Genetics Institute Inc, Cambridge, MA), KG1a in Iscove’s Modified Dulbec-
co’s Medium (IMDM; PAA Laboratories GmbH) supplemented with 10% FCS and 2 nM 
L-glutamine (ICN, Zoetermeer, the Netherlands), and UT7-GM in IMDM with 10% FCS 
and 10 ng/mL GM-CSF. OCI-M3 (OCI/AML3) was cultured in α-MEM (Lonza) supple-
mented with 10% FCS. Cultures were kept at 37°C and 5% CO2. Bone marrow or periph-
eral blood cells of AML patients were collected and cryopreserved as described earlier15. 
The Medical Ethical Committee of the University Medical Center Groningen approved 
the protocol. Patients were classified according to the French-American-British AML 
classification21. Cytogenetic analysis was done as described earlier22. Prior to analysis, 
mononuclear cells were thawed, treated with DNase (Boehringer Mannheim, Almere, 
the Netherlands), washed, and incubated in α-MEM, supplemented with 12.5% FCS, 
12.5% horse serum, 20 ng/mL IL-3, 20 ng/mL granulocyte colony-stimulating factor, 
and 20 ng/mL thrombopoietin at 37°C and 5% CO2.
Reagents
Simva statin and GGTI-298 were obtained from Merck Chemical Ltd (Nottingham, UK). 
Tipifarnib was provided by Janssen Research Foundation. Zaragozic acid A, squalene, 
mevalonate, farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP) 
were obtained from Sigma-Aldrich (Zwijndrecht, the Netherlands). ROCK inhibitor 
Y27632 was purchased from Cayman Chemical, MEK inhibitor U0126 was obtained 
from Promega (Madison, WI) and PI3K inhibitor LY294,002 from Enzo Life Sciences 
(Raamsdonksveer, the Netherlands).
Cytotoxicity assay
Cytotoxicity was determined with the use of the Cell Titer-Glo Luminescent cell 
viability assay (Promega) according to the manufacturer’s instructions. Plates 
(96-well) were prepared with 10,000 cells per well in 100 μL medium supplemented as 
described above. Upon treatment with simva statin, the half maximal effective concen-
tration (EC50) in the various cell lines was determined as the concentration at which 
cytotoxicity was increased with 50% compared with untreated cells. To determine 
which agents could prevent simva statin-induced cytotoxicity, the cells were incubated 
with simva statin alone (for concentrations see figure legends), or in the presence of 
mevalonate, FPP, GGPP, or squalene. Fixed concentrations of mevalonate (250 µM), FPP 
(20 µM) and GGPP (10 µM) were used. These concentrations were optimal for preventing 
simva statin-induced cytotoxicity (data not shown). To mimic the simva statin-induced 
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cytotoxicity, cells were incubated with zaragozic acid A, GGTI-298, tipifarnib, U0126, 
Y27632, or LY294,002. After 48 hours, viability was assessed in duplicate.
Quantitative real-time PCR
Total RNA was isolated with the use of the RNeasy mini kit (Qiagen, Venlo, the Nether-
lands) and reverse transcribed with the use of RevertAid™ H Minus M-MuLV reverse 
transcriptase (Fermentas, St Leon-Roth, Germany). Quantitative PCR was done with 
the use of the ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, 
CA). Primers and probes for the human ABC transporters and HMG-CoAR and LDLR 
were described earlier23. As endogenous control the housekeeping gene glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used. The primers were obtained from 
Invitrogen (Breda, the Netherlands). The probes were labeled by a 5’ 6-carboxyfluo-
rescein (FAM) reporter and quenched by 6-carboxytetramethylrhodamine (TAMRA) at 
its 3’ end (Eurogentec, Maastricht, the Netherlands). We used 3 μL of diluted cDNA in 
each PCR reaction in a final volume of 15 μL, containing 900 nM of sense and antisense 
primers, 200 nM of the Taqman probe, 5 mM MgCl2, KCl, TrisHCl, 0.2 mM dATP, dCTP, 
dGTP, dTTP, and dUTP, and 0.5 U of AmpliTaq DNA polymerase (qPCR Core Kit, Euro-
gentec). The PCR program was 95°C for 10 minutes, followed by 40 cycles of 15 seconds 
at 95°C and 1 minute at 60°C. The expression of genes was standardized for the expres-
sion of GAPDH. Serial cDNA dilutions of the AML samples were used to generate cali-
bration curves. The expression of each gene in each sample was analyzed in duplicate.
Western blotting
For phospho-ERK expression determination, cells (0.5 × 106 per mL) were cultured in 
medium without GM-CSF, supplemented with 5% FCS in the presence of simva statin and 
mevalonate, GGPP, or FPP. After 48 hours, GM-CSF (10 ng/mL) was added for 15 minutes. 
Whole cell extracts were obtained by lysing 5 × 105 cells in boiling Laemmli sample 
buffer for 5 minutes. Proteins were separated by 10% SDS-PAGE and transferred to a 
polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA) in Tris-buffer, 
with the use of a semidry electroblotter from Bio-Rad Laboratories (Veenendaal, the 
Netherlands). After blocking in 0.1% Tween-20 and 5% bovine serum albumin (BSA) 
in Tris-buffered saline (TBS), membranes were probed with antibodies according to 
the manufacturer’s protocols. Antibodies used were ERK1/2 (K23,;Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) and phospho-ERK1/2 (Thr202/Tyr204; Cell Signaling 
Technology Inc., Beverly, MA). Antibody binding was visualized with enhanced 
chemiluminescence detection after incubation with a horseradish peroxidase (HRP)-
conjugated secondary antibody (Dako, Glostrup, Denmark).
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For DnaJ, Rap1, and Ras expression, cells (0.5 × 106 per mL) were cultured as 
described above, in the presence of simva statin, GGTI-298, or tipifarnib. Proteins 
were separated by 10% SDS-PAGE, and transferred to a PVDF membrane as described 
above. After blocking in 0.1% Tween-20, 5% skim powdered milk, and 2% BSA in TBS, 
membranes were probed with antibodies against DnaJ (HDJ-2; Labvision, Fremont, 
CA), Rap1a, N-Ras or β-actin (Santa Cruz Biotechnology, Inc.). The unprocessed form 
of DnaJ displays reduced mobility in SDS-PAGE compared with its processed counter-
part. Unprocessed Rap1 was determined with the use of an antibody that exclusively 
detects the unprocessed form (Rap1a). Antibody binding was visualized with enhanced 
chemiluminescence detection, or with the use of an Odyssey infrared scanner (Li-Cor 
Biosciences, Lincoln, NE) after incubation with HRP-conjugated, Alexa680-, or 
IRDye800-labeled secondary antibodies (Invitrogen). Densitometry was carried out 
with the use of ImageJ24.
Statistical analysis
Student’s t-test was used to calculate differences between sensitive and insensitive cell 
lines. Data were expressed as mean ± SD. All p values are given for two-sided tests and 
p≤0.05 was considered significant.
Results
Variability in simva statin-induced cytotoxicity in AML cell lines
To evaluate the cause of heterogeneity in simva statin-induced cytotoxicity, we iden-
tified AML cell lines with either a strong or a limited susceptibility to simva statin-
mediated cytotoxicity (Figure 2A). Based on an estimated EC50, we divided the cell lines 
into two groups: sensitive (EC50≤5 µM; NB4, OCI-M3 and HL60) or insensitive (EC50≥50 
µM; UT7-GM, TF-1 and KG1a) to simva statin. The same division could not be made 
when these cell lines were exposed to the cytotoxic agent cytarabine (data not shown), 
e.g., KG1a was much more sensitive to cytarabine than OCI-M3. These data indicate 
that the difference in responsiveness to simva statin is not a general phenomenon. In 
addition, no relation between responsiveness and cell cycle status or proliferation rate 
was observed (data not shown).
In the following experiments, the concentration of simva statin used for the 
different cell lines was based on their individual EC50 values. First, we investigated 
whether mevalonate, the metabolite directly downstream of HMG-CoAR (Figure 1), was 
able to prevent simva statin-induced cytotoxiticy. As depicted in Figure 2B, mevalonate 
prevented cytotoxicity by 91-100% in the sensitive cell lines and by 36-91% in the 
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insensitive cell lines. The difference between sensitive and insensitive cell lines was not 
statistically significant (p=0.20). In addition, inhibition of phosphorylation of ERK by 
simva statin could be prevented by co-exposure to mevalonate (Figure 4D).

































































































Figure 2. Mevalonate prevents simva statin-induced cytotoxicity in differentially sensitive cell lines. (A) Cell 
lines were treated with 2.5 to 100 μM simva statin or (B) with simva statin alone (NB4: 1 μM; OCI-M3: 2.5 μM; 
HL60: 5 μM; UT7-GM: 50 μM; TF-1: 50 μM; KG1a: 100 μM) or in combination with mevalonate (250 μM) for 
48 hours. The percentage of viable cells relative to the untreated cells was measured by a chemolumi-
nescence assay. Cell lines are shown in order of decreasing sensitivity to simva statin. Experiments were 
done at least three times in duplicate. Data are shown as mean ± SD. (C) mRNA expression of cholesterol 
metabolism genes in response to simva statin. Cells were treated for 48 hours with 5 and 25 μM simva-
statin. The mRNA expression levels of HMG-CoAR, LDLR, ABCA1, and ABCG1 were determined by quanti-
tative real-time PCR and normalized to GAPDH. Cell lines are shown in order of decreasing sensitivity to 
simva statin. Experiments were done at least 3 times in duplicate. Data are shown as mean ± SD. 
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Next, we questioned whether the differences in the degree of statin-induced 
cytotoxicity between the sensitive and insensitive cell lines was due to differences in 
biological effectiveness of simva statin. Therefore, simva statin-affected gene expression 
was studied. Genes encoding HMG-CoAR and LDLR, which mediate the first step of 
cholesterol synthesis and LDL-cholesterol influx, respectively, are reported to be dose-
dependently upregulated upon treatment with statins25. ABC transporter genes ABCA1 
and ABCG1, responsible for cholesterol efflux (Figure 1), are downregulated by statins 
in cells with significant de novo production of cholesterol25. All cell lines showed a 
dose-dependent increase in expression of HMG-CoAR and LDLR (Figure 2C) and, if 
expressed, a decrease in ABCA1 and ABCG1 mRNA expression (Figure 2C) at low doses 
of simva statin. No relationship existed between basal expression levels of HMG-CoAR, 
LDLR, ABCA1, or ABCG1 and simva statin-induced cytotoxicity. These observations 
imply that simva statin was similarly active in all tested cell lines.
The cholesterol synthesis route is not responsible for simva statin-induced cytotoxicity
We next established that the cholesterol synthesis route is not involved in simva-
statin-induced cytotoxicity. Squalene, a cholesterol precursor produced downstream 
of mevalonate (Figure 1), could not prevent simva statin-induced cytotoxicity in AML 
cell lines (Figure 3A). In addition, we mimicked the effects of simva statin with ZGA, 
a squalene synthase inhibitor acting downstream of simva statin in the cholesterol 
synthesis pathway (Figure 1). ZGA did not induce cytotoxic effects in any of the cell 
lines tested (Figure 3B). These results clearly indicate that inhibition of the cholesterol 
synthesis route within the mevalonate pathway is not critically involved in simva-
statin-induced cytotoxicity.


















































Figure 3. Differences in simva statin response are not linked to the cholesterol synthesis route. Cell lines were 
treated with (A) simva statin alone or in combination with squalene (5 μM) or with (B) ZGA (10 and 50 μM) 
for 48 hours. The percentage of viable cells relative to the untreated cells was measured by a chemo-
luminescence assay. Cell lines are shown in order of decreasing sensitivity to simva statin. Experiments 
were done at least three times in duplicate. Data are shown as mean ± SD. Simva statin concentrations: 
NB4: 1 μM; OCI-M3: 2.5 μM; HL60: 5 μM; UT7-GM: 50 μM; TF-1: 50 μM; KG1a: 100 μM.
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GGPP and FPP prevent simva statin-induced cytotoxicity in simva statin-sensitive AML cell 
lines
To assess whether the isoprenylation pathway is involved in simva statin-induced cyto-
toxicity, we firstly determined whether two compounds involved in this route, i.e., 
FPP and GGPP (Figure 1), are able to prevent simva statin-induced cytotoxicity. Cyto-
toxicity induced by simva statin could be partially prevented by FPP (Figure 4A,C) and 
to a larger extent by GGPP (Figure 4B,C). The protective effects of FPP and GGPP were 
more pronounced in the sensitive cell lines compared to the insensitive cell lines, 
with an average rescue of 56% ± 27% versus 16% ± 15% for FPP (Figure 4C; p=0.08), 
and 78% ± 29% versus 19% ± 17% for GGPP (p=0.04). Similarly, simva statin-mediated 



































































































































































Figure 4. The effects of GGPP and FPP on simva statin-induced cytotoxicity and phospho-ERK expression. Cell 
lines were treated with simva statin alone (NB4: 1 µM; OCI-M3: 2.5 µM; HL60: 5 µM; UT7-GM: 50 µM; TF-1: 
50 µM; KG1a: 100 µM) or in combination with (A) FPP (20 µM) or (B) GGPP (10 µM) for 48 hours. The 
percentage of viable cells relative to the untreated cells was measured by a chemoluminescence assay. 
Cell lines are shown in order of decreasing sensitivity to simva statin. Experiments were done four times 
in duplicate. Data are shown as mean ± SD. (C) Percentage of rescue as calculated by ((average viability 
simva statin + GGPP/FPP – average viability simva statin)/(100-average viability simva statin))×100%. 
(D) Cells were cultured in starvation medium (5% FCS, no GM-CSF) with simva statin alone (NB4: 5 µM; 
OCI-M3: 5 µM; HL60: 5 µM; UT7-GM: 100 µM; TF-1: 100 µM; KG1a: 100 µM) or in combination with meva-
lonate (250 µM), FPP (20 µM), or GGPP (10 µM) for 48 hours. Cells were stimulated with GM-CSF for 15 
minutes prior to harvesting. Phosphorylated (pERK) and total ERK (tERK) expression was determined by 
Western blot analysis. Representative Western blots of 3 experiments are shown. *p<0.05.
Statin-response in AML related to Ras-isoprenylation • 95
5
the sensitive cell lines (Figure 4D). Again, this effect was less pronounced in the insen-
sitive cell lines. Combining GGPP and FPP slightly, but not significantly, increased the 
rescue compared with either GGPP or FPP alone (data not shown). These data show that 
the isoprenylation route is involved for simva statin-induced cytotoxicity, and suggest 
that the differences in simva statin response found between AML cell lines may reside 
in this route.
Differential inhibition of isoprenylation by simva statin in AML cell lines
To analyze whether simva statin differentially affects protein isoprenylation, we deter-
mined the effect of simva statin on isoprenylation of DnaJ, a protein that is exclusively 
farnesylated26, and of Rap1, a protein that is exclusively geranylgeranylated27. Simva statin 
inhibited farnesylation in a dose-dependent manner in the cell lines (Figure 1, 5A). In 
two of the insensitive cell lines, TF-1 and KG1a, even the highest concentration of simva-
statin resulted only in a minor inhibition of farnesylation. Overall, the insensitive cell 
lines TF-1 and KG1a showed a significant lower degree of inhibition of farnesylation 
(p<0.04) than the sensitive lines. Similarly, the inhibitory effects of tipifarnib, a specific 
inhibitor of FTase, on farnesylation were most pronounced in the sensitive cell lines 
(e.g., at 5 µM p=0.01). Cytotoxic effects of tipifarnib occurred at low concentrations 
(EC50 0.2-5 µM), with the most pronounced effects on sensitive cells (p<0.05 at all tested 
concentrations; Figure 5D).
In the sensitive cell lines, geranylgeranylation was inhibited by simva statin to a 
comparable degree as by GGTI-298, a specific inhibitor of GGTase, which served as a 
positive control (Figure 1, 5B). This inhibition of isoprenylation was already present 
at very low concentrations (1 µM; p=0.002) of simva statin in the sensitive cell lines, 
whereas in the insensitive cell lines this inhibition was achieved at a 10-fold higher 
concentration (p=0.02). Interestingly, also GGTI-298 inhibited geranylgeranylation in 
the sensitive cell lines, but did not efficiently inhibit this in the insensitive cell lines 
(Figure 5B). GGTI-298 induced cytotoxicity at low concentrations in the sensitive cell 
lines (EC50 5 µM; Figure 5E), whereas the insensitive cell lines were less sensitive to 
GGTI-298 (e.g., p=0.01 at 10 µM). When combining tipifarnib and GGTI-298, as to cover 
both the farnesylation and geranylgeranylation routes, we observed additive effects 
and more pronounced differences between the sensitive and insensitive cell lines 
(p=0.003 at 1 µM tipifarnib plus 5 µM GGTI-298; Figure 5F). These data confirm that 
the geranylgeranylation route and the farnesylation route are differentially affected by 
simva statin in the sensitive and insensitive cell lines.
In addition, we assessed the effect of simva statin on isoprenylation of Ras. We used 
an antibody directed against N-Ras, because N-Ras could be detected in all cell lines, 
in contrast to K-Ras and H-Ras (data not shown), and only by using this antibody a 
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clear distinction could be made between prenylated and unprenylated Ras. Again, 
inhibition of isoprenylation in sensitive cell lines was already significant at the lowest 
concentration (1 μM, p=0.03), whereas the insensitive cell lines showed inhibition at 
higher concentrations, which was only significant at 100 μM (p=0.02).
The Ras/MEK/ERK route is differentially affected by simva statin in AML cell lines
Rho is exclusively geranylgeranylated, whereas Ras can be both geranylgeranylated and 
farnesylated (Figure 1)11,12. To dissect these separate processes, inhibitors of the Rho 
route and two distinct routes downstream of Ras were explored. The ROCK inhibitor 
Y27632 (acting downstream of Rho) increased cytotoxicity only at high concentrations 
(EC50 85-140 µM), and there was no difference in effects between sensitive and insensitive 
cell lines (Figure 6A). LY294,002, a PI3K inhibitor acting downstream of Ras, increased 
cytotoxicity at low concentrations (EC50 14-30 µM), but no differences between sensitive 
and insensitive cell lines were observed (Figure 6B). The MEK inhibitor U0126 (down-
stream of Ras) increased cytotoxicity at low concentrations (EC50 4-22 µM), and this 
effect was more pronounced in the sensitive cell lines (p=0.003; Figure 6C). These data 
together indicate that mainly the Ras/MEK/ERK route is differentially affected by simva-
statin in sensitive versus insensitive cell lines, which is supported by the finding that 
the latter require at least a 10-fold higher simva statin concentration for the inhibition 
of ERK phosphorylation (>50 µM) than the sensitive cell lines (5 µM; Figure 6D).
← Figure 5. Effect of simva statin on farnesylation and geranylgeranylation. Cells were treated with increasing 
concentrations of simva statin for 48 hours. After harvesting, prenylation status of (A) DnaJ, (B) Rap1, and 
(C) N-Ras was determined by Western blot analysis. Ratios of unprocessed versus processed DnaJ and 
N-Ras and unprocessed Rap1 (Rap1a) versus β-actin are shown, as determined by densitometry with the 
use of ImageJ. (A) 0.2 µM tipifarnib – positive control (+); 2.5 µM GGTI-298 – negative control (-). (B) 0.2 µM 
tipifarnib – negative control (-); 2.5 µM GGTI-298 – positive control (+). (C) G: 2.5 μM GGTI-298; F; 0.2 μM 
tipifarnib. (D) Representative examples of Western blots are given of a sensitive and an insensitive cell 
line: for DnaJ and N-Ras, the faster migrating band represents prenylated DnaJ or N-Ras (proc(essed)), 
and the slower band represents unprenylated DnaJ or N-Ras (unproc(essed)). Unprenylated Rap1 levels 
were compared with β-actin levels. To investigate the effect of isoprenylation inhibitors on the cell lines, 
cells were treated with (E) tipifarnib, (F) GGTI-298, and (G) the combination of both agents for 48 hours. 
The percentage of viable cells relative to the untreated cells was measured by a chemoluminescence 
assay. Cell lines are shown in order of decreasing sensitivity to simva statin. Data are representative of 3 
independent experiments (A-D), or experiments were done at least three times in duplicate (E-G). Data 
are shown as mean ± SD. *p<0.05.
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Figure 6. Effect of U0126, Y27632 and LY294,002 on viability. Cells were treated with (A) Y27632, (B) LY294,002, 
and (C) U0126 for 48 hours. The percentage of viable cells relative to the untreated cells was measured 
by a chemoluminescence assay. Cell lines are shown in order of decreasing sensitivity to simva statin. 
Experiments were done at least three times in duplicate. Data are shown as mean ± SE. *p<0.05 (D) Effect 
of simva statin on ERK phosphorylation. Cells were cultured in starvation medium (5% FCS, no GM-CSF) 
with simva statin for 48 hours. Cells were stimulated with GM-CSF for 15 minutes prior to harvesting. 
Phosphorylated and unphosphorylated ERK expression were determined by Western blot analysis. Cell 
lines are shown in order of decreasing sensitivity to simva statin. Representative Western blots of 3 exper-
iments are shown. C = unstimulated control.
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Simva statin affects the isoprenylation pathway in primary human AML cells
To establish whether the mechanism of (heterogeneous) simva statin-induced cyto-
toxicity in cell lines also holds true for primary human AML cells, we examined the 
ability of mevalonate, GGPP, and FPP to prevent simva statin-induced cytotoxicity in 
these cells after 24 hours of culture. The studied AML patient group (n=11) was clas-
sified according to the French-American-British classification system as follows: M0 
(n=1), M1 (n=4), M2 (n=1), M3 (n=1), M4 (n=2), and M5 (n=2). The median age of the 
patients was 57 years (range 35-80 years). Karyotype analysis was done in 10 of 11 
patients: a normal karyotype (n=6) and an abnormal karyotype (n=4) were displayed 
(t(11;20), t(15;17), inv(16), and inv(3q,-7,-10)). In all patient AML cells tested, mevalonate 
could (partially) prevent simva statin-induced cytotoxicity; in 57% of the samples the 
level of rescue exceeded 80%, whereas in the remaining samples this value varied 
between 25-74%. GGPP and FPP could (partially) prevent cytotoxic effects of simva-
statin in 57% and 86% of the AML samples, respectively. This rescue was on average 46% 
(range 19-100%) when applying GGPP and 52% (range 9-100%) when FPP was used. 
Thus, consistent with our cell line data, we observed also in patient AML cells hetero-
geneity in the degree of rescue by GGPP and FPP. Maximal inhibition of geranylgera-
nylation and farnesylation was achieved with simva statin concentrations similar to 
those used in the cell lines, but again, differences in concentrations required for this 
inhibition between the AML patient samples were present, ranging from 25 to >100 
µM simva statin for inhibition of farnesylation, and from 1 to 5 µM for inhibition of 
geranylgeranylation. These differences were also observed when treating the cells with 
simva statin, tipifarnib, or GGTI-298, although higher concentrations of these agents 
were required to induce cytotoxicity than in the cell lines (concentration required for 
25% cytotoxicity of simva statin: EC25 25-350 µM in primary AML cells versus 0.5-50 µM 
in cell lines; tipifarnib: 5-50 µM versus 0.04-1 µM; GGTI-298: 25-70 µM versus 2.5-10 µM).
Discussion
In this study, we showed that differences in sensitivity of human AML cells to simva-
statin-mediated cytotoxicity are related to differential effects of the drug on the 
Ras/MEK/ERK signaling pathway. These differential effects can be assigned to interfer-
ence with the isoprenylation route rather than with the cholesterol synthesis route, 
as unambiguously demonstrated in AML cell lines, as well as in primary human 
AML cells. In earlier studies on differentially sensitive myeloma cells, simva statin 
response appeared to be related to P-glycoprotein (P-gp) expression28. Indeed, some 
statins have been identified as substrates for multidrug resistance pumps, including 
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P-gp29. However, our study shows that expression of cholesterol metabolism genes is 
modulated in a similar fashion in sensitive and insensitive cell lines at low simva-
statin concentrations, yet, not all cell lines were equally sensitive to cytotoxic actions 
of simva statin at these concentrations. Therefore, it is unlikely that variable activity of 
drug efflux pumps is responsible for the observed differential effects of simva statin.
Statin-induced cytotoxicity has been attributed to its ability to inhibit cholesterol 
synthesis1,30,31. Thus far, it has been shown that AML cells in vitro display an enhanced 
cholesterol metabolism3-5. Moreover, upon in vitro treatment with cytarabine or 
daunorubicin, AML cells increase their cholesterol contents, which has been suggested 
to protect the cells against the cytotoxic actions that are crucial for effective therapy6. 
Based on these considerations, clinical trials have been initiated to assess whether 
interference with the cholesterol synthesis pathway by using statins indeed promotes 
the efficacy of chemotherapy-mediated cell death30,32,33. However, in our study we show 
that statin-induced cytotoxicity is not caused by inhibition of cholesterol synthesis 
per se. We show that the cholesterol synthesis inhibitor ZGA, that interferes with the 
actions of squalene synthase, did not cause cytotoxicity in the AML cells at concentra-
tions reported to suppress de novo sterol synthesis34,35. We also found that squalene, 
a cholesterol precursor, was not able to prevent simva statin-induced cytotoxicity as 
did mevalonate. Together, these findings indicate that simva statin does not exert its 
cytotoxic effects by blocking the cholesterol synthesis pathway. This is in agreement 
with results obtained with endometrial cells and squamous cell carcinoma cells36,37, 
although conflicting data on the effects of cholesterol inhibition on cell survival have 
been published38-40.
We show that simva statin-induced cytotoxicity could be prevented by GGPP and 
FPP, indicating that simva statin-induced cytotoxicity is likely mediated by interference 
with the isoprenylation route. Some reports suggest a role for protein geranylgeranyla-
tion, rather than for farnesylation, in statin-induced cytotoxicity in other (hemato-
logical) malignancies. This is in part based on the observation that the geranylgeranyl-
transferase inhibitor GGTI-298 was less cytotoxic than the farnesyltransferase inhibitor 
FTI-277, when used at comparable concentrations11,41,42. However, tipifarnib, the FTI 
used in the current study, was much more potent than GGTI-298. Moreover, we show 
that simva statin does inhibit farnesylation in AML cell lines, and that simva statin-
induced cytotoxicity can partially be prevented by FPP. The reduced ability of FPP 
to prevent simva statin-induced cytotoxicity compared with GGPP may be due to the 
production of squalene (Figure 1)31,34,43. The idea that FPP does not efficiently prevent 
simva statin-induced cytotoxicity, because it acts as precursor of squalene, strengthens 
our conclusion that blockade of the cholesterol synthesis pathway is not crucial for 
statin-induced toxicity.
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Also in primary human AML cells we observed a (partial) prevention of simva-
statin-induced cytotoxicity by GGPP and FPP, as well as inhibition of isoprenylation 
by simva statin at concentrations comparable with those used in cell lines. However, 
higher concentrations of simva statin, tipifarnib, and GGTI-298 were required to 
induce cytotoxic effects. Apparently, compared to cell lines, primary AML cells are less 
dependent for their survival on the Ras-mediated signaling, the route we identified as 
being responsible for simva statin-induced cytotoxicity.
Thus, our data indicate that inhibition of both geranylgeranylation and farnesyla-
tion by simva statin plays a major role in statin-induced cytotoxicity in AML cells. It 
has been shown that Rho is exclusively geranylgeranylated11, whereas Ras is both gera-
nylgeranylated and farnesylated12. By using specific blockers of these separate routes, 
we were able to show that inhibitors of the Ras route, rather than inhibitors of the 
Rho route, mimicked the effects of simva statin. This is in line with the finding that 
lova statin-induced apoptosis can significantly be repressed by constitutive activa-
tion of the Ras/MEK/ERK pathway44. In addition, downregulation of the Ras/MEK/ERK 
pathway has been shown to potentiate statin-induced apoptosis35. Because Ras can be 
both farnesylated or geranylgeranylated, and combining FPP and GGPP does not render 
a higher rescue than either of the compounds alone, the Ras transduction pathway 
is most likely not the only pathway involved in simva statin-induced cytotoxicity. Of 
course, several other proteins can become isoprenylated, e.g., Rheb proteins, nuclear 
lamins, Rac, and CDC4245-47.
Sensitivity to statin-induced cytotoxicity has been reported to be cell type-
dependent48, but the present study shows that even within the same cell type, i.e., AML 
cells, marked differences in statin-induced cytotoxicity can be observed. This hetero-
geneity is in accordance with our previous report, in which we identified a differen-
tial degree of cytotoxicity within sorted primary CD34+ AML samples15. We show that 
especially the activity of the Ras/MEK/ERK pathway is to a major extent responsible for 
differences in cytotoxicity. A 2-fold higher concentration of the ERK inhibitor U0126 
was required in insensitive cell lines to induce effects comparable to those in sensitive 
cell lines. Likewise, we observed a relationship between simva statin-mediated cyto-
toxicity and simva statin-induced inhibition of Ras-isoprenylation as well as phospho-
ERK inhibition. This difference cannot be ascribed to variation in the incidence of 
RAS mutations: the cell lines NB4, HL60, and TF-1 carry activating RAS mutations, 
whereas OCI-M3 and KG1a, do not7,13. In addition, it has been shown that in primary 
AML cells statin sensitivity is not associated with RAS mutations or Ras protein over-
expression7, and AML cells were shown to be much more sensitive to lova statin than 
ALL cells, although the extent of RAS mutations was approximately equal in both 
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cell types16. So, although we found that the Ras pathway holds the key to the differ-
ences in simva statin response between AML cell lines, the differences are not related 
to Ras (over)activity.
In summary, we show that cytotoxic effects of simva statin in AML cell lines and 
primary human AML cells can be assigned to interference with the isoprenylation route 
of the mevalonate pathway, rather than with cholesterol synthesis. The differences in 
simva statin-induced cytotoxic effects could, at least in part, be explained by differences 
in the Ras/MEK/ERK pathway within this isoprenylation route. Heterogeneity in simva-
statin effects of this route was also found within AML patient samples. Our findings 
can potentially be useful to identify AML patients that may benefit from simva statin 
co-treatment.
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Abstract
It is currently unknown whether the in vitro effects statins display in acute myeloid 
leukemia (AML) cells, including lowering of cholesterol, inhibition of isoprenylation, 
and sensitization to chemotherapy, also occur in vivo. Therefore, AML mononuclear 
cells (MNCs) from 12 patients before and after 7 days of high-dose (7.5-15 mg/kg/day) 
simva statin treatment were studied. Parallel mouse studies were performed to have, 
besides AML cells, also access to liver tissue, a major target of statins. Serum cholesterol 
levels were lowered by simva statin in all patients, however, only limited changes in the 
mRNA expression of cholesterol metabolism genes were seen in patient and mouse 
MNCs compared to murine liver cells. Still, 29% of the patients displayed an increased 
in vitro chemosensitivity of their AML cells upon simva statin treatment. Gene set 
enrichment analysis on microarray data of AML patient MNCs and CD34+ cells, as well as 
Western blot analysis for the isoprenylated proteins DnaJ and Rap1 on murine and AML 
patient MNCs demonstrated that in vivo simva statin treatment resulted in inhibition of 
geranylgeranylation in murine MNCs and in a subset of patient MNCs. In summary, our 
data show that simva statin treatment results in chemosensitization and inhibition of 
geranylgeranylation in AML cells of a subset of patients.
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Introduction
Acute myeloid leukemia (AML) is a clonal hematopoietic disease, characterized by 
the accumulation of immature myeloid blasts in the bone marrow. Despite intensive 
treatment only 5-15% of AML patients over 65 years of age can be cured, which is mainly 
due to the occurrence of resistance to therapeutic agents. Different mechanisms have 
been identified that protect AML cells against the cytotoxic effects of chemotherapy, 
including adaptation of cellular cholesterol homeostasis1,2. Cellular cholesterol levels 
are maintained by balanced de novo synthesis, influx, and efflux. Cholesterol synthesis 
is initiated by 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoAR), which is the 
rate-controlling enzyme of the mevalonate pathway that yields cholesterol as well as 
isoprenoids. The low-density lipoprotein receptor (LDLR) is responsible for cholesterol 
influx into cells3. The cholesterol efflux pumps ABCA1 and ABCG1 promote the transfer 
of cellular cholesterol to ApoA-I and HDL, which is regulated by liver X receptor, a 
nuclear receptor that is activated by oxidized cholesterol derivatives (oxysterols)4-6.
Different studies have shown that cholesterol metabolism is increased in AML cells, 
as reflected by high mRNA levels of HMG-CoAr and LDLR, as well as increased activi-
ties of the corresponding proteins7-9. In addition, AML cells increase their cholesterol 
levels upon in vitro exposure to chemotherapeutic drugs, which renders these cells 
less susceptible to these drugs10,11. Consequently, a role for statins to improve standard 
antileukemic treatment has been suggested. 
Statins inhibit HMG-CoAR activity, resulting in a blockade of cholesterol synthesis, 
as well as inhibition of isoprenoid production. Isoprenoids are required for the attach-
ment of small GTPases (e.g., Ras and Rho) to the plasma membrane, and their subse-
quent participation in signal transduction pathways that regulate growth and survival. 
Examples hereof are the PI3K/Akt and Ras/MEK/ERK pathways12. The cytotoxic effects of 
statins have originally been attributed to their serum cholesterol-lowering capacity13. 
However, in vitro studies with AML cell lines and primary AML cells have suggested 
that the cytotoxic effects of simva statin are caused by a blockade of the isoprenylation 
route, rather than a blockade of cholesterol synthesis14. 
We aimed to verify whether the in vitro observed effects by statins are actually 
present in MNCs of AML patients treated with simva statin. Additionally, we used 
a mouse model to validate our findings in more detail. This allowed us to compare 
the results on hematopoietic cells with liver cells, which is the major and intensively 
studied target organ of statins. The results show that in a subset of patients treatment 
with simva statin sensitizes AML cells to in vitro chemotherapy. In addition, gera-
nylgeranylation is inhibited in AML cells from simva statin-treated patients, with only 
minor effects on the expression of cholesterol metabolism genes. 
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Materials and methods
Patients and patient material
Patient samples were obtained from a phase 2 feasibility study, in which AML patients 
were treated with high-dose simva statin. For this study, eligible patients were those 
with de novo or relapse AML, who would receive intensive chemotherapy or palliative 
chemotherapy. Simva statin was administered orally at a dosage of 7.5-15 mg/kg/day 
during 7 days. Eight patients were treated with 7.5 mg/kg/day simva statin, and 4 patients 
received 15 mg/kg/day. On day 7 of the simva statin treatment chemotherapy was 
initiated. The study was approved by the Medical Ethical Committee of the Univer-
sity Medical Center Groningen. All patients provided written informed consent. Bone 
marrow (BM) or peripheral blood (PB) samples were collected before and after 7 days 
of simva statin treatment, but before chemotherapy application. The mononuclear cell 
(MNC) fraction was stored and thawed as described earlier15. Serum lipid levels were 
monitored with the use of standard laboratory techniques. 
For additional experiments, BM or PB MNCs were used that were collected from AML 
patients at diagnosis after informed consent, as well as granulocyte colony-stimulating 
factor mobilized peripheral blood stem cells from patients eligible for autologous 
hematopoietic stem cell transplantation, in accordance with institutional guidelines. 
Animals
As the liver is the primary target of statins, it was of interest to compare our findings 
in BM cells with those in liver cells. To have access to liver cells, and to extend our 
data on human AML BM cells, a mouse study was done. Eleven to 13 weeks old male 
C57Bl/6OlaHsd mice were purchased from Harlan (Horst, the Netherlands) and housed 
under clean conventional conditions. All experimental protocols were approved by the 
institutional ethical committee on animal experiments. The mice were fed normal chow 
(RMH-B; Arie Blok, Woerden, the Netherlands), chow containing 0.1% w/w simva statin 
(Merck Chemical Ltd., Nottingham, UK) for 7 days, chow containing 2% w/w WelChol 
(Colesevelam HCL; Daiichi Sankyo Inc., Munich, Germany) for 14 days, or the combi-
nation of the two diets (7 days WelChol, followed by 7 days WelChol + simva statin). 
After treatment, a PB sample was taken. The animal was thereafter sacrificed, and liver 
was harvested and snap frozen. BM cells were flushed from the femurs and tibias. After 
standard erythrocyte lysis, nucleated cells were treated as described below. Primary rat 
liver cells were obtained and cultured as described by Vrenken et al16.
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Cell sorting and culture of human AML cells and murine BM cells
The patient AML MNCs were incubated with a fluorescein isothiocyanate (FITC)-conju-
gated antibody against CD34 (Becton Dickinson, San Jose, CA). Sorting of CD34+ cells 
was done with the use of a MoFlo Cell Sorter (DakoCytomation, Carpinteria, CA). 
CD34+ cells and total MNCs were cultured in LTC medium as described by van Gosliga 
et al17. All cultures were kept at 37°C and 5% CO2. 
Mouse BM cells were cultured in StemSpan (StemCell Technologies, Grenoble, 
France) supplemented with 10% FCS, 20 ng/mL recombinant mouse interleukin-11 
(R&D Systems, Minneapolis, MN), 300 ng/mL polyethylene glycol-complexed recom-
binant rat stem cell factor (Amgen, Thousand Oaks, CA), and 10 ng/mL Flt3-ligand 
(Amgen). BM progenitor frequencies were determined by methylcellulose cultures and 
FACS analysis as described in the supplementary data.
Cell viability 
Viability of human (CD34+) AML cells and mouse BM cells was determined by the Cell 
Titer-Glo Luminescent cell viability assay (Promega, Madison, WI) according to the 
manufacturer’s instructions. Plates (96-well) were prepared with 100 μL medium 
supplemented as described above and 10,000 cells per well. The cells were incubated 
with cytarabine (Mayne Pharma Benelux, Brussels, Belgium) with the use of easy load 
pipet tips (Greiner Bio-One, Alphen aan den Rijn, the Netherlands), and after 24 hours 
viability was assessed in duplicate.
Microarray experiments
Human AML CD34+ and CD34- cells were sorted as indicated above, and RNA from these 
subfractions and from the total MNC fraction was isolated with the use of the RNeasy 
mini kit or the RNeasy micro kit (Qiagen, Venlo, the Netherlands), depending on the 
amount of sorted cells, in accordance with the manufacturer’s protocol. RNA concen-
tration, quality, and integrity were determined with the use of the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Amstelveen, the Netherlands). Genome-wide expression 
analysis was done on Illumina BeadChip Arrays Sentrix Human-6 (46k probe sets; 
Illumina Inc., San Diego, CA). Typically, 0.5-1 µg was used in labeling reactions, and 
hybridization with the arrays was done according to the manufacturer’s instructions. 
Gene Set Enrichment Analysis
GSEA was done with the software package GSEA 2.0, developed by the Broad Institute of 
MIT and Harvard18,19, as described elsewhere20. All 37,804 genes were ranked according 
to differential expression between pre- and post-simva statin treatment samples based 
on a paired t-test. This ranked list of genes was compared against a large collection of 
112 • Chapter 6
functional gene sets to determine if there was enrichment of one of these gene sets 
in pre- or post-treatment samples. Ranked expression data for all 37,804 genes was 
compared against a large collection of functional gene sets to determine if there was 
enrichment of one of these gene sets in pre- or post-treatment samples. A total of 156 
functional genes sets as reported in the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database, 125 from the Biocarta database (http://www.biocarta.com), and 83 
from the GenMAPP database were analysed. The statistical significance of enrich-
ment was determined by a randomization test based on 1,000 gene permutations. For 
each functional set the false discovery rate (FDR) was calculated, which represents the 
estimated probability that a given enrichment score represents a false-positive finding. 
Only gene sets with an enrichment p-value of <0.05 and an FDR of <0.25 are reported. 
Leading-edge subset analysis
The leading-edge subset is defined as the subset of genes in a functional gene set that 
appears in the ranked list of 37,804 genes at, or before, the point in which the running 
enrichment score reaches its maximum deviation from zero. The genes within this 
subset can be interpreted as the most important in the enrichment of the functional 
gene set. Leading-edge subsets were defined for all statistically enriched functional 
gene sets (p<0.05). Subsequently, overlap between leading-edge subsets from signifi-
cantly enriched functional gene sets identified in the different databases was deter-
mined to discover genes belonging to more than one leading-edge subset, which might 
be considered key genes.
Quantitative real-time PCR
RNA was isolated from human AML MNCs, CD34+, and CD34- cells, and from mouse BM 
and PB MNCs with the use of the RNeasy mini kit (Qiagen) and was reverse transcribed 
with the use of RevertAid™ H Minus M-MuLV reverse transcriptase (Fermentas, St 
Leon-Roth, Germany). Quantitative PCR was done with the use of the ABI Prism 7700 
Sequence Detector (Applied Biosystems, Foster City, CA) as described earlier15. Primers 
and probes for the human and murine ABC transporters and HMG-CoAR and LDLR 
were used as described earlier21-25. The housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) served as endogenous control for patient material, and 18S 
for mouse material. Primers were obtained from Invitrogen (Breda, the Netherlands). 
Western blotting 
To determine DnaJ and Rap1 protein expression, cells (0.5 × 106 per mL) were cultured 
in the presence or absence of simva statin (Merck Chemical Ltd.) for 24 hours. Whole 
cell extracts were obtained by lysing 5 × 105 cells in boiling Laemmli sample buffer 
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for 5 minutes. Proteins were separated by 10% or 12.5% SDS-PAGE and transferred to 
a polyvinylidene difluoride membrane (Millipore, Bedford, MA) in Tris-buffer with 
the use of a semidry electroblotter from Bio-Rad Laboratories (Veenendaal, the Neth-
erlands). After blocking in 0.1% Tween-20 containing 5% skim powdered milk and 
2% bovine serum albumin in tris-buffered saline, membranes were probed with anti-
bodies against DnaJ (HDJ-2; Labvision, Fremont, CA), Rap1 (total), and Rap1a (unpre-
nylated; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) according to the manufac-
turer’s protocols. Antibody binding was visualized with enhanced chemiluminescence 
detection, or with the use of an Odyssey infrared scanner (Li-Cor Biosciences, Lincoln, 
NE) after incubation with a horseradish peroxidase (HRP)-conjugated (Dako, Glostrup, 
Denmark), Alexa680-, or IRDye800-labeled secondary antibody (Invitrogen). Densi-
tometry was carried out with the use of ImageJ26. 
Statistics
The non-parametric Wilcoxon Signed Rank test was used to test whether there were 
differences in serum lipid concentrations, blood parameters, and gene expression 
between before and after treatment of AML patients with simva statin. Student’s t-test 
was used in the other analyses.
Results
Treatment of AML patients with simva statin decreases in vivo cholesterol synthesis
From 12 patients BM or PB samples before and after high-dose simva statin treatment 
were available. Main characteristics of the patients are shown in Table 1. The simva statin 
dosage administered was 7.5 mg/kg/day in eight patients and 15 mg/kg/day in four. To 
monitor the in vivo effectiveness of simva statin, serum lipid levels were analyzed before 
and at the end of simva statin treatment. Serum cholesterol levels were decreased after 
7 days of simva statin treatment (4.0 ± 1.0 mmol/L versus 2.3 ± 0.7 mmol/L; p=0.002). 
The lathosterol/cholesterol ratio (0.71 ± 0.57 versus 0.23 ± 0.21; p=0.02), which is 
generally used as a measure for total body cholesterol synthesis27, was also reduced 
after statin treatment (Figure 1A). LDL levels were decreased as well (p=0.004), but 
HDL levels remained unchanged and triglycerides slightly decreased (p=0.01; Figure 
S1). Comparable changes in serum lipid levels were observed in patients receiving 
7.5 mg/kg/day simva statin versus 15 mg/kg/day. No distinct changes were found in the 
total white blood cell counts, platelet counts, or hemoglobin levels (Table 2). The blast 
percentages of the peripheral blood were also monitored before and after treatment, 
and showed no significant changes (Table 2).
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Treatment with simva statin increases in vitro sensitivity of sorted AML CD34+ cells to 
chemotherapy in a subset of patients
In vitro simva statin sensitizes primary AML cells to chemotherapy2. We investigated 
whether the AML cells exposed to simva statin in vivo are more sensitive to in vitro 
chemotherapy than their untreated counterparts. Previous studies have shown that the 
stem cell enriched CD34+ (AML) cell fraction displays higher levels of cholesterol meta-
bolism genes24,28, and is therefore likely more dependent on high cholesterol turnover. 
Therefore, we sorted CD34+ AML cells from samples that were collected before and at 
the end of simva statin treatment. In 7 out of 12 patients sufficient CD34+ cells could 
be sorted for the experiments. In vitro culture with cytarabine for 24 hours increased 
cytotoxicity in 2 out of 7 AML CD34+ cells exposed in vivo to simva statin (Figure 1B). 
On average, viability of these 2 responsive samples was 60% ± 2% before and 37% ± 11% 


















































Figure 1. In vivo effects of simva statin on serum lipid levels and in vitro chemosensitivity of AML patients. 
(A) Serum levels of cholesterol and the lathosterol/cholesterol ratio of patients before (d0) and after 7 
days (d7) of treatment with 7.5 mg/kg/day (closed circles), or 15 mg/kg/day (open squares) simva statin. 
(B) Viability of sorted CD34+ cells obtained from patients before (d0) and after (d7) treatment with 7.5 
mg/kg/day (closed circles), or 15 mg/kg/day (open squares) simva statin upon in vitro treatment with 0.01 
mg/mL cytarabine as shown for individual patients. *p<0.05.
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viability before and 95% ± 5% after in vivo simva statin (Figure 1B), indicating that only 
the samples that were initially sensitive to chemotherapy alone became more sensitive 
by simva statin pretreatment. 
Mononuclear cells of AML patients treated with simva statin show limited changes in 
cholesterol metabolism gene expression
To delineate the changes that occur in AML cells upon treatment of the patients with 
simva statin, microarray experiments were done on paired AML MNCs (n=10) and on 
paired sorted CD34+ AML cells (n=4; from the other patients no sufficient number 
of cells could be isolated), obtained before and at the end of simva statin treatment. 
Treatment with simva statin is known to result in upregulation of HMG-CoAR and LDLR 
mRNA levels, and downregulation of ABCA1 and ABCG1 mRNA levels29. In the majority 
of patients, simva statin treatment resulted in slight increases in HMG-CoAR (6 out of 10) 
and LDLR (8 out of 10) mRNA levels in AML MNCs (1.3-fold ± 0.2, range 1.1-1.6-fold; and 
1.8-fold ± 0.9, range 1.1-3.9-fold, respectively), whereas ABCA1 (7/10) and ABCG1 (6/10) 
were decreased (2.3-fold ± 1.0, range 1.2-4.1-fold; and 3.4-fold ± 1.6, range 1.7-6.1-fold, 
respectively; Figure 2A,C). However, these changes were not significant and not evident 
in all samples, despite the consistent decline in serum cholesterol levels (Figure 1A). In 
addition, the degree of gene expression changes in BM cells did not relate to the degree 
of decrease in serum cholesterol levels. In sorted CD34+ AML cells comparable results 
were obtained (Figure 2B,C). The expression levels of the tested genes were confirmed 
Table 2. Blood parameters of AML patients before and after simva statin treatment
AML WBC (×109/L) Plt (×109/L) Hb (mmol/L) Blasts (%)
d0 d7 d0 d7 d0 d7 d0 d7
1 14.4 9.3 70 54 4.4 5.2 13 22 
2 88.3 61.6 31 38 6.6 5.5 84 98 
3 15.3 21.4 51 85 6.2 6.7 1 2 
4 3.8 3.4 18 44 6.1 5.8 6 15 
5 1.1 1.3 15 14 6.3 5.4 ND ND 
6 2.9 8.3 205 101 5.3 5.4 56 31 
7 5.4 6.8 18 16 5.6 6 89 83 
8 1.2 1.5 184 163 6.9 6.5 ND ND 
9 2.2 2.4 19 40 7.3 5.9 ND ND 
10 5.8 0.9 18 10 4.5 4.8 ND ND 
11 1.9 1.8 111 105 6.6 6 ND ND 
12 11.9 3.2 65 112 6.9 6 4 1 
WBC: white blood cells; Plt: platelets; Hb: hemoglobin; d0: before simva statin treatment; d7: at day 7 
of simva statin treatment; ND: not determined.
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by qPCR (Figure S2). Overall, the changes were limited and reached no statistical signif-
icance, although a trend towards a decrease of ABCA1 (p=0.07) and ABCG1 (p=0.09) 
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d0 d7 d0 d7 d0 d7
Figure 2. Cholesterol metabolism gene expression in cells of individual patients before and after simva statin 
treatment, as determined by microarray analysis. Gene expression of HMG-CoAR, LDLR, ABCA1 and ABCG1 
in (A) the total fraction of AML MNCs (n=10) and (B) sorted CD34+ cells (n=4) before (d0) and after 7 
days of treatment with 7.5 mg/kg/day (closed circles), or 15 mg/kg/day (open squares). (C) Average ± SD 
expression of total AML MNCs (closed circles) and CD34+ cells (open squares) before and after simva-
statin treatment. 
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Biological pathway analysis 
Changes in expression at the single gene level were limited between simva statin-
treated and control AML MNCs. However, small changes in a set of genes belonging 
to a single biological pathway, when coordinated, can be biologically relevant. To 
identify such pathways affected by simva statin treatment in AML cells, GSEA was 
performed (Figure 3). Using KEGG pathway definitions, GSEA identified 41 pathways 
enriched in simva statin-exposed samples (Table S1), of which the most significantly 
enriched pathways are shown in Table 3A. No pathways were enriched in untreated 
samples when p<0.05 and false discovery rate (FDR) <0.25 were used. GSEA revealed 
18 and 12 pathways enriched in simva statin-exposed AML samples (Table 3B,C,S2,S3) 
according to Biocarta and GenMAPP, respectively. In simva statin-exposed CD34+ AML 
samples, enrichment of 12 KEGG pathways and 5 GenMAPP pathways was present, and 
3 KEGG pathways were enriched in untreated CD34+ AML samples (Table S4). In simva-
statin-exposed CD34- AML samples, enrichment was found in 24 KEGG pathways and 
13 GenMAPP pathways, and untreated CD34 - AML samples showed enrichment of 3 
GenMAPP pathways (Table S5). 
Based on the mechanism of action of simva statin, we expected to find pathways 
involved in cholesterol synthesis as well as cell signaling due to inhibition of isopre-
nylation of small GTPases. These pathways were indeed affected, e.g., the Rho 
pathway requires isoprenylated Rho and the VEGF pathway may involve isoprenyla-
tion of Ras. However, the genes that contributed to enrichment of the cholesterol (or 
steroid) synthesis pathway did not include HMG-CoAR or LDLR, which are known to 
be increased in vitro. Instead, they included squalene epoxidase, which catalyzes the 
first oxygenation step of the cholesterol precursor squalene in cholesterol synthesis, 
and phosphomevalonate kinase, which catalyzes one of the steps resulting in the 
conversion of mevalonate into isopentenyl diphosphate. In addition, other metabolic 
CA B
Figure 3. Examples of GSEA enrichment plots for the most enriched pathways in samples from simva statin-
treated AML patients based on (A) KEGG, (B) Biocarta, and (C) GenMAPP pathways.
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pathways requiring acetyl-CoA, and pathways involved in immune responses were 
enriched. With the exception of the cholesterol biosynthesis pathway, the pathways 
identified in the total AML MNC fraction were distinct from those identified in the AML 
CD34+ fraction, suggesting that the effects of simva statin can differ between primitive 
and mature cells. Leading edge analysis revealed key regulatory genes common to the 
Table 3. Gene sets enriched in MNCs using pathway definitions from KEGG, Biocarta, and 
GenMAPP with p<0.001
Pathway p-value FDR Enriched in 
KEGG
Hematopoietic cell lineage <0.001 0.00 post
Cell adhesion molecules <0.001 0.00 post
Natural killer cell mediated cytotoxicity <0.001 0.00 post
Type I diabetes mellitus <0.001 0.00 post
T cell receptor signaling pathway <0.001 0.00 post
Biosynthesis of steroids <0.001 0.01 post
VEGF signaling pathway <0.001 0.01 post
Antigen processing and presentation <0.001 0.01 post
Cytokine cytokine receptor interaction <0.001 0.02 post
Wnt signaling pathway <0.001 0.02 post
MAPK signaling pathway <0.001 0.05 post
Calcium signaling pathway <0.001 0.05 post
Regulation of actin cytoskeleton <0.001 0.11 post
Biocarta
Caspase pathway <0.001 0.01 post
Chemical pathway <0.001 0.01 post
TCR pathway <0.001 0.01 post
GPCR pathway <0.001 0.02 post
Rho pathway <0.001 0.02 post
HIVNef pathway <0.001 0.05 post
GenMAPP
Apoptosis GenMAPP <0.001 0.00 post
Apoptosis <0.001 0.00 post
Apoptosis KEGG <0.001 0.00 post
Pyruvate metabolism <0.001 0.00 post
Propanoate metabolism <0.001 0.01 post
Calcium regulation in cardiac cells <0.001 0.06 post
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identified pathways, such as AKT1 and MAPK3 (ERK1) for KEGG pathways, and PRKCB1 
and PRKCA for Biocarta (Table S6), suggesting that isoprenylation-dependent signaling 
may have been affected.
Differential effects of simva statin on cholesterol metabolism gene expression in murine 
bone marrow and liver cells
Next, we questioned whether absence of changes in cholesterol metabolism genes in 
MNCs despite the physiological decrease of serum cholesterol levels reflects cell type-
dependent effects. Therefore, a mouse model was used, which enabled to make a 
distinction between the effects of simva statin on hematopoietic cells and liver cells, 
the latter being the major source of cholesterol production. Mice treated with simva-
statin or simva statin in combination with WelChol, to mimic the increased cholesterol 
metabolism in AML cells, displayed no different cell counts and BM and PB composition 
compared with their untreated counterparts (Table S7). BM progenitor frequencies, as 
determined by FACS analysis and CFC assay, remained unchanged, although a slight 
increase in LSK number (6.3 ± 0.5% to 8.3 ± 1.4%; p=0.03) upon simva statin treatment 
was observed (Figure S3). 
In addition, we compared changes in expression of cholesterol metabolism genes 
in murine BM MNCs with liver cells upon in vivo treatment with simva statin. In liver 
cells, simva statin induced LDLR and HMG-CoAR mRNA expression by 2- (p=0.02) and 
12-fold (p<0.001), respectively, whereas no changes in ABCA1 and ABCG1 expression 
were noticed (Figure 4). BM MNCs showed no changes in LDLR and HMG-CoAR expres-
sion upon simva statin treatment. In contrast to liver cells, ABCA1 and ABCG1 mRNA 
expression was reduced in simva statin-treated MNCs (1.6-fold (p=0.004) and 2.1-fold 
(p=0.005), respectively). Pretreatment with WelChol, to induce cholesterol synthesis, 
increased the expression of LDLR 2-fold (p=0.009), and HMG-CoAR was 8-fold increased 
(p<0.001) in liver cells. HMG-CoAR increased even 47-fold in these cells when WelChol 
treatment was combined with simva statin (p=0.003). In contrast, treatment with both 
WelChol and simva statin did not affect the expression of cholesterol metabolism genes 
in the BM MNC. In addition, the expression in hematopoietic cells that are discon-
nected from the BM microenvironment (i.e., PB MNCs) was not affected by simva statin 
treatment (Figure 4). 
Simva statin treatment of patients and mice inhibits geranylgeranylation in bone marrow 
cells
An alternative way in which statins might affect BM MNCs is by inhibition of farnesylation 
and/or geranylgeranylation. This would be in line with our GSEA data, demonstrating 
that simva statin affected pathways involved in signal transduction (Table 3, S1-3) that 
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often require isoprenylation of upstream regulators. Therefore, we determined whether 
in vivo simva statin treatment of mice also resulted in inhibition of isoprenylation. No 
inhibition of farnesylation was observed in mouse BM MNCs and liver cells upon in 
vivo treatment with simva statin. However, in vivo treatment of mice with simva statin 
resulted in differential effects on geranylgeranylation in BM and liver cells: simva statin 
increased unprocessed Rap1 levels, a protein that is exclusively geranylgeranylated, 
in BM MNCs (Figure 5A), which could not be demonstrated in liver cells (Figure 5B). 
In addition, in 1 of the 4 AML patients tested, inhibition of geranylgeranylation was 
detected (Figure 5C), whereas no inhibition of farnesylation was observed. The limited 
available material from the patients that showed in vitro chemosensitization by simva-
statin treatment precluded to assess the isoprenylation status in these patients’ BM cells.
 
Inhibition of geranylgeranylation occurs at low concentrations of simva statin 
Next, we analyzed whether the limited effects of treatment with simva statin on 
cholesterol metabolism gene expression in BM MNCs may be related to the relative 
low concentration achieved in the BM compartment. In vitro treatment of primary 
human and mouse BM MNCs showed that effects on cell survival, cholesterol metabo-






















































































Figure 4. mRNA expression of cholesterol metabolism genes in liver cells, bone marrow (BM) MNCs and 
peripheral blood (PB) MNCs of mice after in vivo simva statin treatment. mRNA expression of (A) HMG-CoA 
reductase; (B) LDL receptor; (C) ABCA1; and (D) ABCG1 was determined in BM, PB, and liver cells of mice 
that were fed with a diet containing 0.1% w/w simva statin (S), 2% w/w welchol (W), or both (W+S). 
C: control chow fed mice. Mean ± SD is shown for 11 (control and simva statin), or 3 (welchol and simva-
statin + welchol) mice per group. 18S served as a housekeeping gene. Expression is shown as the relative 
expression versus 18S, with the first control set at one. ND: not determined. *p<0.05.
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concentrations that are not likely to be achieved in vivo (>5 µM)30 when incubated for 
24 hours (Figure S4, 6A). Inhibition of Rap1 geranylgeranylation, however, occurred at 
concentrations as low as 0.2 µM simva statin in the culture medium, and was maximal at 
1-5 µM in both mouse and human normal BM MNCs (Figure 6B). In contrast, in primary 
hepatocytes inhibition of geranylgeranylation was observed only at concentrations of 
25 µM or higher (Figure 6B). These data show that, although at these concentrations all 
theoretically predicted effects of simva statin can occur, only inhibition of geranylgera-
nylation takes places at low, in vivo achievable concentrations.
Discussion
The present study is the first to demonstrate that treatment of AML patients with 
high-dose simva statin inhibits isoprenylation in their MNCs, but does not affect the 
expression of cholesterol metabolism genes in these cells, despite a reduction in serum 
cholesterol levels. This striking finding provides a novel insight in the mechanism 
behind statin-induced effects in normal and leukemic hematopoietic cells. 
Figure 5. Inhibition of isoprenylation upon in vivo treatment with simva statin. (A,B) Inhibition of geranyl-
geranylation of Rap1 and of farnesylation of DnaJ in control mice (chow) and mice treated for 7 days 
with 0.1% w/w simva statin in (A) BM MNCs and (B) liver cells. Unprenylated (unpren) and total levels 
of Rap1 are shown, as well as unprenylated and prenylated (pren) levels of DnaJ for 7 mice in each 





Mouse BM MNCs Mouse liver cells 
c       s            c       s             c        s             c       s
1 2 3 4





















In vivo simva statin actions in AML cells • 123
6
Statin treatment resulted in an increased in vitro sensitivity of AML CD34+ cells to 
chemotherapy in about one third of the patients. These findings extend in vitro data 
demonstrating that AML cells display an increased sensitivity to chemotherapy upon 
statin treatment10,11. Differences in response to chemotherapy combined with statins 
were reported before in a clinical study with pravastatin combined with idarubicin and 
high-dose ARA-C13. These differences were associated with the occurrence of choles-
terol rebounds after the initial decrease of cholesterol levels, but can also be due to 
other interpatient differences in cholesterol metabolism13,31. However, in our study 
chemosensitivity was not related to basal or simva statin-affected expression levels of 
cholesterol metabolism genes. Only AML samples that are in vitro sensitive to chemo-
therapy became more sensitive when in vivo pretreated with simva statin. This is in 
line with a former report showing that in vitro combination treatment with lova statin 
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Figure 6. In vitro effects of simva statin on prenylation status. Inhibition of farnesylation of (A) DnaJ and 
geranylgeranylation of (B) Rap1 after 24 hours of treatment with simva statin in primary mouse BM 
MNCs, rat hepatocytes, human AML MNCs and normal human MNCs. Representative blots of at least 3 
experiments are shown. unpren: unprenylated protein; pren: prenylated protein.
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and daunorubicin or cytarabine was only more effective in AML samples that displayed 
sensitivity to chemotherapy alone32.
Simva statin treatment of the AML patients resulted in a significant decline in serum 
cholesterol levels, reflecting a decreased cholesterol synthesis by the liver. We observed 
indeed that cholesterol metabolism gene expression was affected in mouse liver cells 
by statin treatment. However, in the total or CD34+ cell fraction from AML patients 
who underwent simva statin treatment only limited effects were found on the mRNA 
expression of single cholesterol metabolism genes. This challenges previous in vitro 
reports describing that statins predominantly affect cholesterol metabolism in AML 
cells2,10. Apparently, simva statin-mediated effects are dependent on the cell type inves-
tigated, which was already suggested by in vitro data showing varying sensitivities of 
different cancer cell lines to statin treatment33. Alternatively, the plasma concentration 
of simva statin might not be sufficiently high due to low bioavailability34,35. Peak plasma 
levels upon treatment with 4 mg/kg/day lova statin, a statin that is pharmacokinetically 
comparable to simva statin35,36, ranged from 0.1-3.9 µM30. With in vitro experiments, 
we showed that this concentration has limited effects on the expression of cholesterol 
metabolism genes in AML cells. 
Studying the expression of single genes did not reveal clear changes upon simva-
statin treatment. However, subtle, but coordinated changes in gene expression within 
a certain pathway can have significant biological effects. With GSEA, we showed that 
signaling pathways were affected by simva statin treatment of which some participants 
require isoprenylation. This observation elaborates on the previous finding that the 
synthesis of isoprenoids, products of the mevalonate pathway, is inhibited by statins 
in vitro14,37. Prenylated proteins mainly belong to the superfamily of Ras-GTPases, 
which are involved in a number of cellular processes, including cell signaling, cell 
differentiation and proliferation38. In many AML patients Ras (predominantly N-Ras) 
is constitutively active due to mutations or autocrine production of growth factors39,40. 
Interestingly, in vitro data indicate that Ras signaling can be affected by statins, which 
results in inhibition of a number of downstream signaling pathways, including the 
MEK/ERK pathway29,41,42. 
It appeared that simva statin mainly inhibited geranylgeranylation in AML cells of 
simva statin-treated patients. Our in vitro data reflect these findings, as we observed 
inhibition of geranylgeranylation in AML MNCs and mouse BM cells at low simva statin 
concentrations, whereas other effects, e.g., inhibition of farnesylation or changes in 
cholesterol metabolism genes, could only be observed at concentrations that were 
25- to 100-fold higher. These high concentrations are also required to inhibit ERK phos-
phorylation, and to induce cytotoxic effects14. As such high simva statin levels cannot 
be achieved in vivo30, it is unlikely that in vivo treatment with statins will be effective 
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in totally blocking Ras/MEK/ERK signaling. For future research it would be attractive 
to combine statins with tipifarnib, a farnesyltransferase inhibitor, since the combined 
use of these agents additively blocked ERK-signaling in AML cells in vitro15, and might 
affect both farnesylation and geranylgeranylation at clinical achievable concentrations. 
However, the Ras-signaling pathway is not the only pathway affected by statins, as 
demonstrated by GSEA. Therefore, other affected pathways may coordinately modulate 
cellular properties of AML cells and contribute to (clinical) effects. 
Inhibition of geranylgeranylation, as well as chemosensitization was not found in 
all patients. Our previous in vitro data showed that within different patient samples a 
heterogeneity in response to simva statin exists14,15. Not surprisingly, this also holds true 
for the clinical setting, and may be even more influenced by interpatient differences 
that do not read out in vitro, such as varying simva statin plasma levels due to variation 
in for example CYP3A4 activity31.
GSEA on the total AML MNC fraction also revealed pathways involved in immune 
signaling to be affected by simva statin. These findings challenge to interpret the studies 
in AML patients that underwent allogeneic stem cell transplantation differently. Here, a 
reduced incidence of graft versus host disease was observed when the donors had been 
using low-dose simva statin43. These effects of simva statin may be attributed to their 
effect on prenylated proteins (e.g., Ras, Rac, Rho, Rap1, and CDC42), which are indeed 
involved in immune function44. In addition, statins are also able to block lympho-
cyte function-associated antigen-1 (LFA-1), and thereby T cell adhesion, activation, and 
proliferation in a HMG-CoAR-independent way45,46, which may have attributed to the 
effects on the immune pathways as well.
In summary, the present study demonstrates that treatment of AML patients with 
simva statin inhibits geranylgeranylation in a subset of patients, in the absence of 
marked changes in cholesterol metabolism gene expression in AML MNCs. This finding 
breaks with the conventional idea that inhibition of cholesterol synthesis does the trick 
in the treatment of AML patients with simva statin. Our findings encourage further 
research to exploit statin-induced inhibition of geranylgeranylation in AML patients. 
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Supplementary data
Materials and methods - mouse stem cell and progenitor assays
To quantify the number of mouse progenitors after diet, the number of colony-
forming units-granulocyte/macrophage (CFU-GM) was determined with the use of 
standard methylcellulose cultures (0.8% methylcellulose (Sigma-Aldrich), 30% FCS in 
a-MEM (StemCell Technologies)) supplemented with 20 ng/mL recombinant murine 
granulocyte-macrophage colony-stimulating factor (rmGM-SCF; R&D systems) and 
100 ng/mL polyethylene glycol-complexed recombinant rat stem cell factor (peg rrSCF; 
Amgen). Cells were cultured at 37°C and 5% CO2, and counted on day 7 with the use of 
an inverted microscope.
Stem cell and progenitor frequencies were determined by FACS-analysis on the 
basis of the combinatorial expression of cell surface antigens. Cells were stained 
with a panel of biotin-conjugated lineage-specific antibodies (containing antibodies 
to CD3e, CD11b (Mac1), CD45R/B220, Gr-1 (Ly-6G and Ly-6C), and TER-119 (Ly-76)), 
phycoerythrin (PE)-conjugated Sca-1, allophycocyanin (APC)-conjugated antibody to 
c-Kit, PacificBlue-conjugated antibody to CD34, and PE-Cy7-conjugated antibody to 
CD16/32. After being washed, cells were incubated with streptavidin-APC-Cy7. All anti-
bodies were purchased from BD Biosciences. The fluorescence activated cell-sorting 
analyses were done on a LSR-II (BD Biosciences). Lineage-depleted (Lin-) BM cells were 
defined as the 5% of cells showing the least APC-Cy7 intensity. Hematopoietic stem 
cells (HSCs) were defined as Lin-Sca-1+c-Kit+ and progenitors as Lin-Sca-1-c-kit+. In 
addition, the progenitor cell fraction was separated into common myeloid progenitors 
(CMP; Lin-Sca-1+c-kit+CD34+CD16/32lo), granulocyte-macrophage progenitors (GMP; 
Lin-Sca-1+c-kit+CD34+CD16/32+), and megakaryocyte-erythroid progenitors (MEP; Lin-
Sca-1+c-kit+CD34-CD16/32-). Data were analyzed with the use of FlowJo (Tree Star, 
Ashland, OR) software.






































































Figure S1. In vivo effects of simva statin on serum lipid levels and in vitro chemosensitivity of AML patients. 
Serum levels of lathosterol, LDL, HDL, and triglycerides of patients before (d0) and after 7 days (d7) of 
treatment with 7.5 mg/kg/day (closed circles) or 15 mg/kg/day (open squares) simva statin. *p<0.05.
Figure S2. Verification of microarray expression data of cholesterol metabolism genes by quantitative RT-PCR. 
Expression of HMG-CoAR, LDLR, ABCA1, and ABCG1 in 3 total MNC fractions and one CD34+ cell fraction, 
as determined by microarray analysis, was compared with qPCR expression levels by linear regression.
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Figure S3. In vivo effects of simva statin on progenitor frequencies of mouse BM cells. (A) FACS analysis for 
stem cells and progenitors and (B) a colony forming assay using BM MNCs from control mice (chow) and 
from mice treated with 0.1% w/w simva statin (simva). LSK and progenitors are shown as a percentage 
within the 5% lineage-negative cells; CMP, GMP and MEP are shown as a percentage of the total progen-
itor fraction. Mean ± SD is shown for 4 control mice and 5 simva statin-fed mice. *p<0.05.
Figure S4. In vitro effects of simva statin cell viability and gene expression. Cell viability of (A) mouse BM and 
(B) human AML MNCs upon treatment with different simva statin-concentrations for 24 hours. mRNA 
expression of cholesterol metabolism genes in (C) mouse BM and (D) human AML MNCs upon simva-
statin treatment. Control was set at 1. 18S (mouse) or GAPDH (human) served as a housekeeping gene. 
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Table S1. Results of gene set enrichment analysis of MNCs using pathway definitions from KEGG
Pathway p-value FDR Enriched in 
Hematopoietic cell lineage <0.001 0.00 post
Cell adhesion molecules <0.001 0.00 post
Natural killer cell mediated cytotoxicity <0.001 0.00 post
Type I diabetes mellitus <0.001 0.00 post
T cell receptor signaling pathway <0.001 0.00 post
Biosynthesis of steroids <0.001 0.01 post
VEGF signaling pathway <0.001 0.01 post
Antigen processing and presentation <0.001 0.01 post
Cytokine cytokine receptor interaction <0.001 0.02 post
Wnt signaling pathway <0.001 0.02 post
MAPK signaling pathway <0.001 0.05 post
Calcium signaling pathway <0.001 0.05 post
Regulation of actin cytoskeleton <0.001 0.11 post
Focal adhesion 0.001 0.06 post
Leukocyte transendothelial migration 0.001 0.05 post
JAK STAT signaling pathway 0.001 0.07 post
Tight junction 0.001 0.06 post
Axon guidance 0.002 0.01 post
Small cell lung cancer 0.002 0.05 post
Pathogenic Escherichia coli infection EPEC 0.002 0.04 post
B cell receptor signaling pathway 0.002 0.04 post
Toll like receptor signaling pathway 0.003 0.06 post
Pancreatic cancer 0.003 0.06 post
Long term potentiation 0.005 0.05 post
Fc epsilon RI signaling pathway 0.005 0.05 post
Pyruvate metabolism 0.005 0.04 post
Pathogenic Escherichia coli infection EHEC 0.006 0.04 post
Fatty acid metabolism 0.010 0.06 post
Adipocytokine signaling pathway 0.011 0.11 post
Glioma 0.012 0.12 post
Benzoate degradation via CoA ligation 0.012 0.05 post
Apoptosis 0.013 0.11 post
Arachidonic acid metabolism 0.018 0.11 post
Neuroactive ligand receptor interaction 0.022 0.26 post
Renal cell carcinoma 0.027 0.16 post
TGF beta signaling pathway 0.028 0.18 post
PPAR signaling pathway 0.031 0.14 post
Glycolysis and gluconeogenesis 0.034 0.16 post
Propanoate metabolism 0.036 0.12 post
Adherens junction 0.037 0.18 post
ECM receptor interaction 0.044 0.18 post
Pentose and glucuronate interconversions 0.046 0.13 post
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Table S2. Results of gene set enrichment analysis of MNCs using pathway definitions from Biocarta
Pathway p-value FDR Enriched in 
Caspase pathway <0.001 0.01 post
Chemical pathway <0.001 0.01 post
TCR pathway <0.001 0.01 post
GPCR pathway <0.001 0.02 post
Rho pathway <0.001 0.02 post
HIVNef pathway <0.001 0.05 post
BCR pathway 0.002 0.02 post
Calcineurin pathway 0.002 0.01 post
P53hypoxia pathway 0.002 0.04 post
CREB pathway 0.003 0.03 post
Biopeptides pathway 0.003 0.05 post
Fas pathway 0.003 0.05 post
AMI pathway 0.003 0.05 post
CTLA4 pathway 0.003 0.03 post
NOS1 pathway 0.005 0.04 post
Csk pathway 0.007 0.04 post
Mitochondria pathway 0.007 0.04 post
Death pathway 0.008 0.05 post
VIP pathway 0.009 0.06 post
FceR1 pathway 0.010 0.08 post
PAR1 pathway 0.012 0.07 post
NKcells pathway 0.012 0.05 post
GATA3 pathway 0.020 0.08 post
TEL pathway 0.021 0.08 post
Stem pathway 0.022 0.07 post
Ceramide pathway 0.023 0.08 post
Erk pathway 0.025 0.09 post
IL12 pathway 0.025 0.08 post
ECM pathway 0.025 0.11 post
PGC1a pathway 0.027 0.11 post
PDGF pathway 0.029 0.14 post
PPARa pathway 0.030 0.13 post
NO2IL12 pathway 0.031 0.10 post
MEF2D pathway 0.033 0.13 post
SppA pathway 0.038 0.15 post
ATM pathway 0.046 0.15 post
NDKdynamin pathway 0.047 0.18 post
134 • Chapter 6
Table S3. Results of gene set enrichment analysis of MNCs using pathway definitions from GenMAPP
Pathway p-value FDR Enriched in 
Apoptosis GenMAPP <0.001 0.00 post
Apoptosis <0.001 0.00 post
Apoptosis KEGG <0.001 0.00 post
Pyruvate metabolism <0.001 0.00 post
Propanoate metabolism <0.001 0.01 post
Calcium regulation in cardiac cells <0.001 0.06 post
GPCRDB class A rhodopsin like 0.001 0.12 post
Smooth muscle contraction 0.002 0.09 post
Peptide GPCRs 0.003 0.06 post
Mitochondrial fatty acid betaoxidation 0.004 0.01 post
Cholesterol biosynthesis 0.005 0.03 post
Glycolysis 0.011 0.11 post
Glycolysis and gluconeogenesis 0.012 0.11 post
Gluconeogenesis 0.013 0.10 post
Valine leucine and isoleucine degradation 0.019 0.10 post
Integrin mediated cell adhesion KEGG 0.030 0.17 post
Lysine degradation 0.035 0.15 post
Citrate cycle TCA cycle 0.049 0.13 post
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Table S4. Results of gene set enrichment analysis of CD34+ cells using pathway definitions from KEGG and 
GenMAPP
Pathway p-value FDR Enriched in 
KEGG      
Regulation of autophagy 0.005 0.10 pre
Glycan structures degradation 0.011 0.10 pre
N glycan degradation 0.018 0.10 pre
Ribosome <0.001 0.02 post
Selenoamino acid metabolism 0.008 0.16 post
Androgen and estrogen metabolism 0.003 0.17 post
Valine leucine and isoleucine degradation 0.005 0.23 post
Cysteine metabolism 0.028 0.21 post
Methionine metabolism 0.020 0.20 post
Aminophosphonate metabolism 0.021 0.18 post
Nitrogen metabolism 0.026 0.22 post
Histidine metabolism 0.028 0.20 post
Purine metabolism 0.004 0.21 post
Ubiquitin mediated proteolysis 0.020 0.21 post
Naphthalene and anthracene degradation 0.027 0.21 post
GenMAPP      
Ribosomal proteins <0.001 0.00 post
Cholesterol biosynthesis 0.008 0.16 post
Ubiquitin mediated proteolysis 0.003 0.15 post
Nitrogen metabolism 0.023 0.24 post
Nuclear receptors 0.014 0.19 post
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Table S5. Results of gene set enrichment analysis of CD34- cells using pathway definitions from KEGG and 
GenMAPP
Pathway p-value FDR Enriched in
KEGG      
T cell receptor signaling pathway <0.001 0.01 post
Antigen processing and presentation <0.001 0.02 post
Natural killer cell mediated cytotoxicity <0.001 0.08 post
Regulation of actin cytoskeleton <0.001 0.08 post
Cytokine cytokine receptor interaction <0.001 0.11 post
Focal adhesion 0.001 0.20 post
JAK STAT signaling pathway 0.003 0.14 post
Tight junction 0.003 0.16 post
VEGF signaling pathway 0.003 0.11 post
B cell receptor signaling pathway 0.006 0.11 post
Glycerolipid metabolism 0.006 0.12 post
Leukocyte transendothelial migration 0.007 0.19 post
Hematopoietic cell lineage 0.009 0.17 post
Glutathione metabolism 0.012 0.14 post
Axon guidance 0.012 0.19 post
Galactose metabolism 0.013 0.15 post
Wnt signaling pathway 0.014 0.23 post
Type II diabetes mellitus 0.020 0.17 post
Fc epsilon RI signaling pathway 0.022 0.21 post
Adipocytokine signaling pathway 0.030 0.23 post
Glycolysis and gluconeogenesis 0.032 0.21 post
Apoptosis 0.041 0.22 post
Parkinsons disease 0.047 0.20 post
Regulation of autophagy 0.049 0.19 post
GenMAPP      
Cell cycle KEGG <0.001 0.06 pre
DNA replication reactome 0.007 0.09 pre
Pyrimidine metabolism 0.008 0.08 pre
Apoptosis <0.001 0.03 post
Integrin mediated cell adhesion KEGG 0.003 0.08 post
Apoptosis KEGG 0.003 0.09 post
Apoptosis GenMAPP 0.005 0.08 post
Nuclear receptors 0.007 0.07 post
Ubiquitin mediated proteolysis 0.012 0.14 post
GPCRDB class A rhodopsin like 0.013 0.23 post
Ovarian infertility genes 0.013 0.09 post
Galactose metabolism 0.017 0.07 post
Glutathione metabolism 0.017 0.10 post
Glycolysis 0.022 0.16 post
Gluconeogenesis 0.024 0.17 post
Striated muscle contraction 0.049 0.24 post
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Table S6. Results of leading edge analysis using p<0.05 and FDR<0.25









PPP3CC Calcineurin A-gamma 10
ITGB1 Integrin beta-1; CD29 9
PIK3R1 PI3K regulatory subunit 1 9
EGFR EGFR 8








CALM3 calmodulin 3 11
CALM2 calmodulin 2 11
MAPK8 JNK 10
PPP3CC Calcineurin A-gamma 10
MAPK1 ERK2 8
NFATC2 nuclear factor of activated t-cells 8
NFATC1 nuclear factor of activated t-cells 8
PRKAR1A PKA type I-alpha 8
PIK3R1 PI3K regulatory subunit 1 7
GenMAPP
ALDH1B1 Aldehyde dehydrogenase 6
ALDH9A1 Aldehyde dehydrogenase 6
ALDH1A1 Aldehyde dehydrogenase 6
ALDH1A2 Aldehyde dehydrogenase 6
ALDH1A3 Aldehyde dehydrogenase 6
LDHC Lactate dehydrogenase 5
LDHB Lactate dehydrogenase 5
EHHADH Enoyl-CoA hydratase 4
ACAT2 Acetyl-CoA acetyltransferase 4
NFKB1 NF-kB 4
PDHB Pyruvate dehydrogenase 4
PKM2 Pyruvate kinase isoenzymes M1/M2 4
PKLR Pyruvate kinase isozymes R/L 4
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Table S6. Continued
Gene symbol Protein n gene sets
CD34+    
KEGG
LCMT1 Leucine carboxyl methyltransferase 5
LCMT2 Leucine carboxyl methyltransferase 5
PRMT3 Protein arginine N-methyltransferase 5
PRMT6 Protein arginine N-methyltransferase 5
METTL2B Methyltransferase-like protein 2B 4
PRMT2 Protein arginine N-methyltransferase 4
PRMT7 Protein arginine N-methyltransferase 4
PRMT5 Protein arginine N-methyltransferase 4
HEMK1 HemK Methyltransferase 4
CTH cystathionase 4
CARM1 coactivator-associated arginine methyltransferase 4
Table S7. Cell counts and blood parameters of mice treated with simva statin and/or welchol
  Control
 
Simva statin  Welchol Simva statin + 
welchol
BM
% LYMPH 58.3 ± 4.5 60.3 ± 5.0 66.7 ± 0.8* 63.2 ± 1.2†
% GRAN 13.4 ± 3.2 11.6 ± 3.3 9.2 ± 0.4 10.9 ± 0.6†
% MID 28.3 ± 2.1 28.1 ± 2.1 24.1 ± 0.5* 24.5 ± 2.8*‡
PB
WBC (106/mL) 6.1 ± 2.1 7.0 ± 2.1 7.6 ± 1.5 7.3 ± 1.1
% LYMPH 86.8 ± 3.5 81.7 ± 7.2* 90.8 ± 0.9 85.3 ± 2.5
% GRAN 2.9 ± 1.5 3.2 ± 1.6 1.6 ± 0.6 2.7 ± 0.8
% MID 10.3 ± 2.6 15.1 ± 6.2* 7.6 ± 0.5 12.0 ± 1.7
HCT (L/L) 0.37 ± 0.03 0.37 ± 0.03 0.40 ± 0.01 0.39 ± 0.00
MCV (fl) 40.9 ± 1.7 41.0 ± 1.7 39.8 ± 0.1 39.4 ± 0.4
RBC (109/mL) 9.0 ± 0.7 9.0 ± 0.6 10.0 ± 0.2* 9.9 ± 0.2
HGB (mmol/L) 9.0 ± 0.7 9.1 ± 0.6 9.6 ± 0.2 9.3 ± 0.0
MCH (fmol) 1.0 ± 0.04 1.0 ± 0.04 1.0 ± 0.01 0.9 ± 0.02
MCHC (mmol/L) 24.5 ± 0.5 24.6 ± 0.5 24.1 ± 0.2 24.1 ± 0.2
RDW (%) 14.9 ± 0.6 14.8 ± 0.6 15.6 ± 0.3 15.7 ± 0.1
MPV (fl) 6.8 ± 0.2 6.9 ± 0.2 7.0 ± 0.1 7.2 ± 0.4*
PLT (106/mL) 540 ± 116 619 ± 109 605 ± 45 613 ± 279
BM: bone marrow; PB: peripheral blood; LYMPH: lymphocytes; GRAN: granulocytes; MID: other cells 
including monocytes, eosinophils, basophils and precursor white cells; WBC: white blood cells; HCT: 
hematocrit, MCV: mean corpuscular volume; RBC: red blood cells; HGB: hemoglobin; MCH: mean 
corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red blood cell 
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Summary
Despite intensive treatment protocols and new developments in leukemia research, 
the long-term survival rates of adult AML patients are still low. For patients with a 
favorable prognosis, 5-year survival is about 50%, which is 4% in patients with an 
unfavorable prognosis, and these numbers are even lower for patients over 65 years. 
These low cure-rates are mainly due to the resistance of the patient’s cancer cells to 
chemotherapy. As a consequence, there is a strong need for new therapeutic options 
to treat AML. 
AML cells display an aberrant cholesterol homeostasis. In addition, these cells 
increase their cholesterol levels upon in vitro exposure to chemotherapeutic agents. 
As this acute cholesterol response is thought to protect against the cytotoxic effects 
of chemotherapy, blocking this response by cholesterol synthesis inhibitors could be 
able to sensitize the cells to cytotoxic agents. Therefore, a role for cholesterol synthesis 
inhibitors like statins has been put forward as a promising addition to standard anti-
leukemic therapy in AML patients. 
The aim of this thesis was to explore the potential benefits of the use of statins in 
treatment of AML. We focused on the use of statins in combination with other agents, 
as well as on the mechanism(s) behind (heterogeneity in) statin-induced effects. 
In chapter 2, recent data on the role of cholesterol and the mevalonate pathway in 
AML are discussed. In addition, potential ways for intervention with the mevalonate 
pathway are described, among which is the application of the widely used plasma 
cholesterol-lowering statins.
In chapter 3, the potency of lova statin to induce cytotoxic effects in AML cells was 
investigated in the absence and presence of commonly used chemotherapeutics. The 
majority of studies investigating cotreatment with statins make use of the total AML 
mononuclear cell fraction. However, we focused on the primitive AML CD34+ cell 
fraction, which is enriched for leukemic stem cells, and compared this fraction with 
the more mature CD34- cells from the same patients. In both cell fractions, combining 
lova statin and chemotherapy resulted in more pronounced cytotoxic effects, as deter-
mined by viability measurements and colony assays. Lova statin alone was more 
effective in both normal and AML CD34+ cells than in the AML CD34- cell fraction, 
indicating that primitive cells are more dependent on cholesterol synthesis for their 
survival. An interesting finding of this study was the difference in response within the 
AML CD34+ patient samples to lova statin; some AML samples responded similarly to 
normal CD34+ cells, whereas other samples showed a reduced sensitivity to lova statin. 
This distinction was, when subdividing CD34+ cells into a primitive CD34+CD38- fraction 
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and a more mature CD34+CD38+ fraction, most clearly seen in the CD34+CD38- subfrac-
tion. These data imply that in a subset of AML patients especially the more primitive 
CD34+ AML cell fraction displays a relative statin resistance. In the other, statin-sensi-
tive patients chemotherapy was potentiated by lova statin. 
In chapter 4 it was investigated whether simva statin-induced effects could be 
potentiated by cotreatment with tipifarnib, an inhibitor of farnesylation. Tipifarnib 
is a farnesyltransferase inhibitor, which has been studied as a single agent in clinical 
trials in AML patients, resulting in variable outcomes. The beneficial effects of tipi-
farnib may be circumvented by alternative prenylation by geranylgeranyltransferase. 
However, simva statin should, in theory, be able to block both geranylgeranylation 
and farnesylation. Therefore, combined treatment with simva statin and tipifarnib was 
expected to result in additional effects. Again, CD34+ AML cells were compared with 
the CD34 - cell fraction. Both cell line data and data on patient AML cells showed that 
the combination of simva statin and tipifarnib resulted in additive cytotoxicity, which 
coincided with a decrease in ERK phosphoryation. However, ERK phosphorylation was 
not decreased when either compound alone was used. In line with chapter 3, variability 
in responsiveness to simva statin was mainly found within the AML CD34+ subfraction. 
The AML samples could be divided in a normal and an abnormal responder group, and 
additive effects by cotreatment with tipifarnib only occurred in the normal responder 
group. From chapter 3 and 4 we can therefore conclude that it is of importance to study 
the CD34+ cell fraction, as the differences in response may have remained unnoticed 
when using the total mononuclear cell (MNC) fraction. In addition, almost all AML 
samples that were not sensitive to simva statin were also not sensitive to tipifarnib, or 
the combination. These findings suggest a common mechanism of resistance, which, 
regarding the targets of both compounds, likely resides in the mevalonate pathway. 
The aim of chapter 5 was to obtain more insight in the mechanism behind the vari-
ability in responsiveness to statins among patient samples, as observed in chapters 3 
and 4. To this end, cell lines with different sensitivities were tested, which all showed 
similar simva statin-induced changes in cholesterol metabolism gene expression, indi-
cating that simva statin was functional in all cell lines. By discriminating between the 
cholesterol synthesis route and the isoprenylation route, using inhibitors and activators 
of either pathway, it appeared that simva statin-induced cytotoxicity is not mediated by 
inhibition of cholesterol synthesis. In contrast, add-back experiments with intermedi-
ates of the isoprenylation route, i.e., farnesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP), revealed that the isoprenylation pathway is responsible for 
simva statin-induced cytotoxicity. Also in primary AML cells simva statin-induced 
cytotoxic effects could be prevented by adding FPP or GGPP. Moreover, the isopre-
nylation pathway appeared to be responsible for the aforementioned differences in 
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sensitivity: inhibition of isoprenylation and ERK activity by simva statin and other, more 
specific inhibitors was less efficient in insensitive cells. Together, our data indicate an 
important role for the isoprenylation route in the mechanism behind (heterogeneity 
in) statin-induced cytotoxicity.
 The aim of chapter 6 was to assess whether the in vitro observed effects of simva-
statin, i.e., inhibition of cholesterol metabolism and isoprenylation, and chemosensi-
tization, can also be detected in the in vivo situation. Besides using AML cell samples 
from patients that were treated with high-dose simva statin, mice were treated with 
simva statin as well. Upon treatment of AML patients with a high dosage simva statin, no 
consequent changes in the expression of the cholesterol metabolism genes HMG-CoAR, 
LDLR, ABCA1, and ABCG1 were observed in bone marrow MNCs of these patients, 
despite significant decreases in serum cholesterol levels in all patients. Still, in about 
30% of the patients simva statin treatment sensitized the AML CD34+ cells to chemo-
therapy. The unexpected absence of changes in cholesterol metabolism gene expres-
sion was further investigated in mice. It appeared that, although liver cells displayed 
increased levels of HMG-CoAR and LDLR mRNA after simva statin treatment, murine 
bone marrow cells did not show increased levels of these genes. Results of gene set 
enrichment analysis on microarray data of AML patient cells revealed a set of pathways 
affected by simva statin treatment that are dependent on isoprenylation. In combina-
tion with previous observations (chapter 5), this suggested that isoprenylation could 
be affected in bone marrow cells. Indeed, in mouse bone marrow cells, but not in liver 
cells, geranylgeranylation was inhibited, and in one of the four tested patient samples 
this inhibition was also detected. In vitro experiments showed that only inhibition 
of geranylgeranylation, but not farnesylation inhibition, takes place at physiological 
concentrations. In addition, this inhibition could solely be detected in bone marrow, 
but not in liver cells. The absence of inhibition of cholesterol synthesis and farnesyla-
tion is therefore likely dependent on the achieved simva statin concentration. Overall, 
we showed that in vivo simva statin concentrations are high enough to result in inhi-
bition of geranylgeranylation, whereas inhibition of farnesylation and cholesterol 
synthesis remained unchanged in bone marrow MNCs.
General discussion and future perspectives
Stem cell-enriched fraction versus total mononuclear cell fraction
Hematopoietic stem cells (HSCs) constitute the target for leukemic transformation 
for most AML subtypes1. Alternatively, more differentiated hematopoietic progenitors 
can acquire mutations that make these cells display stem-cell like properties1. These 
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leukemic stem cells possess unique properties that distinguish them from mature 
leukemic blasts. For example, the cells reside mostly in a quiescent cell cycle state 
and highly express a number of adenosine triphosphate (ATP)-binding cassette (ABC) 
transporters. ABC transporters transport a variety of substrates across extra- and intra-
cellular membranes, and some of them are able to extrude chemotherapeutic agents 
from cells. As a consequence of the acquired chemoresistance, leukemic stem cells, in 
contrast to AML blasts, are not eradicated efficiently. Failure to adequately destroy this 
cell population often results in relapse of the disease.
Stem cell-enriched fractions of normal and leukemic hematopoietic cells display 
an increased expression of the cholesterol transporters ABCA1 and ABCG12,3. In 
addition, the cholesterol synthesis and influx mediators HMG-CoAR and LDLR are 
highly expressed in primitive hematopoietic cells3. This apparent increased cholesterol 
dependency suggests that these cells may be more sensitive to blocking of cholesterol 
synthesis by statins than their mature counterparts. In chapter 3 we tested this hypoth-
esis and showed that both normal and AML CD34+ cells are more sensitive to lova-
statin than CD34- cells. Another indication that (AML) CD34+ cells respond differently 
to statins than more mature cells is presented in chapter 6. Upon treatment of patients 
with simva statin, the pathways that were affected were different between CD34+ and the 
CD34- and total MNC fraction. In the MNC and CD34- fraction pathways involved in cell 
signaling and immune responses were mainly affected, whereas the affected pathways 
in CD34+ cells particularly involved protein synthesis. Interestingly, the cholesterol 
biosynthesis pathway was affected in CD34+ cells, not CD34- cells, which again confirms 
the idea that CD34+ may be more dependent on cholesterol synthesis than more mature 
cells. These data add to other reports that describe differences between CD34+ and CD34- 
AML cells regarding long-term cell growth and susceptibility to apoptosis4,5. However, 
we have to increase our sample sizes and functionally test our findings further to be 
able to draw more solid conclusions.
Another interesting feature of CD34+ cells is, as described in chapter 3 and 4, 
that differences in statin sensitivity are mainly found in this subfraction. Within the 
CD34+CD38- fraction, which is even more enriched for stem cells6, the difference in 
statin response among samples is most pronounced as compared with CD34+CD38+ 
cells. Therefore, it is useful to look at the most primitive subfraction of cells to predict 
which patients may benefit from statin treatment. Differences in response to simva-
statin were also observed in total AML MNC samples in chapter 5, which could be a 
reflection of the high percentage of CD34+ cells in some AML samples and the differ-
ences in response of these CD34+ cells. 
The downside of using CD34+ cell fractions is the generally low number of CD34+ 
cells present in the already limited amount of patient material, which limits the 
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number of experiments that can be done with a single AML sample. We have done 
microarray experiments to compare gene expression profiles of CD34+ AML cells with 
those of CD34- cells. Comparable experiments with statin-treated AML cells could 
potentially provide more information on the mechanisms behind the difference in 
statin response between primitive and more mature AML subfractions. However, our 
experience is that it is not feasible to isolate sufficient numbers of CD34+ cells from 
every patient sample. In addition, insight in cellular events that are triggered by statins 
in specific subfractions might be obtained in the future by phospho-protein FACS 
analysis. This novel method requires only low cell numbers and allows to assess the 
activity of proteins like ERK in CD34+ cells compared with the CD34- fraction. Moreover, 
it will allow to distinguish between primitive cells and progenitor subfractions, such 
as common myeloid progenitors, granulocyte-macrophage progenitors, and megakar-
yocyte-erythroid progenitors. This method, set up for the measurement of phospho-
STAT57, can be extended with other phospho-proteins. This type of experiments could 
provide answers to the questions why primitive hematopoietic cells are more sensitive 
to statins than more mature cells, and why heterogeneity in statin response resides in 
this primitive subfraction.
Lately, there has been a lot of discussion about the real identity of the leukemic 
stem cell. Although these cells were earlier characterized by the expression of CD34 
and the lack of CD38 expression8,9, there is now evidence that also among CD34+CD38+ 
cells and even CD34- cells leukemia-initiating capacity exists10,11. This previously unrec-
ognized heterogeneity in leukemic stem cells makes it difficult to develop targeted 
treatment modalities. 
Mechanism of action
Chapter 5 describes that simva statin-mediated inhibition of the isoprenylation 
pathway, rather than of the cholesterol synthesis pathway, results in cytotoxic effects 
in AML cells. Isoprenoids GGPP and (partially) FPP were able to prevent simva statin-
induced cytotoxicity, whereas squalene, a precursor of cholesterol, was not. This is an 
interesting finding, since it was initially thought that statin-induced cytoxicity in AML 
was mediated by blocking cholesterol synthesis12,13. 
Research in multiple myeloma and lymphoma revealed a major role for protein 
geranylgeranylation, not farnesylation, in simva statin-induced cytotoxicity14,15. This 
was based on the finding that, in contrast to FPP, GGPP rescued statin-induced effects, 
and that a geranylgeranyltransferase inhibitor (GGTI-298) was more effective than a 
farnesyltransferase inhibitor (FTI-277) in inducing cell death. We, however, found that 
the FTI tipifarnib was more effective in AML cells than GGTI-298. Moreover, the partial 
rescue by FPP can be explained by the fact that FPP is also used for the production of 
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squalene. Therefore, our data certainly do not exclude a role for inhibition of farnesyla-
tion by simva statin.
The simva statin-mediated block of the production of the isoprenoids FPP and GGPP 
results in decreased activation of proteins, like Ras and Rho, that require these isopre-
noids for their proper function. This, in turn, leads to impaired cell signaling processes. 
We have shown that simva statin inhibits phosphorylation of ERK, a downstream target 
of Ras, and that inhibition of Ras-signaling mimics statin-induced cytotoxic effects. 
In addition, constitutive activation of the Ras/MEK/ERK pathway has been shown to 
repress statin-induced apoptosis in AML cells16. Therefore, it is likely that this route 
plays an important role in statin-induced cytotoxicity. However, there are a number of 
additional proteins that require isoprenylation for their proper function17. This makes 
it difficult to pinpoint the exact route(s) via which statin-effects are exerted. Clearly, 
more research is required to obtain a more complete picture of the mechanisms 
involved. It is conceivable that, with new potential targets, more specific drugs can be 
designed to circumvent the side effects caused by high-dose statins.
Simva statin exerts its various effects at different concentrations. For example, inhi-
bition of geranylgeranylation generally occurs at concentrations that are 25-100 fold 
lower than the concentration required for inhibition of farnesylation and ERK-phos-
phorylation. Evidently, this has consequences for the in vivo situation, as the maximal 
dosage that can be safely given to patients results in plasma concentrations of up to 
4 μM18. We were the first to investigate the molecular effects of in vivo applied simva-
statin and found that in mice, and in a subset of patients, simva statin treatment resulted 
particularly in inhibition of geranylgeranylation, and not of farnesylation. This finding 
indicates that for inhibition of geranylgeranylation sufficiently high plasma simva-
statin levels are reached. Whether this inhibition results in biological effects remains 
to be elucidated, and should be addressed in further studies in AML mouse models and 
AML patients, as discussed below in more detail. 
To gain more insight in the processes affected by in vivo simva statin treatment, 
we performed a microarray analysis on AML cell samples from patients treated with 
simva statin. This analysis revealed a number of pathways affected by the treatment, 
among which are many signal transduction routes that remain to be functionally 
confirmed. Cellular signaling pathways can be affected by disruption of lipid rafts. 
Lipid rafts are cholesterol-rich domains in cellular membranes, where mediators of 
signal transduction are concentrated. Inhibition of cholesterol synthesis by statins can 
result in disruption of lipid rafts19. However, our data indicated that a specific inhibitor 
of cholesterol synthesis, zaragozic acid A, does not induce cytotoxic effects in AML cell 
lines. This excludes the possibility that (only) inhibition of cholesterol synthesis, and 
the consequent disruption of lipid rafts, is responsible for cytotoxicity in AML cells. 
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Our in vitro studies were done in the presence of serum, a source of cholesterol. It 
is possible that the cholesterol-influx from the medium into the cell has overcome 
the initial cholesterol-mediated statin effects. However, experiments performed in low 
serum concentrations did not affect statin sensitivity20. 
Cotreatment with other agents
Although statins will not be used as single agent in AML treatment, these drugs are of 
potential interest in combination with other standard regimens or novel therapeutics. 
In this thesis, cotreatment of statins with the chemotherapeutics cytarabine, daunoru-
bicin, and the clinically available farnesyltransferase inhibitor tipifarnib was investi-
gated and indeed showed favorable additive effects. 
In vitro chemotherapy results in increased cellular cholesterol levels in AML cells13. 
This acute cholesterol response can be blocked by statin treatment, and results in 
sensitization to chemotherapy in AML cells12. We showed that in vitro and in vivo sensi-
tization to chemotherapy can be observed when using the CD34+ subfraction that is 
enriched for leukemic stem cells. Clinical studies on the combinatory use of statins 
and chemotherapy are rare. The only study in AML patients, in which a high-dose 
statin was combined with chemotherapy, shows that this combination can safely be 
administered to patients. However, the study did not allow to draw valid conclusions 
about the antitumor efficacy of the combination treatment compared with single 
treatment due to the small sample size21. A drawback of statin treatment in combi-
nation with cytarabine is that statins induce cell cycle arrest at the G1 phase22,23, and 
thereby possibly counteract the effects of cytarabine, which eradicates cells that are 
in S phase, resulting in less favorable clinical effects. The moment of administration 
of either compound may therefore influence the therapeutic outcome and should be 
studied further. The effects of daunorubicin are not dependent on cell cycle status, so 
in this case the moment of administration is not likely to influence the results.
Simva statin and tipifarnib are compounds that (partially) interfere with the same 
pathway. Tipifarnib blocks farnesyltransferase, resulting in inhibition of farnesylation 
of proteins. In chapter 5 it is shown that simva statin induces cytotoxic effects not by 
inhibition of the cholesterol synthesis pathway, but by inhibition of the isoprenylation 
pathway, which can be both geranylgeranylation and farnesylation. Ras is a protein 
that can be both geranylgeranylated and farnesylated. Upon treatment with tipifarnib 
only, alternative prenylation by geranylgeranylation may bypass the inhibitory effects 
of tipifarnib on Ras signaling and consequently on cell survival24, which is likely the 
cause of the disappointing clinical effects of tipifarnib monotreatment or combination 
treatment with chemotherapy25-28. As statins are capable of blocking both geranylgera-
nylation and farnesylation, it can be expected that the combined use of a statin and 
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tipifarnib will result in a more pronounced effect on cell survival. This was indeed 
the case, as illustrated in chapter 4, where additive cytotoxic effects were observed in 
vitro for the combination. In addition, phosphorylation of ERK, a downstream target 
of Ras, was inhibited by the combined use of simva statin and tipifarnib, whereas the 
individual compounds at the same concentrations did not affect ERK phosphoryla-
tion. Thus, in AMLs that display increased activation of ERK, e.g., due to constitutively 
active Ras, combined treatment with simva statin and tipifarnib may be more effective 
in inducing cytotoxic effects. Achieved plasma concentrations of tipifarnib are suffi-
ciently high to inhibit farnesylation (0.5-1 μM)29. In addition, we have shown that in 
a subset of patients high-dose statin treatment resulted in inhibition of geranylgera-
nylation in bone marrow cells. Thus, combined treatment with statins and tipifarnib 
is likely to be beneficial in a subset of AML patients and should be investigated in vivo.
To bypass alternative prenylation, combination treatment with a farnesyltrans-
ferase inhibitor and a geranylgeranyltransferase inhibitor (GGTI) may be even more 
effective30, but currently there are no clinically applicable GGTIs. In addition, although 
FTIs and GGTIs are indeed reported to act synergistically30, the combined treatment 
would clinically not be feasible due to high toxicity31.
Heterogeneity in response
Among patient AML samples there are marked differences in response to in vitro statin 
treatment. From a clinical point of view, it is of importance to know which patient will 
respond to statin treatment, as this would allow to predict which patient would benefit 
from treatment. We tried to find the rationale behind this heterogeneity in response by 
using AML cell lines with differences in susceptibility to simva statin. Chapter 5 shows 
that AML cell lines with a decreased susceptibility to simva statin show less efficient 
inhibition of isoprenylation by simva statin, lower basal phosphorylated ERK levels, 
and that simva statin-induced cytotoxicity can less efficiently be prevented by interme-
diates of the isoprenylation pathway. Moreover, isoprenylation inhibitors, as well as a 
MEK inhibitor, were less effective in statin-insensitive cell lines. These findings demon-
strate a role for the Ras/MEK/ERK signal transduction pathway in statin resistance. This 
is an interesting observation, since activating RAS-mutations are found in about 30% 
of the AML patients, and autocrine production of growth factors and cytokines by AML 
cells or mutations in their receptors can activate the Ras/MEK/ERK survival route as 
well32,33. However, from our cell line data and data from others34,35 can be concluded that 
the Ras status of the AML cells can be dissociated from their response to simva statin. 
Still, it appears that sensitive cell lines are more dependent on the Ras/MEK/ERK route 
for their survival than insensitive cell lines.
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In insensitive cell lines, a ~10-fold higher simva statin concentration is required 
to obtain similar effects to those in sensitive cell lines. However, only a 2-fold higher 
concentration of the MEK inhibitor is required for comparable cytotoxic effects in 
the insensitive cell lines. Thus, the heterogeneity in sensitivity to statins cannot be 
explained solely by differences in the MEK/ERK pathway. However, inhibitors of the 
Rho-ROCK pathway and the PI3K/Akt pathway were equally effective in the sensitive 
and insensitive cell lines, indicating that these routes do not account for the heteroge-
neous response to simva statin. The isoprenylation route needs to be further dissected 
to elucidate more routes involved in simva statin resistance. Microarray analysis on a 
high number of sensitive and insensitive cell lines will aid us in finding these differen-
tially regulated pathways. 
Whether the isoprenylation pathway is also the key to differences in statin sensi-
tivity among primary AMLs remains to be investigated. Intervention with the isopre-
nylation pathway was not equally effective among the AML samples, but this heter-
ogeneity in isoprenylation inhibition did not correlate with statin responsiveness. 
However, we should realize that the absence of this correlation may be due to the cells 
used: in these experiments the total MNC fraction, not the CD34+ fraction, was used, 
and differences in statin sensitivity were mainly observed in the CD34+ fraction. It can 
be expected that for patient AML samples, and ultimately for patients in the clinic, 
that the mechanisms behind heterogeneity in response to statins are more complicated 
than can be predicted on the basis of cell line studies. Many different AML subtypes 
exist, with for example different differentiation statuses, cytogenetics, or additional 
mutations, which all contribute to the phenotype of these cells. This phenotype affects 
sensitivity to therapy, like observed with all-trans retinoic acid (ATRA) treatment in 
patients with promyelocytic leukemia (M3) and tyrosine kinase inhibitors in patients 
with c-Kit mutations, and this is likely to hold true for statin treatment as well. In 
patients, the mechanism behind simva statin response may be even more complicated 
by different activities of CYP3A4 among patients, the enzyme that converts statins, such 
as lova statin and simva statin, into their active form36. 
An important follow-up project would be to extend the simva statin clinical trial 
and define patients with and without biological and clinical response to (co-)treatment 
with simva statin. Microarray analysis on material of these AML patients could provide 
us with genes and pathways that are differentially expressed or regulated between the 
normal and abnormal simva statin responders. By pinpointing biomarkers, it should 
in the future be possible to predict which patients may benefit from statin treatment.
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Microenvironment
The in vitro experiments shown in this thesis have been done in culture medium. A 
disadvantage of this approach is that the cells are studied outside their natural environ-
ment, called the microenvironment, or niche. Increasingly, the microenvironment is 
considered to play an important role in normal hematopoiesis and leukemogenesis37. 
The microenvironment can interact with AML cells and produce cytokines for growth 
and survival38. One way in which this microenvironment can be mimicked is by using 
a stromal cell line4. The bone marrow stroma is known to consist of several cell types, 
including fibroblasts, adipocytes, osteoblasts, and endothelial cells. There is evidence 
that these stromal cells can protect leukemia cells against the cytotoxic effects of 
chemotherapy39. In addition, statins affect growth and differentiation of stromal cells 
at clinically relevant concentrations40,41. Future experiments should therefore be done 
to assess what the influence of stromal cells is on statin sensitivity of leukemic cells, 
and to determine the effects of statins on these cells and the consequences for leukemic 
cell survival.
Another feature of the bone marrow microenvironment is the oxygen level, which 
is much lower (about 2%) in the bone marrow niche as compared to oxygen levels in 
the peripheral blood (21%)42. This low oxygen level has a significant impact on the 
metabolic state of the cell and on the amount of available energy in the form of ATP. 
Therefore, we initiated experiments where sensitivity to simva statin was assessed 
under low and high oxygen conditions. 
In human AML cell lines, we tested simva statin sensitivity by assessing cell counts 
after 24 pre-incubation under normoxic (21% O2) or hypoxic (2% O2) conditions, followed 
by 48 hours of simva statin treatment. Especially in the simva statin-sensitive cell lines, 
but also in TF-1 cells, simva statin was less effective in lowering cell numbers under 
hypoxic conditions (Figure 1A). This was also found in primary human AML MNCs. 
Inhibition of both farnesylation and geranylgeranylation by simva statin appeared to 
be not notably affected by hypoxia, and thus appeared not responsible for the dimin-
ished statin sensitivity. More striking was the finding that GM-CSF-induced phospho-
rylated ERK was (almost) completely downregulated under hypoxia (Figure 1C). This 
is in contrast to other findings, where upregulation of phospho-ERK was observed in 
AML cells, albeit under higher O2 levels (6%), and without stimulation by cytokines43, 
but appears to be in line with the findings under hyperoxia44. In this latter study, 
increased phospho-ERK levels were observed under high (95%) oxygen compared with 
normoxic conditions. In addition, we showed that U0126, a MEK inhibitor, was less 
effective under hypoxia, and even seemed to increase cell proliferation when applied 
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under hypoxic conditions (Figure 1D and data not shown). The decreased activation of 
ERK was not GM-CSF receptor-dependent, since no difference in STAT5 phosphoryla-
tion was observed under both conditions (Figure 1C and data not shown). 
Alternatively, downregulation of phospho-ERK under hypoxic conditions may be 
linked to metabolic changes. Cells under hypoxic conditions switch their metabolism 
towards anaerobic glycolysis, thereby generating less energy, which is accompanied 
many cellular changes in order to facilitate an adaptation to the hypoxic conditions. 
Hypoxia-inducible factors mediate a number of these cellular responses to hypoxia 
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by regulating gene expression. However, CoCl2 treatment, which stabilizes hypoxia-
inducible factor 1α (HIF1α) and thus mimics hypoxia-induced HIFα activity, did not 
change phospho-ERK levels (data not shown). 
AMP-activated protein kinase (AMPK) acts as an energy sensor and regulates a 
number of metabolic processes, including fatty acid metabolism and sterol synthesis45. 
Under hypoxic conditions, AMP-activated protein kinase (AMPK) is upregulated45. 
It has been reported that HMG-CoAR is downregulated by AMPK45. This potentially 
explains why cells under hypoxic conditions are less sensitive to simva statin treatment, 
as HMG-CoAR is the direct target of statins. However, our preliminary data do not show 
changes in HMG-CoAR gene expression under hypoxia, and therefore do not support 
this hypothesis. 
An explanation for the absence of active ERK may be that the decreased choles-
terol synthesis under hypoxia results in a decreased lipid raft formation. In contrast 
to ERK, STAT5 is not lipid raft-dependent46, which explains why STAT5 is still phos-
phorylated by GM-CSF stimulation under hypoxia. Other insights come from data on 
macrophages cultured under hyperoxic conditions, i.e., 95% O2, that show an increase 
of pERK compared to normoxia44. This increase was due to a decreased ERK-directed 
phosphatase activity. Preliminary microarray data generated by our lab revealed 
increased expression of a subset of phosphatases in cord blood CD34+ cells grown 
under hypoxia. This may well correlate with increased phosphatase activity, which 
provides another possible explanation for the hypoxia-mediated decrease in ERK phos-
phorylation. We are currently investigating the stated hypotheses concerning the inhi-
bition of phospho-ERK. 
← Figure 1. Decreased cytotoxicity by simva statin in AML cells under hypoxia is MEK/ERK dependent. (A) NB4, 
(B) HL60 and (C) TF-1 cells were cultured under normoxic (21% O2) or hypoxic (2% O2) conditions for 24 
hours, replated under the same conditions, and treated for 48 hours with different concentrations of 
simva statin. Cells were counted and dead cells were excluded by trypan blue staining, which remained 
constant upon treatment. Data are presented as mean ± SD (n=4). (D) Primary human AML cells (n=3) 
were cultured under normoxic or hypoxic conditions for 24 hours, and treated for 24 hours with different 
concentrations of simva statin, after which cell counts were determined as described above. Data are 
presented as mean ± SD. (E) After culturing and treatment as described, cell lines were stimulated for 
15 minutes with GM-CSF prior to harvesting. Western blot was done for phospho-ERK, total ERK, which 
served as a loading control, phospo-STAT5, phospho-p38, Rap1a, a protein that is exclusively geranyl-
geranylated, and DnaJ, a protein that is exclusively farnesylated. The Rap1a blot shows the unprenylated 
protein; of DnaJ the upper band represents the unprenylated protein, the lower band is the prenylated 
protein. Experiments were done at least 3 times and a representative example of each protein blot for 
HL60 cells is shown; comparable results were obtained in NB4 and TF-1 cells. (F) Cells were treated with 
MEK inhibitor U0126 and cell counts were done. Data are shown as mean ± SD (n=3) for NB4; comparable 
results were obtained with HL60 cells. Student’s t-test was done to calculate significance levels.
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Together, our preliminary data show that AML cells are less sensitive to statin 
treatment under hypoxic conditions that resemble their natural environment. This 
decreased sensitivity may be, at least in part, due to decreased activity of ERK. The exact 
mechanism behind this diminished ERK activity and the alternative pathways that take 
care of survival of these cells under influence of hypoxia remain to be determined. 
It also unclear how these findings can be translated to patients and what the conse-
quences may be for clinical treatment. As hypoxic conditions, which are present in the 
bone marrow, decrease sensitivity of AML cells to simva statin, the administered simva-
statin dosage should be even higher than the one derived from previous in vitro data. 
The use of a NOD-SCID mouse model would provide us with the natural bone 
marrow microenvironment. The only report on statin use in a SCID mouse model 
describes that, upon injection of HL60 cells, simva statin reduced the number of these 
cells35. However, as we show in this thesis, these cells are already sensitive to a low dose 
simva statin, in contrast to primary AMLs, making it a less suitable model. To obtain a 
more reliable idea of the situation in patients, patient AML cells should be transplanted 
into NOD-SCID mice47. The disadvantage of this approach is that the heterogeneity 
between patients makes it difficult to interpret the results obtained, and not all AML 
samples are able to engraft in mice48. Moreover, as the Ras/MEK/ERK route is important 
for cell survival, and as this pathway is deactivated under hypoxia, there are likely 
other survival pathways active that are not, or less affected by simva statin.
Role of simva statin concentrations 
In vitro findings do not always reflect the in vivo situation, which may be caused by the 
influence of the microenvironment on the tested cells, as described above. In addition, 
pharmacokinetic aspects that apply when statins are administered to patients are 
also likely to play a role. Although in vitro experiments revealed simva statin-induced 
changes of the expression of cholesterol metabolism genes, similar changes were not 
observed in MNC cells of simva statin-treated AML patients. However, simva statin 
treatment did exert its actions, as it reduced serum cholesterol levels in the patients. 
In addition, inhibition of isoprenylation could be observed in MNCs of mice and a 
subset of patients treated with simva statin. Inhibition of isoprenylation occurred in 
vitro at low concentrations, whereas changes in cholesterol metabolism gene expres-
sion were noted at higher, physiologically irrelevant concentrations. Therefore, it is 
evident that certain biological effects of statins are dependent on the plasma concen-
tration that is achieved.
There are a number of factors that influence the physiologically achieved concentra-
tion of statins. For example, statins undergo an extensive first pass metabolism by the 
liver when orally applied36. This results in a low bioavailability, and, as a consequence, 
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the plasma concentrations are much lower than one would expect based on the dosage 
applied. With an applied dosage of 4 mg/kg, maximum lova statin plasma levels of 
0.1-3.9 μM could be achieved in cancer patients18. A way to circumvent the first pass 
effect is by administering the drug intravenously. Unfortunately, intravenously appli-
cable formulations of statins are not available49.
Both lova statin and simva statin are substrates for CYP3A4, which has, as already 
discussed, a variable activity in humans36. This can be caused by genetic differences 
and extrinsic factors, such as food and drug intake, which makes it difficult to predict 
the actual concentration that will be achieved in the patient. Inhibition of CYP3A4 may 
result in higher statin plasma levels50, although intraindividual differences will still be 
apparent. Furthermore, this approach increases the risk on side effects, and may only 
be feasible when the patient is extensively monitored. Besides CYP3A4, there are several 
other gene products that vary among patients, and that contribute to the in vivo phar-
macokinetics of statins51.
Another disadvantage of statins like simva statin and lova statin is their short 
half-life, resulting in peak-concentrations that last for only a few hours36. This is in 
contrast with the situation during in vitro experiments, in which statin concentra-
tions remain high throughout the experiment. As a consequence, the drug has to be 
administered frequently as to achieve continuous maximum drug levels. Synthetic 
statins are available with a longer half-life (rosuvastatin, atorvastatin), but these statins 
are reported to be less effective in AML cells in vitro than the natural compounds52. A 
clinical trial with pravastatin, a natural statin with a relatively long half-life, showed 
encouraging clinical responses in AML patients21. For example, the complete remission 
rate of newly diagnosed patients with unfavorable cytogenetics and first relapse 
patients was higher than the historical complete remission rates. However, the small 
number of enrolled patients as well as the retrospective comparison do not allow to 
conclude whether the treatment was beneficial.
Increasing the statin dosage to achieve higher plasma levels will likely result in 
more side effects. We and others have shown preclinically that treatment with statins 
in combination with other agents such as chemotherapeutics and farnesyltransferase 
inhibitors can have additive cytotoxic effects in AML cells. This suggests that the use 
of lower, nontoxic dosages of both compounds may be an interesting approach for the 
treatment of AML patients. 
Conclusion
Interference with the mevalonate pathway with statins is a potentially interesting ther-
apeutic direction for the treatment of AML. We have shown by in vitro experiments that 
statins are effective in inducing cytotoxic effects by blocking isoprenoid synthesis and 
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the subsequent signal transduction routes, but not by inhibiting cholesterol synthesis. 
However, in vivo effects are less pronounced, probably due to limited plasma statin 
concentrations reached. Statins exert most of their effects on AML cells at concentra-
tions that cannot be achieved in patients, without inducing severe side effects. Also 
the influence of the microenvironment should be taken into account: preliminary 
data revealed that simva statin is less effective under hypoxic conditions. Interest-
ingly, inhibition of geranylgeranylation occurs at low concentrations in vitro and in 
the in vivo situation. We showed that one way to increase the efficacy of statins may 
be to combine statin treatment with other agents like farnesyltransferase inhibitors. 
The potential of this combination treatment should be investigated further by doing 
in vivo studies. Future research is warranted to further improve our knowledge on 
especially the in vivo effects on statins, taking into account the role of the microenvi-
ronment, and pinpointing the cellular effects that occur at low concentrations in AML 
cells. In addition, patient samples differ in their response to statins, especially within 
the more primitive CD34+ cell fraction. This heterogeneity in response is present in 
patients as well. We have made a start in dissecting the mechanism behind the hetero-
geneity in cellular responses. However, more research is required to reveal the exact 
mechanism(s) of action, which can hopefully lead to the identification of predictive 
biomarkers for statin treatment effects in AML patients. 
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Hematopoiese, acute myeloide leukemie en de (leukemische) stamcel
Hematopoiese omvat de vorming van de verschillende bloedceltypen tijdens het leven 
van een organisme. Dit proces begint bij de onrijpe hematopoietische stamcel (HSC), 
die zichzelf vermenigvuldigt en daarnaast dochterbloedcellen produceert. Deze doch-
tercellen ontwikkelen zich vervolgens in een aantal stappen tot volgroeide bloedcellen, 
waaronder rode en witte bloedcellen. Het proces van hematopoiese is dus volgens een 
hiërarchische structuur opgebouwd. De processen van vermenigvuldiging en ontwik-
keling (differentiatie) van de bloedcellen worden zorgvuldig gereguleerd. Bij patiënten 
met acute myeloide leukemie (AML) zijn deze processen ontregeld. Daardoor differen-
tiëren de cellen zich niet meer, maar vermenigvuldigen zich nog wel. Dit resulteert in 
een ophoping van onrijpe bloedcellen (blasten) in het beenmerg, en op termijn ook in 
het bloed. AML wordt behandeld met chemotherapie en in bepaalde gevallen wordt de 
patiënt getransplanteerd met beenmergstamcellen van een gezonde donor. Ondanks 
het feit dat er de afgelopen jaren veel vooruitgang is geboekt in de behandeling van AML 
patiënten, zijn de vooruitzichten voor deze patiënten op de langere termijn zeer matig. 
Daarom is het van belang onderzoek te verrichten naar andere vormen van therapie.
De laatste jaren is de aandacht verschoven van het uitroeien van de opgehoopte 
leukemische blasten naar het uitschakelen van de leukemische stamcellen (LSCs). Net 
als de HSCs zorgen de LSCs voor bloedcelvorming, maar dan voor de leukemische 
cellen in plaats van de normale bloedcellen. Behandeling met chemotherapeutica 
doodt weliswaar de meeste leukemische cellen, maar het is inmiddels bekend dat 
chemotherapie waarschijnlijk niet in staat is de LSCs volledig uit te roeien, wat tot 
gevolg heeft dat de ziekte uiteindelijk vaak terugkomt. Daarom is het van belang op 
zoek te gaan naar een behandeling die de LSCs wel volledig uitroeit. Zowel de HSCs als 
de LSCs dragen een bepaald eiwit op hun oppervlak. Dit eiwit, CD34, stelt ons in staat 
om de stamcellen van de volwassen cellen te scheiden en zo te onderzoeken of een 
behandeling effectief is voor deze specifieke subpopulatie. 
Het cholesterol metabolisme in acute myeloide leukemie
Het is bekend dat er een relatie is tussen AML en een verstoord cholesterol metabo-
lisme. Cholesterol is een vetachtige stof die nodig is voor de opbouw van de celmem-
branen. Daarin zorgt cholesterol voor de ‘stevigheid’ van de celmembraan en voor het 
functioneren van signaaleiwitten die aan de membraan verbonden zijn. De hoeveel-
heid cholesterol binnen een cel wordt nauwkeurig gereguleerd door middel van 
gecontroleerde opname, afgifte en productie. Cholesterol wordt gemaakt in een aantal 
stappen welke onderdeel zijn van de mevalonaatroute. Het enzym HMG-CoA reductase 
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(HMG-CoAR) speelt hierin een belangrijke rol. Opname van cholesterol verloopt via 
de LDL receptor (LDLR) en afgifte van cholesterol gaat via transporters die ABCA1 en 
ABCG1 worden genoemd.
In AML-cellen is aangetoond dat de genexpressie en activiteit van HMG-CoAR en 
LDLR hoger is dan in normale beenmergcellen. Dit is hangt samen met een langere 
overleving van de cellen. Daarnaast laten deze cellen een acute verhoging van hun 
cholesterolspiegels zien zodra ze in vitro (= in kweek) worden blootgesteld aan chemo-
therapie. Men denkt dat deze acute cholesterol respons de cellen beschermt tegen de 
toxische effecten van chemotherapeutica. Deze bevindingen hebben geleid tot de 
hypothese dat cholesterolverlagers, zoals statines, een effectieve toevoeging kunnen 
zijn op de huidige antileukemische therapieën. 
Doel van het onderzoek
Het doel van dit proefschrift was om het effect van statines op AML-(stam)cellen vast 
te stellen, waarbij is gefocust op het gebruik van statines in combinatie met andere 
geneesmiddelen en op het achterliggend mechanisme van de gevonden effecten. 
Samenvatting
In hoofdstuk 2 wordt een up-to-date overzicht gegeven van de rol van cholesterol en de 
mevalonaatroute in AML. Ook worden mogelijke manieren van interventie met deze 
route beschreven, waaronder de algemeen gebruikte cholesterolverlagende statines. 
In hoofdstuk 3 is gekeken of de cholesterolverlager lova statine in staat was om 
het effect van veelgebruikte chemotherapeutica zoals cytarabine en daunorubicine te 
versterken. Hiervoor zijn uit het beenmerg van patiënten primitieve, CD34-positieve 
AML cellen (de zogenaamde CD34+ fractie) geïsoleerd en bestudeerd en deze fractie 
hebben we vergeleken met de rijpere CD34- fractie van dezelfde patiënten. In beide 
fracties resulteerde de combinatiebehandeling met lova statine en chemotherapie in 
meer uitgesproken celdodende effecten dan met lova statine of chemotherapie alleen. 
Wanneer de cellen alleen met lova statine werden behandeld bleken de normale en de 
CD34+ AML cellen gevoeliger te zijn dan de CD34- AML cellen. Dit laat zien dat primi-
tieve (stam)cellen voor hun overleving afhankelijker zijn van cholesterolsynthese dan 
de rijpere cellen. Een andere bevinding van deze studie was het verschil in gevoelig-
heid tussen de CD34+ AML patiëntenmonsters: sommige AML-monsters waren gevoelig 
voor lova statine, terwijl andere monsters een (sterk) verminderde gevoeligheid voor 
lova statine lieten zien. Deze bevindingen impliceren dat in een deel van de AML-
patiënten met name de primitievere CD34+ AML celfractie een relatieve statine-resis-
tentie vertoont. In de andere, gevoelige patiëntenmonsters werd het effect van chemo-
therapie versterkt door lova statine.
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Statines remmen de eerder genoemde mevalonaatroute, wat niet alleen resulteert 
in een afname van de productie van cholesterol, maar ook in verminderde productie 
van bijproducten van deze route, zoals de isoprenoïden farnesylpyrofosfaat (FPP) en 
geranylgeranylpyrofosfaat (GGPP). Deze isoprenoïden kunnen binden aan bepaalde 
eiwitten, een proces dat isoprenylatie heet. Deze binding is nodig voor de functie 
van de eiwitten, opdat ze signalen kunnen afgeven aan de cel en zijn omgeving om 
bijvoorbeeld celvermenigvuldiging of bescherming tegen celdood te bewerkstelligen. 
Een geneesmiddel dat op een andere wijze dan statines interfereert met isoprenoïden 
is tipifarnib. Dit geneesmiddel voorkomt de binding van FPP aan de signaaleiwitten. 
In hoofdstuk 4 is onderzocht of de effecten van de cholesterolverlager simva statine 
konden worden versterkt door mede te behandelen met tipifarnib. Ook hier werden 
CD34+ AML cellen vergeleken met CD34- cellen. Zowel experimenten met gekweekte 
cellen (cellijnen) als met cellen van AML patiënten lieten zien dat het combineren van 
simva statine met tipifarnib de celdodende effecten versterkte, met name in de AML 
CD34+ celfractie. Dit viel samen met een afname van de actieve vorm van het signale-
ringseiwit ERK door de combinatiebehandeling. Dit verschijnsel trad echter niet op 
wanneer dezelfde concentratie simva statine of tipifarnib apart werden gebruikt. 
Ook in deze experimenten werd een verschil in gevoeligheid binnen de CD34+ AML 
fractie gevonden. Er kon onderscheid worden gemaakt tussen AML-monsters met een 
‘goede’ en een ‘slechte’ respons, waarbij de versterkte effecten door combinatiebehan-
deling alleen zichtbaar waren in de goede respons-groep. Bijna alle AML-monsters 
die ongevoelig waren voor simva statine waren ook ongevoelig voor tipifarnib of de 
combinatie ervan. Dit suggereert dat er een gemeenschappelijk resistentiemecha-
nisme is, die, gezien de aangrijpingspunten van beide stoffen, zeer waarschijnlijk in de 
mevalonaatroute gelokaliseerd is. De resultaten van hoofdstuk 3 en 4 geven aan dat het 
van belang is om de CD34+ celfractie binnen de totale fractie te bestuderen, aangezien 
verschillen in gevoeligheid waarschijnlijk onopgemerkt blijven als de totale (mononu-
cleaire) celfractie wordt gebruikt.
Het onderzoek beschreven in hoofdstuk 5 had als doel meer inzicht te verkrijgen 
in het mechanisme achter de verschillen in gevoeligheid van patiëntenmateriaal voor 
statines die we hebben waargenomen in hoofdstuk 3 en 4. Hierbij is gebruik gemaakt 
van verschillende cellijnen die allemaal een andere gevoeligheid voor simva statine 
vertonen. Uit deze onderzoekingen is naar voren gekomen dat de celdodende effecten 
van simva statine niet tot stand komen door remming van de cholesterolsynthese, 
maar door remming van de isoprenylatieroute. Ook in AML cellen van patiënten kon 
dit mechanisme van simva statine worden aangetoond. Bovendien laten we zien dat de 
isoprenylatieroute verantwoordelijk is voor het optreden van de hierboven vermelde 
verschillen in gevoeligheid voor simva statine. Samengevat laten deze gegevens zien 
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dat de isoprenylatieroute een belangrijke rol speelt in de statine-geïnduceerde celdood 
en de variatie in statine-geïnduceerde celdood.
In hoofdstuk 6 is onderzocht of de effecten van simva statine die in vitro zijn 
waargenomen, namelijk de remming van het cholesterolmetabolisme en isoprenylatie 
en het gevoeliger maken van cellen voor chemotherapie, ook worden waargenomen 
in de in vivo (= in leven, in dieren en mensen) situatie. Hiervoor zijn AML patiënten 
behandeld met een hoge dosering simva statine. Bij de start en het staken van de simva-
statine-behandeling zijn AML-monsters genomen welke we hebben onderzocht. Op 
vergelijkbare wijze zijn ook muizen behandeld en onderzocht. De resultaten toonden 
aan dat behandeling van AML patiënten met een hoge dosis simva statine resulteerde 
in inconsistente veranderingen in expressie van cholesterolmetabolisme-genen in 
beenmergcellen, ondanks een sterke afname in de serum cholesterolspiegels in alle 
patiënten. Toch vonden we in 30% van de patiënten dat behandeling met simva statine 
de AML CD34+ cellen gevoeliger maakte voor chemotherapie. Het onverwacht uitblijven 
van veranderingen in cholesterolmetabolisme-genen is verder onderzocht in muizen. 
Omdat statines na inname als eerste de lever bereiken, verwachtten we dat choles-
terolmetabolisme-genen in levercellen veranderd tot expressie zouden komen. In de 
levers van muizen bleek dit inderdaad het geval, echter, de genen bleven onveranderd 
in beenmergcellen van de muizen na behandeling met simva statine. Op patiënten-
materiaal dat was verkregen voor en na behandeling met simva statine is vervolgens 
een microarray analyse gedaan. Hiermee kan de expressie van praktisch alle genen 
in een cel vastgesteld worden. Met deze microarraygegevens is een ‘gene set enrich-
ment analysis’ uitgevoerd, een methode waarmee aangetoond kan worden welke 
signaleringsroutes verrijkt zijn, bijvoorbeeld na behandeling met simva statine. Deze 
analyse bracht een aantal routes aan het licht die afhankelijk zijn van isoprenylatie. 
In combinatie met eerdere bevindingen (hoofdstuk 5) suggereerde dit dat isopre-
nylatie werd beïnvloed in beenmergcellen. Inderdaad bleek dat in beenmergcellen van 
muizen geranylgeranylatie, een vorm van isoprenylatie, geremd was. Ook in een deel 
van de geteste patiëntenmonsters werd remming van geranylgeranylatie aangetoond. 
Remming van farnesylatie, de andere vorm van isoprenylatie, was niet zichtbaar in 
beenmerg van muizen noch patiënten. In vitro experimenten lieten zien dat alleen 
remming van geranylgeranylatie in beenmergcellen plaatsvond bij concentraties die 
in de patiënt bereikt kunnen worden. De afwezigheid van remming van cholesterol-
synthese en farnesylatie in het beenmerg is daarom wellicht te verklaren door een te 
lage simva statine concentratie in het bloed. Samengevat lieten deze studies zien dat 
in vivo bereikte simva statineconcentraties hoog genoeg zijn om geranylgeranylatie in 
beenmergcellen te remmen, terwijl remming van farnesylatie en cholesterolsynthese 
bij deze concentratie niet optreedt.
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Conclusies van het onderzoek
Blokkering van de mevalonaatroute met statines is een potentieel interessante thera-
peutische benadering voor de behandeling van AML. In dit proefschrift is aangetoond 
dat de gevoeligheid voor statinebehandeling erg varieert tussen patiënten(monsters). 
Omdat het van belang is te kunnen voorspellen welke patiënten baat zullen hebben bij 
een bepaalde behandeling, in dit geval statines, is het belangrijk om te weten waardoor 
dergelijke verschillen in gevoeligheid optreden. Dit onderzoek heeft aangetoond dat 
deze verschillen (voor een groot deel) in de isoprenylatieroute liggen en dat deze route 
ook verantwoordelijk is voor de celdodende effecten van statines. Een probleem is 
dat deze effecten niet allemaal te bewerkstelligen waren met een hoge dosis simva-
statine in patiënten. Echter, bij deze niet-toxische dosis vindt wel remming van gera-
nylgeranylatie plaats in een deel van de patiënten. Door statines te combineren met 
andere geneesmiddelen zou deze remming verder kunnen worden benut. We hebben 
in vitro aangetoond dat chemotherapie en tipifarnib de effecten van statines kunnen 
ver sterken, ook in de meer primitieve cellen, maar de geschiktheid van dergelijke 
combinatiebehandelingen zal verder onderzocht moeten worden in in vivo studies. 
Ook zal meer onderzoek verricht moeten worden om nauwkeuriger de mechanismen 
achter de verschillen in gevoeligheid voor statines te onthullen. Hierdoor kunnen op 
den duur biomarkers geïdentificeerd worden aan de hand waarvan men kan voor-









Vier jaar onderzoek zijn voorbij gevlogen en na veel bloed (beenmerg), zweet en 
tranen is dan eindelijk mijn proefschrift klaar! Vanzelfsprekend hebben ook vele 
anderen begedragen aan de totstandkoming van dit proefschrift, zij het op een directe 
of indirecte manier, en ik zou graag de laatste paar bladzijden willen wijden aan het 
bedanken van iedereen. 
Edo, Liesbeth en Folkert, bedankt voor het vertrouwen dat jullie in me hebben 
gesteld om me als AIO aan te nemen op het ‘cholesterolmetabolisme-in-AML-project’. 
Begeleid te worden door drie drukbezette professoren met ieder hun verschillende 
ideeën, standpunten en interesses is niet altijd even gemakkelijk, maar ik heb hier 
zeker de waarde van ingezien. 
Beste Edo, je kennis van de literatuur en de daarmee samenhangende rijkdom aan 
inspiratie en ideeën –soms teveel om allemaal uit te kunnen voeren– heb ik enorm 
gewaardeerd. Ook stond je open voor mijn eigen ideeën, en je was altijd geïnteres-
seerd en betrokken bij mijn onderzoek. Af en toe lag er een interessant artikel in mijn 
postvakje, en ondanks de drukke combinatie onderzoek en kliniek, heb ik je regel-
matig op het lab gezien om even iets met mij (of collega’s) te bespreken. Hoewel je niet 
iemand bent die met complimenten strooit –wat me veelvuldig deed afvragen of ik het 
allemaal wel goed deed– heb je af en toe toch laten doorschemeren dat het allemaal zo 
slecht nog niet ging.
Liesbeth, het is meer dan eens voorgekomen dat ik op vrijdag aan het eind van 
de dag mijn te corrigeren artikel naar je opstuurde, en dat ik binnen 24 uur het stuk 
alweer terug had, voorzien van uiterst bruikbaar commentaar. Ik heb je vliegensvlugge 
correcties, je wetenschappelijk enthousiasme en je vermogen om de focus te behouden 
(“wat willen we nou precies laten zien?”) erg gewaardeerd.
Folkert, hoewel je halverwege mijn aanstelling de functie decaan van de Raad van 
Bestuur ging bekleden en het nog drukker dan ooit had, heb je altijd tijd voor me 
gemaakt. Dat schrijven een kunst is wisten we allang, maar dat je die kunst, naast de 
kunst van de wetenschap, zeer goed beheerst is ook iets wat ik enorm heb gewaardeerd 
en waarvan ik ook zeker heb geprofiteerd. Van mijn soms dubieuze zinsconstruc-
ties wist je altijd prachtige proza te maken. Bedankt, uiteraard ook voor alle weten-
schappelijke input!
Ook wil ik graag de leden van de beoordelingscommissie, bestaande uit prof. dr. 
A.K. Groen, prof. dr. H.M. Lokhorst en prof. dr. A.J. Moshage, bedanken voor hun tijd 
en aandacht die zij hebben geschonken aan de beoordeling van dit proefschrift.
&Dankwoord • 171
Na twee jaar pipetteren werd ik ineens bijgestaan door een extra paar handen. Patrick, 
we hebben toch maar mooi samen het ‘in vitro’ stuk bij elkaar gepipetteerd. Ook heb je 
ontzettend veel gedaan voor het hypoxia-stuk, wat ten tijde van het samenstellen van 
dit proefschrift helaas nog niet als een volledig hoofdstuk kon worden opgenomen. Ik 
vind het super dat je, na je eerste hemato-avontuur met mij, nu het volgende avontuur 
aan mag gaan binnen de hematologie-club. Dat je hierdoor ook sinds ik ‘weg’ ben nog 
experimenten voor me hebt kunnen doen, was ook erg mooi meegenomen ;) Patman, 
bedankt voor alles!
Alle collega’s en voormalig collega’s van Hematologie Research wil ik graag bedanken 
voor de leuke tijd op het lab, de kamer en buiten het UMCG (labdagen, promoties, 
biosjes, etentjes en BBQs, bowlingavonturen, pretparkbezoeken, congressen, ...).
Susan, je hebt me als AIO-broekie geïntroduceerd op het lab, waarna ik je ben komen 
versterken (althans, daar gaan we maar even vanuit) op het KWF project. Bedankt 
voor de gezelligheid! Sandra (Olthof), je was een supergezellige collega, en ik vond 
het dan ook erg jammer dat je naar de Stamcel Biologie collega’s overstapte. Gelukkig 
kon ik nog vaak op ‘t lab of bij je thuis komen buurten :) Nu je buiten Groningen een 
leuke baan en de liefde hebt gevonden moeten we de etentjes met Niek en Anouk er 
wel in houden! Ja Niek, knetterbiel, behalve dat ik heb mogen genieten van je kook-
kunsten (haha, nu weet iedereen dat je lekker kunt koken!), heb je mijn wel en wee 
(meer wee dan wel, vooruit) regelmatig aan moeten horen en me dusdanig veel moed 
ingepraat dat dit proefschrift er toch is gekomen! Thanks! Jammer dat je niet mijn 
collega wilde blijven :P. M’n andere (ex-)roommates (op de enige kamer in het tria-
degebouw met airco, of is het ‘eercooo’, Sandra?):  Monika (ik heb je plantje met liefde 
verzorgd; zelfs de koffie van Francesco heeft ie overleefd...), Marta (for you I reserved 
some extra space in this section), Francesco (changing places saved me from many 
colds!), Rikst Nynke, Djoke; en de andere (voormalig) collega’s van de afdeling Hema-
tologie Research: Ingrid (het zonnetje op het lab! Maar buiten het lab hebben we het 
ook gezellig gehad, waaronder 2x pretpark, wiew!), Gwenny, Lyndsay, Marcel, Sandra 
Rizo, Szabolcs (we had some nice walks and talks, and I still need the recipes of your 
Hungarian food!), Carolien (yooooo! Verjaardagen, Slagharen, ASH: ook buiten het 
UMCG was je een gezellige collega!), Sarah (this crazy hat party will follow you forever, I 
guess...), Lina (I cannot practise my Chinese anymore!), Annelies (queen of peptalk!), 
Matthieu (oeh, doe die handdoek-move nog eens, sexyyy!), Vincent, Bart-Jan (de 
mannn die alles kannn (en weet)), Marjan (de mama van het lab! Inmiddels hang ik 
niet meer op als ik iets Frans hoor :D), Annet (tussen alle gekkigheid door kun je best 
een serieus gesprek met je hebben :P), Jeanet (kei-zachte g-gezellig!), Hein, JJ (hoewel 
ik niet een van ‘jouw’ AIOs was, was je altijd bereid om mijn vragen te beantwoorden. 
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Bedankt voor je input en natuurlijk de BBQs!), Gerwin (bedankt voor je kritische blik 
op het ‘in vivo stuk’, en natuurlijk ook voor je input en interesse in mijn NPM-zijstapje), 
Pallavi, Jenny, Paresh en alle studenten: muchas gracias! 
Bij deze wil ik ook graag de collega’s van de andere onderzoeksgroepen, met wie 
ik de afgelopen jaren ook het lab heb gedeeld, bedanken: Berber (ik vind het leuk 
dat we elkaar nog regelmatig spreken! Schier moeten we nog maar eens over doen, 
maar dan met wat meer zon, hoewel onweer op het strand ook best tof is en de 
poffertjes die daarna volgden waren ook jummy!), Erik (mijn reisgenootje naar 
A’dam RAI en San Diego, genoeg tijd voor een aantal leuke conversaties!), Mariska, 
Kim, Henk-Marijn, Frank, Arja, Tiny, Alida, Jenny, Eveline, en iedereen van de 
Medische/Gynaecologische Oncologie, maar in het bijzonder Hetty en Coby (streng 
doch rechtvaardig!): dankjulliewel!
Vanwege mijn muisexperimenten was ik ook bij vlagen bij de Stamcel Biologie te 
vinden. Bertien, jij hebt me ontzettend veel geholpen met de beenmergisolaties en bij 
jou heb ik, jawel, mijn cobblestone-diploma gehaald! Fase-contrast is voor mietjes! 
De resultaten van het microscoopgetuur zijn helaas niet in dit proefschrift terecht 
gekomen, maar ik vond het altijd supergezellig om met je te werken, bedankt! Ronald, 
jij hebt me ook een aantal keer geholpen met de ‘pootjes’ en mijn overige labvragen: 
dankjewel! Volgens mij heb ik iedereen van de SCB wel lastig gevallen met een reeks 
lab-gerelateerde vragen, dus Gerald, Alice (je zou denken dat ik je achtervolg hè: eerst 
MPDI, toen MDL, daarna een stukje SCB...), Bert, Brad, Ellen, Evgenia, Jaring, Karin, 
Lenja, Marta (scoring cobblestones is more fun when you are not alone, and especially 
when the person sitting next to you dedicated a song to them!), Martha, Mathilde, 
Sandra (2x): ik voelde me altijd helemaal welkom en thuis bij jullie (ik herinner me 
even de girls’ night out, inclusief overdosis knoflook en übergoeie film, haha!), bedankt 
voor jullie hulp en gezelligheid!
Wat betreft de muizen ben ik ook nog dank verschuldigd aan de mensen van het 
CDP (voor het vertroetelen van mijn poepies), Juul Baller en Vincent Bloks (voor 
respectievelijk de LXR muizen en de dataanalyse van deze muizen. Helaas zijn deze 
gegevens niet (uitgebreid) opgenomen in dit proefschrift) en Ruud Out (voor de 
femurs en tibiae van de ABCG1 muizen).
Henk en Geert, ik heb een flinke berg cellen moeten sorteren, en zonder jullie 
hulp, gezelschap en de small-talks was het allemaal nooit gelukt en had ik de lange zits 
nooit overleefd! 
De nog niet eerder genoemde co-auteurs ben ik ook dank verschuldigd: Wim 
Sluiter en Rudolf Fehrmann.
Ook de secretaresses van mijn promotoren hebben mij regelmatig over de vloer 
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gehad. In alfabetische volgorde: Ann, Betty, Bianca, Gretha, Sylvia en Willy, bedankt 
voor jullie hulp!
Marta, it was really nice to have you as a roommate! Of course, we were always busy, 
but not too busy to share music, food-ideas (I know when to find you @Wagamama), 
Polish tongue-twisters, and crazy cats, and you should be proud that you know the 
names the most famous boy-bands of the 90’s ;) Dziękuję for being my paranymph!
Néomi, ik ben blij dat je een onderzoeksstage bij ons bent gaan doen, want daar 
heb ik een lief vriendinnetje aan overgehouden. We gaan nog heel veel Disney en Pixar 
films kijken en al die andere plannen uitvoeren :) Super dat je m’n paranimf wil zijn!
Gelukkig heb ik de afgelopen jaren ook vrienden en familie om me heen gehad die 
me er af en toe aan moesten herinneren dat je je buiten het UMCG ook prima kunt 
vermaken. Vriendjes en familie; Anneroos, Berber, Elise, Hanneke, Hilbert & Herma, 
Michiel, Néomi, Niek, Sandra: ik denk met veel plezier terug aan de etentjes, dagjes 
uit, (mini-)vakanties, danslessen, bios-uitjes en thuisfilmpjes, hondenwandelingen, 
Noorderzon, old-school en ‘new-school’ spelletjes, kluspraktijken en wat al niet 
meer. Dankjulliewel!
Lieve papa en mama, jullie hebben altijd vierkant achter me gestaan en me onvoor-
waardelijk gesteund. Misschien heeft het te maken met Drentse bescheidenheid. Of 
het allemaal wel goed zou komen: eerst gymnasium, toen studeren, vervolgens ook 
nog eens promoveren... Ik weet dat jullie ontzettend trots zijn op het feit dat ik dit 
proefschrift heb voltooid, temeer daar jullie weten dat het niet altijd even leuk voor 
me was. Bedankt voor alles! En Paulien, dezelfde ouders en toch totaal verschillend! Ik 
kan nog veel van je leren ;)
Maarten, skattekontie! Een vriendje die in het zelfde promotieschuitje zit is zo ontzet-
tend fijn! Dit boekje zou eens zo dik zijn als ik zou beschrijven waar ik je allemaal 
dankbaar voor ben ;) Dankjewel voor je steun, je liefde, voor al die andere dingen. 
Ik hou van je!
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abbreviations
ABC   ATP-binding cassette
ABCA1   ABC transporter A1
Acetyl-CoA  Acetyl Co-enzyme A
ALL   Acute lymphoid leukemia
AML   Acute myeloid leukemia
AMPK   AMP-activated protein kinase
ApoA-1   Apolipoprotein A-1
ApoE   Apolipoprotein E
ARA-C   Cytarabine
ATP   Adenosine triphosphate
ATRA   All-trans retinoic acid
BM   Bone marrow
BP   Bisphosphonate
CD   Cluster of differentiation
CDC42   Cell division control protein 42 homolog
cDNA   Complementary DNA
CENP   Centromere protein
CFC   Colony-forming cell 
CLP   Common lymphoid progenitor
CMP   Common myeloid progenitor
CR   Complete remission
CYP3A4   Cytochrome P450 3A4
dKO   Double knockout
DNA   Deoxyribonucleic acid
DNR   Daunorubicin
EFS   Event free survival
EPO   Erythropoietin
ERK   Extracellular signal-regulated kinase
FAB   French-American-British
FACS   Fluorescence-activated cell sorting
FCS   Fetal calf serum
FDR   False discovery rate
FLT-3   Fms-related tyrosine kinase-3
FPP   Farnesyl pyrophosphate
FTase   Farnesyltransferase
FTI   Farnesyltransferase inhibitor
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GAPDH   Glyceraldehyde 3-phosphate dehydrogenase
G-CSF   Granulocyte colony-stimulating factor
GDP   Guanosine diphosphate
GMP   Granulocyte/macrophage progenitor
GGPP   Geranylgeranyl pyrophosphate
GGTase   Geranylgeranyltransferase
GGTI   Geranylgeranyltransferase inhibitor
GM-CSF   Granulocyte macrophage colony-stimulating factor
GSEA   Gene set enrichment analysis
GTP    Guanosine triphosphate
GTPase   Guanosine triphosphatase
GVHD   Graft versus host disease
HC   Hypoxycholesterol
HDL    High-density lipoprotein
HIF   Hypoxia-inducible factor
HMG-CoA  3-hydroxy-3-methyl-glutaryl-CoA
HMG-CoAR  3-hydroxy-3-methyl-glutaryl-CoA reductase
HSC   Hematopoietic stem cell
HSCT   Hematopoietic stem cell transplantation
IL-3   Interleukin-3
KO   Knockout
LDL   Low-density lipoprotein
LDLR   Low-density lipoprotein receptor
LFA-1   Leukocyte function-associated antigen 1
LSC   Leukemic stem cell
LSK   Lin- Sca-1+ c-Kit+cells
LT-HSC   Long-term hematopoietic stem cell
LXR   Liver X receptor
MAPK   Mitogen-activated protein kinase
MEK   MAPK/ERK kinase
MEP   Megakaryocyte/erythroid progenitor
MM   Multiple myeloma
MNC   Mononuclear cell
MPP   Multipotent progenitor
mRNA   Messenger RNA
NF-κB   Nuclear factor-kappaB
NOD-SCID  Non-obese diabetic severe combined immunodeficiency
OS   Overall survival
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PB   Peripheral blood
PCR   Polymerase chain reaction
PI   Propidium iodide
P-gp   P-glycoprotein
PI3K   Phosphatidylinositol 3-kinases
qPCR   Quantitative PCR
RNA    Ribonucleic acid
ROCK   Rho-associated, coiled-coil containing protein kinase
SCF   Stem cell factor
SCID   Severe combined immunodeficiency
SR-B1   Scavenge receptor-B1
SREBP   Sterol response element-binding protein
STAT5   Signal transduced and activator of transcription 5
ST-HSC   Short-term hematopoietic stem cell
VEGF   Vascular endothelial growth factor
WHO   World Health Organization
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Presentations on (inter)national meetings/abstracts
Annual meeting of the American Society of Hematology 2010, Orlando, FL, USA.
‘In vivo treatment of AML patients with high-dose simva statin inhibits geranylgera-
nylation in AML cells.’ Blood (ASH Annual Meeting Abstracts), 2010; 116: 3280. 
(poster presentation)
 
Annual meeting of the Hemato-Oncology Foundation for Adults in the Netherlands 
and the Dutch Society of Hematology 2010, Papendal, the Netherlands.
‘Heterogeneity in simva statin-induced cytotoxicity in AML is related to differential 
Ras-isoprenylation, rather than to blockade of cholesterol synthesis.’ (oral presentation)
Annual meeting of the American Society of Hematology 2009, New Orleans, LA, USA
‘Heterogeneity in simva statin-induced cytotoxicity in AML is related to differential 
Ras-isoprenylation, rather than to blockade of cholesterol synthesis.’
Blood (ASH Annual Meeting Abstracts), 2009; 114: 1718. (poster presentation)
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and the Dutch Society of Hematology 2009, Papendal, the Netherlands.
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(oral presentation)
Annual meeting of the American Association for Cancer Research 2008, San Diego, 
CA, USA.
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Annual meeting of the Hemato-Oncology Foundation for Adults in the Netherlands 
and the Dutch Society of Hematology 2008, Papendal, the Netherlands.
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leukemia cells.’ (oral presentation)
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Francisco, CA, USA.
‘Overexpression of NF-kappa B-regulated BCL-2 family member A1/BFL-1 prevents
bile acid induced apoptosis in human hepatoma cells.’ Hepatology 2005; 42: 499A-
500A. (poster presentation)


